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General introduction and outline of this thesis
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Figure 1. Theodor Billroth operating in the auditorium of Vienna General Hospital 




Since Theodor Billroth (Figure 1) performed the first successful gastrectomy in 1881, 
many improvements have been made in the treatment of gastric cancer.1 Postoperative 
mortality has dropped from nearly a 100% in the early days to below 1% nowadays 
in experienced hands.2 Japanese surgeons developed the standardized lymph node 
dissection.3 Many trials have been performed on different surgical techniques, including 
the extent of lymph node dissection.4 And over the past decade, surgery combined with 
multimodality therapy has become standard of care for advanced gastric cancer.5 Another 
recent development is the introduction of nationwide quality assurance programs and 
population-based studies investigating the effects of these programs in gastric cancer 
treatment.6,7 
Although these improvements have contributed to an increased quality of care, gastric 
cancer remains the second cause of cancer death worldwide, and yearly approximately 
one million new patients are diagnosed with gastric cancer.8 In the Western world, recent 
survival figures remain dismal. For the approximately 75,000 newly diagnosed European 
gastric cancer patients each year, 5-year survival is only 24%.9,10 In the Netherlands, 
yearly approximately 1,800 patients are diagnosed with gastric cancer, and 5-year survival 
is 22%.11 This makes gastric cancer a challenging disease, appealing for maximum 
effort to improve care. The studies as described in this thesis reflect on several recent 
developments in the staging and treatment of gastric cancer. 
Research as described in part I of this thesis was performed at the Department of Surgery 
at Memorial Sloan-Kettering Cancer Center in New York, USA. Research described in part II 
and III was performed at the Leiden University Medical Center, Leiden, and the Netherlands 
Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Part i - staging and Prognostication
For over 50 years, the TNM classification has been a standard in classifying the anatomic 
extent of disease.12 In 2010, the 7th edition of the International Union Against Cancer 
(UICC) and the American Joint Committee on Cancer (AJCC) TNM staging system 
was presented.13 In chapter 2, changes between the 6th and 7th edition of the TNM 
classification for gastric cancer are evaluated, and both staging systems are compared 
with regards to complexity and predictive accuracy. 
In the 7th edition TNM classification, tumors of the gastroesophageal junction (GEJ) 
are considered esophageal cancers.14 Furthermore, for esophageal and GEJ cancers, 
tumor grade was introduced as an independent determinant of stage grouping in early 
stage tumors. With the significantly worse prognosis of poorly differentiated early stage 
adenocarcinomas, these tumors might become candidate for preoperative therapy, given 
the accurate identification of these tumors with preoperative staging. In chapter 3, 
preoperatively determined tumor grade is compared to postoperative tumor grade in 
patients who were treated with surgery alone for adenocarcinoma of the esophagus or 
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GEJ, in order to assess the feasibility of clinical decision making based on the 7th edition 
TNM classification for these tumors.15
chapter 4 describes the development of a nomogram - a tool for individual patient 
prognostication - predicting survival for patients who already have survived a certain 
period in time after surgery. Another aim of this study was to explore whether variables 
available with follow-up, such as weight loss and performance status, would improve 
the predictive accuracy of this nomogram in the follow-up setting. In chapter 5, the 
performance of the previously published gastric cancer nomogram was assessed in 
patients who received postoperative chemoradiotherapy.16
Part ii - multimodality treatment 
Surgery is the primary curative treatment for locally advanced gastric cancer. A D2 
dissection is the recommended type of surgery in Western countries, while in the East at 
least a D2 lymph node dissection is performed.17,18 Despite the effort to improve surgical 
quality, the locoregional relapse rate remains high with consequently a poor prognosis.19,20 
Since publication of the results of the US Intergroup 0116 study, indicating a benefit in 
survival for postoperative chemoradiotherapy compared to surgery alone, and the British 
MAGIC study, in which improved survival was found for patients who were treated with 
perioperative chemotherapy, surgery alone is no longer standard of care for patients with 
advanced gastric cancer.21-23 
In chapter 6, an overview of the literature on treatment of resectable gastric cancer is 
presented, including surgery and multimodality therapy. 
In chapter 7, recurrence and survival patterns of patients who received surgery followed 
by chemoradiotherapy are compared with recurrence and survival patterns of patients 
who were treated with surgery alone, separately analyzing the effect of the extent of 
lymph node dissection and whether resection margins were free of tumor cells.24 
chapter 8 focuses on another question regarding multimodality therapy use. While it is 
suggested that more than 15 lymph nodes (LNs) should be evaluated for accurate staging 
of gastric cancer, LN yield in Western countries is low.25,26 The effect of preoperative 
chemotherapy on LN yield in gastric cancer is unknown. The aim of the study described 
in this chapter is to determine whether preoperative chemotherapy is associated with any 
difference in the number of LNs obtained from specimens of patients who underwent 
curative surgery for gastric adenocarcinoma. 
In chapter 9 the outline of the currently accruing CRITICS trial is described in detail.27 
In this study, patients receive three cycles of preoperative ECC (epirubicin, cisplatin, 
and capecitabine), followed by D1+ surgery (D2 dissection without splenectomy or 
pancreatectomy). Postoperative therapy consists of another three cycles of ECC, or 
chemoradiotherapy with capecitabine and cisplatin. 
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Part iii - surgical quality assurance
Improving quality of care for patients with resectable gastric cancer is a major challenge, 
as postoperative mortality is generally high and long term survival leaves room for 
improvement. In Japan, postoperative mortality rates of 0.8% have been reported.2 
However, in Western countries where the incidence of gastric cancer is much lower, and 
gastrectomies are performed in lower volume hospitals, mortality rates vary between 
2% for specialized centers to above 10% for nationwide cancer registries.28,29 Although 
performing randomized studies can significantly improve outcome over a longer period,30 
increasing surgeon and hospital exposure is the key to improvement of treatment results 
after low volume high-risk surgery such as gastrectomy. Many studies have explored the 
relation between hospital volume and outcome and found that increasing surgeon and 
hospital volume are associated with lower postoperative mortality and higher survival 
rates, both in the Western world and in Asia.6 Centralization of gastric cancer surgery is 
currently implemented in the United Kingdom, Sweden, Finland, and the Netherlands. 
An additional instrument for improvement of care is auditing. With auditing, surgeons 
can improve their results by learning from their own outcome statistics benchmarked 
against their peers. Among other variables of interest, in gastric cancer surgery auditing 
provides the opportunity to analyze differences in hospital mortality, the extent of lymph 
node dissection, and the use of laparoscopic techniques. Auditing has proven its value 
in rectal cancer treatment in Europe,31 and audits for gastric and esophageal cancer are 
currently present in Denmark, the United Kingdom, and the Netherlands. 
As an introduction to part III of this thesis, chapter 10 describes the results of a systematic 
review of the literature on quality of care indicators for gastric cancer surgery. In chapter 
11 and chapter 12, trends in incidence and survival of gastric, GEJ, and esophageal cancer 
in the Netherlands are described. 
During the past decade, multimodality therapy has become standard of care for the 
treatment of resectable gastric cancer.23 In the Dutch guidelines for the treatment of 
gastric cancer, the use of perioperative chemotherapy is recommended.32 However, it 
is unknown how well these evidence-based recommendations are implemented in 
daily clinical practice. This question is discussed in chapter 13, where the results of a 
population-based study on the type of treatment for gastric cancer in the Netherlands are 
described, looking at resection rates and the use of multimodality treatment.
In chapter 14, the results of a study on hospital volumes, mortality, and survival for 
esophagogastric cancer surgery in the Netherlands are presented. This study also focuses 
on the relation between annual hospital volume and outcomes after esophagogastric 
cancer surgery. Another related question is whether the type of hospital where surgery is 
performed affects outcomes after esophagogastric cancer surgery. This issue is addressed 
in chapter 15, where outcomes after esophagectomy and gastrectomy are separately 
analyzed for university, teaching non-university, and non-teaching non-university 
hospitals in the Netherlands.
12
In chapter 16, resection rates, outcomes, and annual hospital volumes for esophagogastric 
cancer surgery in the Netherlands are compared with several other European countries. 
Furthermore, the relation between annual hospital volume and outcomes is explored 
in the large dataset used for this study. This study provides the initial step towards a 
European upper gastrointestinal cancer audit.
Finally, the results of this thesis and future perspectives are discussed in chapter 17.
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The objectives of the current study were to evaluate the changes in the 7th edition American 
Joint Committee on Cancer (AJCC) staging system for stomach cancer compared to the 
6th edition and to compare the predictive accuracy of the two staging systems.
patients and methods 
In a combined database containing 2196 patients who underwent an R0 resection for 
gastric adenocarcinoma, differences between the two staging systems were evaluated 
and stage specific survival estimates were compared. Concordance probability and Brier 
scores were estimated for both systems to examine the predictive accuracy.
results
Nodal status cut-off values were changed, leading to a more even distribution for the 
redefined N1, N2, and N3 group. AJCC 6th edition stage II reflected a highly heterogeneous 
population, which is now adequately subdivided in the AJCC 7th edition into stages 
IIA, IIB, and IIIA. The predictive accuracy of N-classification improved significantly as 
measured by concordance. Despite increased complexity, the predictive accuracy of AJCC 
7th stage grouping was significantly worse than that of the AJCC 6th edition.
conclusions
The increased complexity of the 7th edition staging system is accompanied with 
improvements in the predictive value of nodal staging as compared to the 6th edition, 
but was no better in overall stage-specific predictive accuracy. Future refinements of 




Cancer staging is one of the fundamental activities in oncology.1,2 For over 50 years, the 
TNM classification has been a standard in classifying the anatomic extent of disease.3 In 
order to maintain the staging system relevant, the International Union Against Cancer 
and the American Joint Committee on Cancer (AJCC) have collaborated on periodic 
revisions of this staging system, leading to the 7th edition in 2010.4
For gastric cancer, several changes to the 6th edition were made.5 In the 7th edition, all 
gastroesophageal junction (GEJ) tumors are staged as esophageal cancers, except tumors 
arising in the stomach >5cm from the GEJ (Figure 1). The T classification categories 
have been redefined (Table 1) and the T classification of stomach cancer and esophageal 
cancer have been harmonized. N-categories have been modified to better represent the 
distribution of the number of positive lymph nodes. The M1 category has been amended to 
include positive peritoneal cytology. Stage IV now includes only patients with M1 disease. 
Finally, new stage groups have been added to the staging system (IIB and IIIC). The 7th 
edition staging system is more complex, with an increase in the number of permutations 
of TNM groupings from 56 to 80. There are now nine stage groups, compared to seven 
in the AJCC 6th edition (Table 2).
With each staging system revision, there is a tension between improving prognostic value 
of the staging system by adding subdivisions of existing stage groupings and introducing 
new predictive parameters, and the desire to keep the staging system intuitive and simple. 
T - Primary tumor (invasion depth) AJCC 6th edition AJCC 7th edition
  no evidence of primary tumor T0 T0




  submucosa T1b
  muscularis propria T2a T2
  subserosa T2b T3
  serosa T3 T4a
  adjacent structures T4 T4b
N - Regional Lymph Node Metastases




  3-6 N2
  7-15 N2 N3a
  >15 N3 N3b
M - Distant Metastases
  no distant metastases M0 M0
  distant metastases M1 M1
a at least invasion of lamina propria
Table 1. Changes in the AJCC staging system for gastric cancer
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The purpose of this study is to compare the 6th to the 7th edition of the AJCC staging 
system for gastric cancer, first by describing the differences in stage-specific survival, 
and secondly by examining whether the increased complexity of the 7th edition resulted 
in improved prognostic accuracy as compared to the 6th edition. 
Patients and methods
The dataset used for this study is a combination of two large prospectively collected 
databases.
memorial sloan-kettering cancer center 
Between July 1985 and December 2009, 2589 patients with an adenocarcinoma of the 
stomach or GEJ underwent a gastrectomy at the Memorial Sloan-Kettering Cancer Center 
(MSKCC) and were entered in a prospectively maintained database. Patients with tumors 
of the GEJ (Siewert I-III, N = 669), and patients with a noncurative (R1 or R2) resection, 
or M1 disease (N = 358) were excluded. As the dataset focused on curative resections, 
all patients with M1 disease were excluded, all of whom would have been stage IV in 
the 6th and 7th edition staging system. Three patients with T0N+ disease in their final 
pathology could not have a stage group assigned and were excluded, leaving 1559 patients 
for analysis. Most patients underwent a D2 lymph node dissection. Preoperative and 
postoperative therapy were administered according to the ongoing clinical trials and 
the standard of care at MSKCC during the study period. Adjuvant chemotherapy was 
given infrequently from 1985 to 1999. From 2000 to 2009, perioperative chemotherapy 
became more common for advanced stage tumors, whereas postoperative chemoradiation 
was also administered between 2000 and 2007. Follow-up was generally conducted 
according to published NCCN guidelines.6 Survival data were updated when available 
until March 2010. This study was approved by the Institutional Review Board of MSKCC. 
This dataset was used in part to help guide changes to the AJCC 7th edition.
Figure 1. Definition of esophageal and gastric cancer according to the 7th edition AJCC staging 
system
Siewert I Siewert II Siewert III Siewert III Cardia
TNM 7th edition esophageal cancer TNM 7th edition gastric cancer
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dutch gastric cancer trial 
In the Dutch Gastric Cancer Trial (DGCT, 1989-1993), 1078 patients with adenocarcinoma 
of the stomach were randomized for D1 or D2 lymphadenectomy.7-9 None of the patients 
had a tumor of the GEJ, while patients with metastatic disease (N = 367), and patients 
who underwent a non-curative resection (N = 74) were excluded, leaving 637 patients 
who underwent an R0 resection for this study. No adjuvant therapy was given to these 
patients in the curative setting. Follow-up was conducted every 6 months.  Recurrent 
disease was generally confirmed with radiology, endoscopy, and/or histology. Survival 
data were updated when available until November 2007.
 
staging
Since the UICC and AJCC use the same staging definitions, for purposes of clarity 
the UICC/AJCC staging system is referred to as AJCC staging system. Tumor, nodal, 
and metastasis stage and stage grouping are all based on final postoperative pathology. 
All staging parameters (T, N, M) and stage groupings of the 6th and 7th edition staging 
system were calculated based on depth of invasion through the gastric wall, the number 
of positive lymph nodes and the presence or absence of distant metastases. No patients 
were excluded due to incomplete staging data.
Table 2. Stage grouping according to the 6th and 7th edition AJCC staging system
6th edition AJCC staging system 7th edition AJCC staging system
Stage T N M Stage T N M
0 Tis N0 M0 0 Tis N0 M0



























































































IV Any T Any N M1
T: Tumor classification, N: Nodal status, M: Metastases status, Bold: No changes in TNM and stage groups
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statistical analysis
Survival probabilities were estimated with the Kaplan-Meier method, differences in 
survival curves were assessed using the log-rank test. The endpoint in this study was 
disease-specific survival (DSS). DSS was recorded from the date of surgery until the date 
of death of disease, whereas death from other causes and alive at last date of follow-up 
were recorded as censored events.
The concordance index between survival and stage for the two staging systems was 
calculated using a methodology previously described.10 Concordance for a staging 
system can range from 0% to 100%, with 100% representing absolute concordance, 50% 
indicating no association (no better than flipping a coin) and 0% perfect discordance. 
The concordance index for a staging system was calculated by analyzing all possible pairs 
of two patients in the dataset. A pair of two patients is concordant if the patient with 
the higher stage has the shorter survival. Concordant pairs are assigned a value of 1, 
discordant pairs are assigned a value of 0. The concordance of the staging system is 
the sum of the values of all the individual pairs divided by the total number of pairs in 
the dataset. For pairs where the shorter survival time was censored, the stage-specific 
Kaplan-Meier estimate of survival was used. Pairs in which both patients were in the 
same stage group were assigned a value of 0.5. Therefore, the maximum concordance 
of the staging system could never be 100%. The maximum potential concordance in our 
dataset for the 6th edition was 0.818 and for the 7th edition 0.853. Confidence intervals 
and P-values for the difference in concordance indices of the two staging systems were 
calculated using bootstrap resampling. 
To validate the results provided by concordance analysis, the Brier score was used to 
evaluate the expected error of the predictions in both staging systems. For every patient, 
the Brier score measures the difference between the survival probability predicted by 
the staging system, and the observed survival. Kaplan-Meier estimates were used for 
censored observations. The average squared deviation for all patients gives the Brier 
score, in which a lower score represents a better predictive accuracy.
results
patients
All 2196 patients in this analysis underwent a radical (R0) resection for an adenocarcinoma 
of the stomach between July 1985 and December 2009, either at MSKCC (N = 1559) or 
in one of the hospitals participating in the DGCT (N = 637). Patient characteristics are 
summarized in Table 3. Median follow-up was 98 months.
tnm staging
Figure 2 depicts the distribution of T-classification and N-classification of the 6th edition 
and 7th edition staging system for all patients (N = 2196). The redefined N1, N2, and 
N3 classification were more evenly distributed. Among 2196 patients, 674 (31%) were 
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Table 3. Patient characteristics
Total  (N = 2196) MSKCC (N = 1559) DGCT (N = 637)
















































  no tumor
  mucosa
  submucosa
  muscularis propria
  subserosa
  serosa











































Number of evaluated nodes
  median (range) 21 (0-106) 21 (0-84) 22 (1-106)
Patients with at least 15 
nodes evaluated
1671 76 1213 78 458 72
Number of positive nodes
  median (range) 1 (0-63) 1 (0-63) 1 (0-28)
Type of surgery
  total gastrectomy
  proximal gastrectomy
  distal gastrectomy
  esophagogastrectomy



































  preoperative chemotherapy
  postoperative chemotherapy

















Total0 IA IB IIA IIB IIIA IIIB IIIC
0 35 35
IA 476 476
AJCC IB 220 210 430
6th edition II 61 307 99 467
IIIA 163 258 421
IIIB 181 181
IV 1 1 44 140 186
Total 35 476 220 271 308 263 302 321 2196
Bold: patients who stay in the same stage group
Table 4. Distribution of patients according to the 6th and 7th edition AJCC staging system
22 part i
assigned a higher N-classification in the AJCC 7th edition. In the 7th edition staging 
system, the N3 category is divided into N3a (7-15 positive nodes) and N3b (16 or more 
positive nodes). This recognized the unique independent prognostic significance of an 
increasing number of positive nodes, even at the high end.
stage grouping
Differences in stage distribution between the two systems are shown in Table 4. For 
stage IB to IV, both T, N and M, as well as stage group definitions were altered leading 
to a change in stage group for 1302 of 2196 patients (59%). In total, 748 patients (34%) 
moved to a higher stage group, and 186 patients (9%) moved to a lower stage group. 368 
patients (17%) with a stage II tumor in the 6th edition staging system were distributed 
between stage IIA and IIB in the 7th edition staging system. Of note, stage grouping did 
not make use of the N3a/N3b classification.
discrimination between stage groups
Five-year survival estimates for both staging systems are shown in Figure 3 and Table 5. In 
the 6th edition staging system (Figure 3a), Kaplan-Meier survival estimates significantly 
differed for stage IA-IB, IB-II, II-IIIA and IIIA-IIIB, but not for stage 0-IA (P = 0.64) and 
IIIB-IV (P = 0.60). In the new staging system, stage group 0 and IA remain unchanged. 
Differences between the 7th edition stage groups were significant for stage IA-IB, IIA-IIB, 
IIB-IIIA and IIIB-IIIC but not for stage 0-IA (P = 0.64), IB-IIA (P = 0.09) and stage IIIA-
IIIB (P = 0.15, Figure 3b). Figure 4a shows patients from the 6th edition stage II, which 
is subdivided into stage IIA, IIB and IIIA in the 7th edition staging system. Differences 
between the curves were all significant. In Figure 4b the subdivision of 6th edition stage 
IIIA into 7th edition stage IIIA and IIIB is shown; no significant differences between 
the two new stage groups were detected (P = 0.26). Overall, in the AJCC 6th edition, two 
out of six consecutive steps between stage groups were not significantly discriminant, 
while in the AJCC 7th edition, three out of seven consecutive steps were not significantly 
discriminant, indicating that the discriminant value between stage groups has decreased 
between the 6th and 7th edition staging system.
Figure 2. Distribution of all patients over the T classification in the 6th edition (a) and the 7th edition 
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predictive accuracy
The concordance index of T staging did not change significantly from the 6th to the 7th 
edition (P = 0.36) (Table 6). The concordance index of N staging showed an increase 
from 0.659 to 0.665 (P = 0.03). Despite the change in definition for almost every stage 
group and the increased number of stage groups, the concordance estimate for the 7th 
edition was 0.697, which was significantly inferior to that of the 6th edition staging 
system (0.711, P < 0.01). Brier score for T, N and overall stage groupings showed no 
significant improvement from the 6th to the 7th edition.
discussion
The current study describes the impact of the changes made in the 7th edition of the TNM-
classification for stomach cancer by comparing stage-specific survival and predictive 
accuracy of the 6th and 7th edition staging system in a combined dataset with over 2000 
patients who underwent an R0 resection for gastric cancer.
Three earlier single institutional Asian studies have compared the 6th with the 7th TNM-
classification for gastric cancer.11-14 The first study analyzed 9998 patients treated at a 
Korean university hospital and found a more detailed classification of prognosis in the 7th 
Figure 3. Disease-specific survival estimates according to the 6th edition (a) and 7th edition (b) AJCC 


































































Figure 4. (a) AJCC 6th edition Stage II patients (N = 467) are distributed between stages IIA, IIB, and 
IIIA in the 7th edition staging system. (b) AJCC 6th edition Stage IIIA patients (N = 421) are distributed 
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edition staging system, accompanied with increased homogeneity within stage groups.11 
A Chinese study found better prognostic stratification in the 7th edition staging system.12 
Another Korean study evaluated nodal classification in 295 patients, and found that in 
multivariable analysis, N-classification was an independent prognostic factor for survival 
in the 7th edition, but not in the 6th edition staging system.14
One strength of the current study is the use of data from multiple institutions, thereby 
reducing the risk of unique outcome due to single institution bias. However, both series 
are Western, and no Asian dataset was used. Another advantage of the current study is 
the high quality of the data: all patients underwent an R0 resection, and disease-specific 
survival was used as the outcome measure. In the three previously published studies, 
overall survival instead of disease-specific survival was used, and in one study 14.5% of 
the patients underwent an R1 resection.12
With the redefinition of nodal classification, the distribution of patients among the 
N1, N2 and N3 categories is more equal (Figure 2b), while many patients are upstaged 
under the new staging system. A point of discussion on nodal staging in gastric cancer 
is that in the Western world, lymph node yield is generally low,15 certainly in comparison 
with Asian centers.16 This leads to the potential shift of patients into a more advanced 
nodal classification simply by investigating more lymph nodes.17 Several groups have 
suggested the use of lymph node ratio (metastatic/total lymph nodes) instead of nodal 
status because of its higher prognostic accuracy and the elimination of the effect of this 
shift.18-20 In these studies however, cut-off values for lymph node ratio intervals are often 
based on the used dataset. This introduces an advantage for lymph node ratio which has 
a perfect fit on the used dataset, while TNM nodal classification is part of an established 
system. However, decreasing the threshold for N2 and N3 categories in the 7th edition 
staging system considerably reduces the shifting effect. A minimum number of 15 nodes, 
however, remains the recommended threshold for adequate nodal staging.
A limitation of the stage groupings of the 7th edition staging system is that N3a and N3b 
categories were combined as N3, thereby not recognizing the prognostic significance of 
having 7-15 positive nodes versus more than 16 positive nodes in overall stage grouping. 
As the introduction of N3a and N3b as separate categories in overall stage grouping will 
increase complexity of the staging system, while it is unknown if it will improve overall 
predictive accuracy, this issue needs to be further addressed in future staging systems.
There are several benchmarks for comparing the performance of two staging systems. 
First, there should be homogeneity within stage groups; patients within the same stage 
group should have small differences in survival. Secondly, there should be discrimination 
between stage groups; patients in different stage groups should have larger differences 
in survival. Third, a staging system should have good predictive accuracy; patients with 
a higher stage should have a worse survival. And fourth, a staging system should be as 
simple and intuitive as possible in clinical practice, as increased complexity impedes 
clinical utility.
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homogeneity within stage groups
Establishing homogeneity within stage groups requires grouping of TNM-combinations 
that have similar survival estimates (Table 2). For homogeneity testing, results are highly 
dependent on the size of the dataset. Ahn et al. showed improved homogeneity of two 
homogeneous stage groups in the 7th edition compared to one homogeneous stage 
group in the 6th edition, using a dataset of nearly 10,000 patients.11 In the current study, 
numbers are smaller and therefore significant homogeneity within stage groups is hard 
to detect (results not shown). 
discrimination between stage groups
Heterogeneity between stage groups can be assessed by comparing stage-specific survival 
estimates for significant differences. Whether differences between stage groups are 
significant is highly dependent on the size of the dataset. Small differences in survival 
estimates between stage groups are more likely to be statistically significant in a large 
dataset. In the current study, stage-specific heterogeneity has decreased in the 7th edition 
when compared to the 6th edition. Although AJCC 6th edition stage II contained a highly 
heterogeneous population (Figure 4a), and distributing these patients between stages 
IIA, IIB, and IIIA in the 7th edition has created three groups with a significantly different 
prognosis, the distribution of 6th edition stage IIIA patients into AJCC 7th edition stages 
IIIA and IIIB has created two stage groups with almost identical stage-specific survival 
(Figure 4b). Wang et al. showed decreased heterogeneity between stage groups in the 7th 
edition as well.12 
Table 5. Five-year and median disease-specific survival (DSS) estimates for stage groupings of the 
6th and 7th edition staging system (N = 2196)
AJCC 6th edition AJCC 7th edition









































Table 6. Predictive accuracy of the 6th and 7th edition AJCC staging system
AJCC edition T-classification N-classification Stage group
Concordance 6th 0.666 (P = 0.36) 0.659 (P = 0.03) 0.711 (P < 0.01)
7th 0.667 0.665 0.697
Brier score 6th 0.165 0.165 0.158
7th 0.163 0.164 0.156
Concordance: higher is better, Brier score: lower is better
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prognostic accuracy for individual patients
Performance of a staging system can also be assessed on the individual patient level, by 
comparing survival of patients with different stages. Several ways of comparing staging 
systems on an individual patient level have been proposed, but there is no standard 
method.21 Commonly-used methods include explained variation (or Brier score), area 
under the receiver operating characteristic curve, the concordance index, and a summary 
measure of separation (SEP). We decided to use the concordance index and Brier score 
to measure the prognostic accuracy of the staging systems, since they analyze different, 
complementary measures. Concordance index is a measure of whether ranking of 
patients by staging is consistent with the ranking of their outcome. Its advantages include 
interpretation (since it is a probability), robustness (since it is based on ranks, it is not 
sensitive to small changes in the data) and availability of appropriate statistical methods 
for estimation. It also incorporates a built-in penalty for staging systems with a higher 
number of categories, so that with equally performing staging systems, the system with 
more categories will have a lower concordance probability. It does not penalize possible 
shifts (miscalibrations) between predicted and observed survival. Therefore, we also used 
Brier score, since it looks at the actual difference (in months) between predicted and 
observed survival, taking possible shifts into account.
In the current dataset, concordance analysis showed no difference for T category, an 
improvement for N category, and a decline for stage grouping. Brier scores consistently 
showed no significant improvement from the 6th to the 7th edition. Therefore, it can be 
concluded that for individual patient outcome, no improvements were detected from the 
6th to the 7th edition staging system.
Only one of the previously published studies compared the two staging systems on an 
individual patient level. It found increased predictive accuracy for the 7th edition staging 
system.12 A disadvantage of the method employed in that study is that the metric used for 
comparison, the Akaike Information Criterion, measures how well the staging system 
fits to the used dataset, without assessing the actual prognostic accuracy.
complexity of the staging system
With an increasing number of stage group categories for the 7th edition of the staging 
system, it has become more complex. Increasing the number of categories of the staging 
system is not unique to gastric cancer.4 With the increasing availability of pathologic 
and molecular data, there is a trend towards incorporating more and more information 
into newer staging systems. Although these new categories might better reflect the 
natural history and prognosis of these diseases, there is a limit to the improvement of 
prognostic accuracy achievable with a categorical anatomic-based staging system like the 
TNM-classification.22,23  At the same time, the goal of creating an intuitive, easy to use 
staging system disappears, and in daily clinical practice, cancer staging consists of using 
complex tables, if it is used at all.
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Meanwhile, tools for individual patient prognostication have been developed that 
significantly outperform the TNM-classification in prognostic accuracy.  For gastric 
cancer, a nomogram has been developed based on a single US-institution database,24,25 
and has been validated in several international patient cohorts.26-28 The question is if the 
TNM-classification should aspire to the same goal of highly accurate individual patient 
prognostication as these nomograms. Prognostication is only one of the five goals of 
the TNM-classification, and all other goals are directed towards a simple intuitive 
international language: to aid the clinician in planning and evaluating treatment, to 
facilitate the exchange of information, and to contribute to research.1
In summary, the 7th edition of the AJCC staging system for gastric cancer has resulted 
in improved predictive accuracy for the N-classification but decreased heterogeneity 
among stage groups. The increased complexity of the 7th edition staging system is not 
accompanied by an improvement in prognostic accuracy of stage grouping. Staging 
represents a compromise in accounting for the most reproducible and prognostically 
relevant factors to aim at a simple, intuitive, useful, common language to describe the 
natural history of a tumor. It should not be confused with more complex multivariable 
prognostication models, which may be useful in defining groups of patients at 
homogenous risk of recurrence, regardless of anatomic TNM characteristics.
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In the 7th edition of the AJCC staging system for esophageal cancer, tumor grade was 
introduced as an independent determinant of stage grouping in early stage tumors. With 
the significantly lower prognosis of poorly differentiated early stage adenocarcinomas, 
these tumors might become candidate for neoadjuvant therapy, given an accurate 
identification of these tumors with preoperative staging. The purpose of this study is 
to investigate the accuracy of preoperative histopathologic grading and the effect of 
preoperative grade on tumor stage/prognostic grouping. 
patients and methods 
Preoperative tumor grade was compared to postoperative tumor grade in 427 patients 
who were treated with surgery without neoadjuvant therapy for adenocarcinoma of the 
esophagus. The impact of preoperative tumor grade on stage/prognostic grouping was 
investigated.
results 
The overall accuracy of preoperative tumor grade assessment was 76% when unknown 
differentiation was regarded as well/moderately differentiated as recommended by 
AJCC, while accuracy was 73% after exclusion of tumors with unknown grade. In 
patients with T1-2N0 stage tumors, 16% were assigned to a lower stage group based 
on preoperative pathology, whereas 5% were assigned to higher stage group. In the T1-
2N0 group, sensitivity for detecting a poorly differentiated tumor was 0.43 (0.30-0.56), 
whereas specificity was 0.94 (0.90-0.98).
conclusions
With increasing use of neoadjuvant therapy, accuracy of preoperative biopsy assessment 
has become increasingly important. In the current study, we demonstrate that accuracy 
of preoperative tumor grade is 73%, leading to changes in AJCC stage/prognostic group 
in 21% of patients with T1-2N0 esophageal adenocarcinomas. Caution should therefore 




The seventh edition of the American Joint Committee on Cancer (AJCC) Staging Manual 
has introduced several major modifications in the staging of gastric and esophageal 
cancer as compared to its sixth edition.1-3 Most importantly, all tumors involving the 
gastroesophageal junction (GEJ) are now classified as esophageal cancers. The only 
exception is for GEJ tumors with the epicenter >5 cm distal to the GEJ which are coded 
as gastric cancer. A second important change is the incorporation of histological grade in 
the stage/prognostic grouping for both adenocarcinoma and squamous cell carcinoma 
esophageal cancer. For T1-2N0M0 adenocarcinomas, the degree of differentiation is 
now an independent determinant of stage/prognostic group. Well and moderately 
differentiated T1N0 adenocarcinomas are staged IA, whereas poorly differentiated T1N0 
adenocarcinomas are grouped together with well to moderately differentiated T2N0 
tumors in stage IB. Poorly differentiated T2N0 adenocarcinomas are stage IIA. For T3 or 
higher stage tumors and tumors with positive lymph nodes, the degree of differentiation 
does not influence stage/prognostic grouping. A third change is the definition of nodal 
(N) status, which is now based on the absolute number of positive lymph nodes and 
is synchronized to nodal stage for gastric carcinoma. Additional changes include the 
definition of tumor stage of Tis (in situ carcinoma), T4, and M classification.
The proposal of the 2010 AJCC staging system for esophageal cancer is based on a 
combined large international database: the Worldwide Esophageal Cancer Collaboration 
(WECC).4 This database contains information of more than 7,000 patients and represents 
the practice of 13 institutions on 3 continents. However, for the staging system, only data 
from the 4,627 patients who received surgery without chemotherapy or radiotherapy 
were used. Therefore, the compliance of the staging system with patients who received 
preoperative or postoperative treatment is debatable.5 Another issue with this dataset is 
the lack of information from preoperative biopsies. The introduction of tumor grade in 
the staging system is entirely based upon postoperative pathologic evaluation. However, 
this information is unavailable when a patient is staged prior to surgery to determine the 
use of neoadjuvant therapy.
Since the use of preoperative chemotherapy and radiation has become increasingly 
established in the treatment of resectable esophageal and GEJ adenocarcinoma,6,7 
accurate preoperative staging has become an issue of increasing clinical relevance, which 
is not only limited to locally advanced tumors. In the AJCC 7th ed., poor differentiation/
tumor grade is used as an independent predictor of poor survival in early stage tumors. 
Stage-specific 10-year survival rates are 66%, 51% and 38% for stage IA (T1N0G1,2), 
IB (T1N0G3/T2N0G1,2), and IIA (T2N0G3), respectively.8  Provided with these data, 
the group of patients with T2N0G3 tumors might become candidates for preoperative 
therapy, given that these tumors can be correctly identified preoperatively.
The purpose of this study was to investigate the accuracy of preoperative assessment of 
tumor grade of esophageal and GEJ adenocarcinoma by comparing preoperative grading 
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on biopsies to the postoperative surgical pathology in individuals who did not undergo 
neoadjuvant therapy. The second purpose was to investigate the impact of preoperative 




Patients were identified from two prospectively maintained databases of gastric and 
esophageal cancer. Between January 1996 and November 2009, 1,440 patients with 
adenocarcinoma of the distal esophagus or GEJ without metastatic disease underwent 
potentially curative surgery at Memorial Sloan-Kettering Cancer Center (MSKCC). 
January 1996 is the time point at which an institutional electronic medical record 
system was introduced and is, therefore, a date from which additional information to the 
prospective database can be obtained. Patients who received preoperative chemotherapy or 
radiation were excluded, leaving 475 patients who did not receive neoadjuvant treatment. 
Since tumor grade was not assessed in patients with T0 and Tis disease (high grade 
glandular dysplasia), these patients (N = 48) were also excluded.  Overall 427 patients 
with both preoperative biopsy and postoperative resection material were available for 
analysis. Patient and pathologic tumor characteristics, treatment, and follow-up data 
were prospectively recorded. The study was approved by the Institutional Review Board 
of MSKCC.
preoperative staging and histology
Preoperative staging was performed with varying combinations of chest radiograph, 
computed tomography (CT), positron emission tomography (PET) scan, endoscopic 
ultrasound (EUS) with biopsies, and diagnostic laparoscopy with biopsies. To avoid 
influence by imaging modalities on the accuracy of preoperative tumor grade analysis, 
each patient was assigned a preoperative stage based on the tumor grade assessed from 
preoperative biopsies, combined with postoperative T-, N- and M-stage. All patients 
underwent preoperative histopathologic evaluation by an in-house pathologist, either by 
evaluation of the submitted slides from referring hospitals, or by review of endoscopic 
biopsy specimens obtained at MSKCC.  Whenever possible, all the material from patients 
who had multiple biopsies was reviewed.  
Tumor grade was defined as well, moderately or poorly differentiated and reflected a 
recording of the poorest grade within the biopsy. In the final analysis, well and moderately 
differentiated tumors were grouped as one entity. When tumor grade was not mentioned 
in the pathology report, it was recorded as ‘unknown’. In the time period 1996-2003, 
pathologists of any subspecialty participated in the assessment of these tumors but since 




All patients underwent a potentially curative resection of the esophagus, the GEJ, the 
stomach or a combination with different types of approaches depending on the tumor 
location and the preference of the surgeon. Surgical techniques included three-phase 
esophagectomy (cervico-thoraco-abdominal), Ivor-Lewis esophagectomy (right thoraco-
abdominal), (left) thoraco-abdominal esophagectomy, transhiatal (cervico-abdominal) 
esophagectomy proximal gastrectomy and total gastrectomy.
postoperative histology and staging
Staging was performed according to the new American Joint Committee on Cancer 
Staging guidelines (7th edition, 2010).1 Depth of tumor invasion, number of positive lymph 
nodes, margin status, and the grade of differentiation were prospectively recorded, and 
used to calculate postoperative AJCC 7th edition T-stage, N-status and stage/prognostic 
group. According to the AJCC stage-grouping recommendation, tumors with unknown 
grades were regarded as well/moderately differentiated tumors. 
Tumor grade was recorded as well, well to moderately, moderately, moderately to 
poorly, or poorly differentiated. These were translated to a trichotomous system of well, 
moderately, and poorly differentiated tumors, recording the poorest grade mentioned. 
In the final analysis, well and moderately differentiated tumors were grouped into one 
entity. Adenocarcinomas of the GEJ were classified according to a modification of the 
Siewert criteria, with type I tumors defined as an adenocarcinoma of the distal esophagus 
which may extend below the esophagogastric junction by less than 25% of the tumor 
mass, type II tumors defined as a carcinoma that straddles the esophagogastric junction, 
and type III tumors as a subcardial gastric carcinoma that involves the GEJ and may 
extend above the GEJ by less than 25% of the tumor mass.9
statistical analysis
Accuracy of preoperative staging was calculated by determining the concordance 
between preoperative and postoperative pathologic grade assessed from biopsies and 
surgical specimens, respectively.  The postoperative pathologic grade was utilized as the 
gold standard reference point. Accuracy was expressed as the percentage of patients with 
the correct grade assigned. Although this yields a number that is easy to understand, it 
fails to reflect on the distribution of patients over different categories. Therefore, Cohen’s 
weighted Kappa test for agreement was used as an additional measurement of accuracy of 
preoperative tumor grade. In general, values of Kappa from 0.20 to 0.39 are considered 
fair agreement, 0.40 to 0.59 are considered moderate, 0.60 to 0.79 substantial, and 0.80 
outstanding.10 Differences between groups were calculated by using Pearson’s chi-square 
test. Survival estimates were calculated using the Kaplan Meier method, while differences 
between survival estimates were analyzed with the Log-Rank test. All statistical analyses 
were performed with SPSS Statistics 17.0.
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results
Demographic, pathologic and surgical data are summarized in Table 1. Seventy-eight 
percent of the patients were male and the mean age was 66.2 years. The average number 
of patients per year who underwent surgery without preoperative therapy decreased 
over time: 37 patients per year in 1996-1999, 32 patients per year in 2000-2004, and 
24 patients per year in 2005-2009. Adenocarcinomas were classified as Siewert I, 
II or III in 30%, 46% and 24%, respectively. Survival for postoperative T1-2N0 well/
moderately/unknown adenocarcinomas was significantly longer as compared to poorly 
differentiated tumors of the same T1-2N0 stage (Figure 1, 80% versus 56%, P = 0.005). 
Patients with preoperative stage IA, who were upstaged IB on postoperative pathology 
had a significantly worse prognosis as compared to those who remained stage IA on 
postoperative pathologic staging (P = 0.014, Figure 2), while there was no significant 
difference in overall survival with patients who were assigned stage IB preoperatively and 
postoperatively (P = 0.454). This analysis could not be performed for patients incorrectly 
staged between stage IB to IIA, because the number of events in this group was too few.
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Postoperative pathology indicated 9% (37/427) of the tumors were well differentiated, 
43% (183/427) moderately differentiated and 47% (199/427) poorly differentiated. 
Postoperative grade was reported in 98% (419/427) of the tumors, and preoperative grade 
was reported in 71% (302/427) of all tumors (Table 2). Based upon the AJCC staging 
guidelines, unknown tumor grade was recorded as well/moderately differentiated. 
Accuracy of preoperative tumor grade assessment in the entire group (T1-4N0-3 patients) 
was 76% (324/427, P < 0.001) (Table 3). Cohen’s kappa test for agreement demonstrated 
a kappa of 0.50 (P < 0.001), which is considered to reflect moderate agreement. Most 
discordance in preoperative grading in biopsies was a result of under-grading, with 29% 
(88/301) of all preoperative well and moderately differentiated tumors being poorly 
differentiated tumors on postoperative surgical pathology (Table 3). After exclusion of 
the patients with unknown preoperative or postoperative grade, accuracy of preoperative 
grading was 73% (238/301, P < 0.001), with a kappa of 0.58 (P < 0.001), indicative of 
moderate agreement. 
The concordance of preoperative grade assessment was comparable when analyzed 
by specialized gastrointestinal (GI) pathologists (80%) or non-GI-pathologists (78%, P 
= NS). Differences in accuracy between the different Siewert groups (Siewert I: 72%, 
Siewert II: 79%, Siewert III: 86%) were borderline significant (P = 0.06). 
Accuracy slightly increased during the consecutive time periods: accuracy was 73%, 81% 
and 83% for the periods 1996-1999, 2000-2004, and 2005-2009. This observation did 
not reach statistical significance.
Since tumor grade only affects stage grouping in T1-2N0 patients, subgroup analyses 
were performed excluding T3 and T4 tumors and tumors with positive lymph nodes. 
Accuracy of preoperative grade assessment in T1-2N0 tumors was 79% (156/197, P < 
0.001), with a kappa of 0.42 (Table 4). Most grading discordance was due to preoperative 
under-grading. After conversion of T1-2N0 tumors into their corresponding pre and 
postoperative stage/prognostic groups, 79% (156/197, P < 0.001) of the patients were 
Figure 1. Kaplan Meier curves for T1-2N0 
tumors, separated by postoperative tumor grade 
(N = 197)
Figure 2. Kaplan Meier curves for T1-2N0 
tumors, separated by preoperative and 
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properly staged (Table 5), with a kappa of 0.57 (P < 0.001). Preoperative under-staging 
occurred in 16% (32/197) of these patients and over-staging in 5% (9/197), respectively. 
Sensitivity in this group to detect a poorly differentiated tumor was 0.43 (0.30-0.56), 
whereas specificity was 0.94 (0.90-0.98). This indicates that of all poorly differentiated 
tumors in the T1-2N0 group, 57% were not identified as such. 




 tumors (N = 427), unknown grade is coded as well/moderately differentiated
Accuracy: 324/427 = 0.76,  Cohen’s Kappa: 0.50




 tumors (N = 427)
     Postoperative grade
Well Moderate Poor Unknown Total
Preoperative grade Well 5 14 6 0 25
Moderate 7 101 42 1 151
Poor 1 14 111 0 126
Unknown 24 54 40 7 125
Total 37 183 199 8 427
       Postoperative grade
Well-Mod, Unknown Poor Total
Preoperative grade Well-Mod, Unknown 213 88 301
Poor 15 111 126
Total 228 199 427




 tumors (N = 197)
Accuracy: 156/197 = 0.79, Cohen’s Kappa: 0.42




 tumors (N = 197)
Accuracy: 156/197 = 0.79, Cohen’s Kappa: 0.57
Postoperative grade
Well-Mod, Unknown Poor Total
Preoperative grade Well-Mod, Unknown 132 32 164
Poor 9 24 33
Total 141 56 197
                                                                                       Postoperative stage group
IA IB IIA Total
Preoperative stage group IA 115 22 0 137
IB 8 37 10 55
IIA 0 1 4 5
Total 123 60 14 197
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discussion
Although T-stage, N-stage and M-stage are strong independent predictors of survival in 
esophageal cancer,11-13 the sixth edition of the AJCC staging system for esophageal cancer 
has been challenged for its heterogeneity of outcome on survival within the different 
stage groups.14 During the past years, several pathologic prognostic factors have been 
proposed for incorporation into the TNM staging system. These include degree of 
differentiation,15 vascular and perineural invasion,16 extracapsular lymph node invasion,17 
tumor length,18,19 clearance of the proximal and distal resection margin,20,21 and status of 
the circumferential margin.22 These proposals however, are primarily based on analyses 
from relatively small series of patients, and in most instances from single institution 
databases. Incorporation of a new factor into the AJCC staging system not only requires 
a structured mechanism of the proposed change,23 but the factor also has to be available 
in the collaborative WECC database. 
In 1991, Robey-Cafferty et al showed in their series of 69 patients with squamous cell 
carcinoma of the esophagus that the degree of tumor differentiation was an independent 
prognostic factor.24 In 2001, Dickson et al. proposed incorporation of tumor grade in 
the staging system based upon a series of 139 consecutive patients who received surgery 
for GEJ carcinoma (mostly adenocarcinoma). The authors demonstrated differences in 
3-year overall survival for well (33.3%) and moderately differentiated tumors (28.9%) vs 
poorly differentiated tumors ( 15.9%) respectively.15 Khan et al confirmed these results in 
a series of 219 patients with N0 squamous cell carcinoma and adenocarcinoma of the 
esophagus, showing that tumor grade was an independent prognostic factor in univariate 
and multivariate analysis.25 Other studies also confirmed a correlation between tumor 
grade and prognosis in univariate analysis, but not in multivariate analysis.26-28 Recently, 
Thompson et al reported in a study of 240 patients with mainly adenocarcinoma, that 
tumor grade was an independent prognostic variable in both univariate and multivariate 
analysis.14 In this study, patients were divided into two groups:  well and moderately 
differentiated, and poorly and undifferentiated. Furthermore, the combined data in 
WECC database also supports the incorporation of tumor grade into the 2010 AJCC 
staging system for esophageal cancer. The inclusion of postoperatively determined 
tumor grade into the staging system may provide outcome information and guidance 
for adjuvant therapeutic strategies. However, the question raised with this addition is 
how reliable is the assessment of tumor grade in small preoperative biopsies?  This is 
particularly relevant when neoadjuvant options are considered with poorly differentiated 
adenocarcinomas of T2N0M0 stage.
In the patient group evaluated, the average number of patients without preoperative 
treatment decreased over the years. This is consistent with increased use of neoadjuvant 
therapy in locally advanced GEJ carcinoma. Poorly differentiated (G3) and early stage 
tumors were associated with a significantly lower survival rate as compared to tumors 
that were graded as well (G1), moderately (G2) or unknown on postoperative pathology 
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(Figure 1). Preoperatively understaged IB tumors (into preoperative stage IA) were 
associated with lower survival as compared to correctly staged IA tumors (Figure 2), 
indicating the significance of accurate tumor grade assessment on preoperative staging. 
In the entire cohort of this study, including patients with ‘unknown’ tumor grade, which 
was regarded as well/moderately differentiated according to AJCC recommendation, 
preoperative tumor grade assessed in biopsies was concordant with that assessed in 
surgical specimens in 76% of the patients. After excluding individuals with unknown 
tumor grade, overall concordance was 73% (kappa value: 0.58) consistent with moderate 
agreement.
However, not all stage/prognostic groups are affected by tumor grade.  In the AJCC 7th 
Edition only stage T1-2N0 tumors are assigned to three separate stage groups when the 
tumor is well and moderately or poorly differentiated. In T1-2N0 tumors, the concordance 
for tumor grade was slightly higher as compared to the entire cohort (79% vs. 76%), 
and therefore 21% of this group was assigned an “inappropriate” stage group based on 
preoperative biopsies: under-staging occurred in 16%, and over-staging in 5%.
The differences in concordance of tumor grade assessed by GI-pathologists and non GI-
pathologists were not statistically significant. To the authors’ best knowledge, this has 
not been described previously.  Siewert type showed borderline significant differences 
favoring higher accuracy of tumor grade assessment in Siewert III tumors.
A number of factors could account for the discordance in assessment of tumor grade 
in biopsy and in surgical resection specimens. These include sampling issue, technical 
quality of the specimen, and, to a lesser extent, the experience of the pathologist. It 
is of note that a significant number of GEJ adenocarcinomas reveal intratumoral 
heterogeneity (Figure 3), exhibiting mixed populations of well to moderately and poorly 
differentiated histopathology within the same tumor. Thus a biopsy specimen may 
not always represent the dominant component of the tumor grade in the entire lesion. 
Therefore, sampling bias may be responsible for discordance in both up-grade and 
Figure 3. Adenocarcinoma of mixed type with 
moderately differentiated (lower left) and poorly 
differentiated component (upper)
Figure 4. Preoperative biopsy (left) and corre-
sponding surgical resection specimen (right) of 
a moderately differentiated adenocarcinoma
Biopsy could be upgraded as a poorly differentiated carcinoma 
due to its proximity to ulcer and the crush artifact
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down-grade between biopsy and resection specimens, respectively. A second significant 
factor responsible for tumor grading discordance is the suboptimal preparation of biopsy 
specimens, which may include excessive air dry effect before formalin fixation, tumor 
tissue adjacent to ulcer and necrosis, or thermal/mechanically generated crush artifacts 
in diminutive specimens. In these situations, an up-grading from a well/moderately to 
a poorly differentiated tumor is a more likely consequence than down-grading from a 
poorly differentiated to a well/moderately tumor (Figure 4).
The very recent introduction of the 2010 staging system into clinical practice has 
precluded the development of treatment algorithms for the different stage/prognostic 
groups and these remain to be established. No prospective studies have been performed 
in the subset of early stage poorly differentiated tumors, and most current clinical trials 
of neoadjuvant therapy for esophageal adenocarcinoma apply different inclusion criteria 
and usually include patients with cT2-3N029 and cT1-3N1 tumors7. However, the FFCD 
9901 trial showed that preoperative CRT followed by surgery has a negative impact on 
postoperative mortality in early stage esophageal cancer patients as compared to surgery 
alone, without a significant difference in overall survival.30 The majority of patients 
in this trial however, had squamous cell carcinoma, while no subgroup analyses were 
performed on poorly differentiated early stage tumors. Furthermore, a WECC database 
analysis showed that the subgroup of patients with T2N0G3 tumors, when treated with 
surgery only, has a significantly worse 10-year survival (38%) as compared to other early 
stage but lower grade tumors (66% and 51%).8 
Since the new AJCC staging system has revealed a prognostic difference for patients 
with IA, IB and IIA esophageal adenocarcinoma that is stratified with the combination 
of tumor stage (T1-2) and tumor differentiation, it is likely that patients with early 
esophageal and GEJ tumors, which are poorly differentiated, may become candidates for 
neoadjuvant therapy. However, in our study, we have demonstrated that the sensitivity 
for grading poorly differentiated early stage tumors correctly is only 0.43. Given this low 
sensitivity there exists the potential risk that more than half of these patients would not 
receive therapy that might be otherwise recommended.
With the increasing use of neoadjuvant chemotherapy and radiotherapy in esophageal 
cancers, it is evident that therapeutic management strategy should be evaluated based 
on a combination of clinical, radiographic, and pathologic assessments.  In future 
modifications of the AJCC staging system, this might be addressed by capturing 
clinical staging information in the WECC database. Precise pathological identification 
is particularly pertinent when assessing tumor differentiation in individuals with early 
stage and lymph node negative esophageal cancer.
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Survival estimates after curative surgery for gastric cancer are based on AJCC staging, or 
on more accurate multivariable nomograms. However, the risk of dying of gastric cancer 
is not constant over time, with most deaths occurring in the first two years after resection. 
Therefore, the prognosis for a patient who survives this critical period, improves.  This 
improvement over time is termed Conditional Probability of Survival (CPS). Objectives 
of this study were to develop a CPS nomogram predicting 5-year disease-specific survival 
(DSS) from the day of surgery for patients surviving a specified period of time after a 
curative gastrectomy, and to explore whether variables available with follow-up improve 
the nomogram in the follow-up setting.
patients and methods
A CPS nomogram was developed from a combined US-Dutch dataset, containing 1642 
patients who underwent an R0 resection with or without chemotherapy/radiotherapy for 
gastric cancer. Weight loss, performance status, hemoglobin, and albumin one year after 
resection were added to the baseline variables of this nomogram.
results
The CPS nomogram was highly discriminating (concordance index: 0.772). Surviving 
one, two, or three years gives a median improvement of 5-year DSS from surgery of 
7.2%, 19.1%, and 31.6%, as compared to the baseline prediction directly after surgery. 
Introduction of variables available at one year follow-up did not improve the nomogram.
conclusions
A robust gastric cancer nomogram was developed, to predict survival for patients alive at 
time points after surgery. Introduction of additional variables available after one year of 
follow-up did not further improve this nomogram.
47chapter 4
introduction
Survival estimates for individual gastric cancer patients are usually based on AJCC 
staging,1 or on more accurate multivariable nomograms.2 A 5-year survival estimate 
based on either AJCC staging or a nomogram, represents the probability for a patient to 
be alive 5 years after surgery. 
However, the risk of dying of gastric cancer is not constant over time, with most deaths 
occurring in the first two years after a curative resection (Figure 1). Therefore, the 
prognosis (and the 5-year survival probability from the day of surgery) of a patient who 
survives this critical period improves conditionally on having survived this period after 
surgery. This improvement of prognosis over time is termed Conditional Probability of 
Survival (CPS).
CPS  is higher as compared to the survival probability at the time of surgery for a variety 
of cancers, including melanoma,3 cancer of the CNS,4 head and neck,5 breast,6 lung,7 
colon,8,9 ovaries,10 and stomach.11 For gastric cancer, the difference between initial and 
conditional survival probability is greatest in patients with high stages who have a 
corresponding poor initial prognosis.11 
Nomograms represent multivariable models predicting survival of individual patients 
based on several patient-specific parameters.12 A US-derived nomogram predicting 
disease-specific survival (DSS) after an R0 resection for gastric cancer showed a high 
predictive accuracy with internal validation,2 as well as external validation in Dutch13, 
German14, and Turkish15 patients. This nomogram is based on patient and tumor 
characteristics of patients who underwent curative surgical resection alone, without 
adjuvant therapy. With the increasing clinical practice of preoperative and postoperative 
therapy for advanced gastric cancer, we felt that these patients should be included in an 
updated nomogram. 
Although the current nomogram accurately estimates 5-year DSS directly after R0 
surgery, it does not estimate the improved conditional survival of patients who remain 
alive at time points following resection, and is therefore not useful in the follow-up setting. 
Furthermore, we hypothesized that factors representing the patient’s clinical status in 
the follow-up setting, such as weight loss and performance status, might contribute to 
and influence the estimate of patient prognosis in the follow-up setting in addition to 
variables available directly after surgery.
The first purpose of the current study is to develop a new, clinically useful nomogram 
predicting 5-year DSS after an R0 resection for gastric cancer, with or without 
chemotherapy and/or radiotherapy. The second purpose is to incorporate into this new 
nomogram the ability to predict conditional 5-year DSS from the day of surgery for 
patients surviving a specified period of time after an R0 resection for gastric cancer. The 
third purpose is to see if the introduction of variables available at one year of follow-up 




The final dataset was derived from two prospective clinical databases. 
The first database was from Memorial Sloan-Kettering Cancer Center (MSKCC), 
prospectively maintained since 1985, and the source of data for the initial gastric cancer 
nomogram.2 This database contains information on 1473 patients who underwent 
curative resection for an adenocarcinoma of the stomach with or without (neo)adjuvant 
therapy, between January 1996 and December 2009. The study was approved by the 
MSKCC Institutional Review Board.
This dataset was combined with a Dutch dataset on which the original nomogram was 
validated,13 containing information on 1078 patients who were randomized to undergo 
D1 or D2 lymph node dissection for adenocarcinoma of the stomach between 1989 and 
1993, without receiving chemotherapy or radiation.16,17 This study was approved by the 
principal investigator of the Dutch Gastric Cancer Trial.
From this combined dataset, patients with M1 disease (N = 441), patients with a positive 
resection margin (R1, R2, N = 216), and patients without all original nomogram variables 
available (N = 245) were excluded. Of the patients who died of unknown cause (N = 40), 
7 were excluded and 33 were included as censored, leaving 1642 patients in the currently 
reported analyses. When the nomogram was regenerated excluding all 40 patients who 
died of unknown cause, no differences in CI were detected. The cause of death was 
based on available information on disease recurrence, which was generally confirmed 
with radiology, endoscopy, and/or histology.
survival analyses
Disease-specific survival (DSS) was calculated from the day of surgery until the day 
of death of gastric cancer (event), or death of other causes or the last day of follow-up 
(censored). The day of R0 surgery was chosen as the starting point for survival as this is 
the moment that all patients were considered ‘disease-free’. The DSS hazard curve was 
plotted using kernel density smoothing.18






















5-Year DSS in this study is defined as the probability of 5-year DSS from the day of surgery.
Conditional Probability of Survival (CPS) was defined as the probability of DSS at five 
years from the day of surgery, given that the patient had not died of gastric cancer at 
a specified period of time (x years) after surgery. Calculations of CPS were performed 
using the standard definition of conditional probability:19
CPS (5|x) = S (5) / S (x)
in which
CPS (5|x) =  DSS probability 5 years after surgery, given the patient did not die of 
  disease x years after surgery
S (5) =  DSS probability 5 years after surgery
S (x) =  DSS probability x years after surgery
For example, a patient’s 1-year survival probability is 0.8, whereas his 5-year survival 
probability is 0.4. The probability of surviving the first 5 years after surgery, given that the 
patient already has survived the first year, is calculated as follows:
CPS (5|1) = S (5) / S (1) = 0.4 / 0.8 = 0.5
So, this patient’s CS (5|1) is 0.5, which is higher than the originally 5-year survival 
probability (5|0), which is 0.4.  
1. new nomogram predicting 5-year dss
The first purpose of the study was to develop a new, clinically relevant nomogram, 
predicting 5-year DSS after an R0 resection for gastric cancer based on patients who 
underwent curative resection, with or without (neo)adjuvant chemotherapy and/or 
radiotherapy. Age, sex, primary site (distal, middle, proximal, and gastroesophageal 
junction), Lauren classification (diffuse, intestinal, mixed), maximum tumor diameter 
(cm), number of positive lymph nodes resected, number of negative lymph nodes resected 
and depth of invasion were entered into the Cox proportional hazards model predicting 
DSS. The effects of age, number of positive and negative lymph nodes, and invasion 
depth were modeled using restricted cubic splines. Although this new nomogram was 
initially developed to predict 5-year DSS, it also has the ability to predict DSS for any 
point in time after surgery, which is necessary for the next step.
As AJCC stage-specific survival is the most common way a prognosis of a patient is 
assessed, all patients were staged according to the 7th edition of the AJCC staging system.1 
Then, the predictive accuracy of the new nomogram was compared to that of the staging 
system.
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2. predicting cps with the new nomogram
The second purpose was to use the newly developed nomogram to predict DSS 5-years 
from the day of surgery, given that the patient had not died of gastric cancer for a specified 
time (x years) after resection. The new nomogram can give a DSS probability for any 
point in time after surgery. To calculate a CPS prediction for an individual patient, both 
the 5-year and the x-year DSS probability are predicted by the nomogram, followed by 
dividing the 5-year DSS probability by the x-year DSS probability. For patients surviving 
one, two and three years after surgery, the probability of surviving the first five years after 
surgery is calculated as follows:
CPS (5|1) = 5-year DSS probability / 1-year DSS probability
CPS (5|2) = 5-year DSS probability / 2-year DSS probability
CPS (5|3) = 5-year DSS probability / 3-year DSS probability
3. introduction of follow-up variables into the new dss-nomogram
The third purpose of this study was to evaluate if introduction of variables available at 
follow-up would improve predictive accuracy of the new nomogram. Variables used in 
this nomogram are all available directly after surgery and do not represent a patient’s 
condition at the moment of follow-up. We hypothesized that weight loss, Eastern 
Cooperative Oncology Group (ECOG) performance status (PS), hemoglobin (HGB) and 
albumin (ALB) might have additional predictive value for DSS to the original variables 
alone, given that the patient had survived a certain period in time.
Weight, PS, HGB and ALB were retrospectively recorded for one year disease-free 
survivors treated at MSKCC (N = 769), within a time interval of three months before 
or after one year of follow-up. Although the original aim was to collect these data for 
one, two and three year survivors, data availability was limited because of retrospective 
collection and smaller number of patients surviving up to two years after surgery. To 
calculate weight loss, two independent weights had to be recorded. If a weight was 
available 1-4 months before the weight measured at follow up, weight loss was calculated. 
If a patient had remained stable or gained weight, a weight loss of 0 was recorded. ECOG 
PS was recorded as 0-1 versus 2-3.
First the predictive accuracy of the nomogram using only original variables was assessed 
in one year disease-free survivors. Secondly, the nomogram was extended with the 
collected follow-up variables. Different combinations of old and new variables were used 
to explore whether incorporation of any or all of these variables improved the concordance 
index.
calculating predictive accuracy of the nomograms
The nomogram was validated using two methods. First, discrimination was quantified 
with the concordance index (CI).20 CI is a measure of how well the predictions match the 
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observed outcomes. In particular, CI is the probability that, in a randomly selected pair 
of patients, the patient with the better prediction also has the longer observed survival. 
CI of a nomogram is calculated by comparing all possible pairs of patients in the dataset, 
and adding scores of all individual pairs. The current dataset contains censored patients, 
who did not die of gastric cancer at the last follow-up. If such a patient has the shorter 
follow-up in a certain pair, it is impossible to determine which of the two patients had 
the best outcome. These pairs are called non-informative, and were excluded from 
the CI calculation. All CIs were corrected for overfit by bootstrapping. A bootstrapped 
significance test was used to assess differences between CIs. 
Secondly, calibration was assessed by grouping patients with respect to their nomogram-
predicted probabilities and then comparing the mean of the group with the observed DSS 
Kaplan-Meier estimate, correcting by bootstrap for overfit. All analyses were performed 
using R (version 2.11.0).
results
Patient characteristics are presented in Table 1. Median follow-up of all patients was 66 
months, and 565 (34%) events (death of disease) occurred in this population.
1. new nomogram predicting 5-year dss
A nomogram predicting 5-year DSS after an R0 resection for gastric cancer directly after 
surgery (0-year survivors) was developed based on the current dataset of 1642 patients 
(Figure 2). Variables that were used in the original nomogram,2 are highly predictive 
in the current dataset. The CI of the new nomogram is 0.772. A calibration plot for 
this nomogram shows a high correspondence between the predicted and actual survival 
(Figure 3a). 
Chemotherapy with or without radiation was administered to 29.5% of the patients. 
However, the addition of a variable in the nomogram indicating the use of chemotherapy 
or radiation did not improve the CI of the new nomogram. When using the current 
dataset to compare the new nomogram with the previously published nomogram,2 there 
was no difference in CI (0.772 versus 0.771, P = 0.18). 
When comparing this nomogram with the AJCC staging system 7th edition, the 
nomogram outperformed the staging system in discriminative ability (CI = 0.772 versus 
0.766, P = 0.03).
 
2. predicting cps with the new nomogram
The new nomogram can predict 5-year DSS from the day of surgery for patients alive 
at time points up to 5 years after an R0 resection for gastric cancer. The probability of 
5-year DSS from the day of surgery shows a median increase of 7.2%, 19.1% and 31.6%, 
respectively for one, two and three-year survivors, as compared to patients for who 5-year 
DSS was predicted directly after surgery (Table 2). 
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This is illustrated in Figure 3b, in which the three curves show the improvement in 
5-year DSS probability from the day of surgery for one, two and three year survivors as 
compared to 0-year survivors. 
3. introduction of follow-up variables into the original dss-nomogram
Weight loss, performance status, HGB and ALB were retrospectively recorded for patients 
that were alive and had not recurred one year after surgery. Table 3 compares the CI of 
the nomogram based on original variables only, with the CI of nomograms with follow-
up variables. Addition of weight loss, hemoglobin, albumin, and performance status or a 
combination of those did not improve the CI of the nomogram that was based on original 
variables only.
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discussion
The original gastric cancer nomogram that was published in 2003 predicts five and nine-
year DSS after an R0 resection of gastric cancer, based on patients who only received an 
R0 resection without chemotherapy or radiation.2 Although this nomogram is highly 
precise, and has been validated in databases from three different countries in Europe,13-15 
the predictive accuracy in patients who received chemotherapy or radiation has not been 
investigated. 
In the present study, a new nomogram was developed, predicting 5-year DSS for patients 
who received an R0 resection for gastric cancer, with or without chemotherapy and/
or radiation. To increase nomogram accuracy, MSKCC data were combined with data 
in which the original nomogram has been previously validated13. Incidence rates for 
Figure 2. Nomogram predicting 5-year disease-specific survival from the day of surgery based on 
1642 patients who underwent an R0 resection for gastric cancer
Instructions
Locate the patient’s sex on the Sex axis. Draw a line straight upwards to the Points axis to determine how many points towards 
gastric cancer-specific death the patient receives for his or her sex. Repeat this process for the other axes, each time drawing 
straight upward to the Points axis. Sum the points achieved for each predictor and locate this sum on the Total points axis. Draw 
a line straight down to the disease-specific survival axes to find the patient’s probability of 5-year DSS from the day of surgery, 
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gastric cancer are generally comparable between the USA and the Netherlands21. When 
comparing the new with the previously published nomogram, no differences in CI 
were detected. This attests to the strength of the initial predictive model and indicates 
robustness of the new nomogram. Overall, the discriminative ability (CI) of the new 
nomogram is relatively high by standards of cancer prognosis. The calibration plot 
(Figure 3a), which shows how well the nomogram predictions (x-axis) correspond with 
the actual unconditional 5-year DSS of the patients in this study (y-axis), reveals a high 
predictive accuracy. Furthermore, the CI of the new nomogram is higher than the CI 
of the AJCC staging system, indicating more accurate predictions are provided by the 
nomogram as compared to the AJCC staging system.
With the original gastric cancer nomogram, there was no accurate way to predict the 
outcome for patients who had survived over a certain period in time after their surgery 
for gastric cancer, as the original nomogram prediction is only useful directly after 
surgery and not after a certain period of follow-up. Using the new nomogram, it is now 
possible to estimate the (improved) probability of 5-year DSS from the day of surgery for 
patients alive at time points after an R0 resection for gastric cancer. The improvement 
in prognosis ranges from a median of 7.2% for 1-year survivors to a median of 31.6% for 
Figure 3. Calibration plots for the 5-year disease-specific survival nomogram (N = 1642) 
(a) predicting 5-year DSS directly after surgery (0-year survivors) 
(b) predicting 5-year DSS conditional on surviving of gastric cancer for 1, 2 or 3 years
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Instructions Figure 3b
In the example the nomogram predicts a 5-year DSS of 40%.
- step 1: draw a line from the original (0-year survival prediction) axis.
- step 2: the probability for this patient to survive the first 5 years after surgery, without dying of gastric cancer is:
     - 40% directly after surgery (0 years survival)
     - 45% after surviving 1 year without dying of gastric cancer
     - 57% after surviving 2 years without dying of gastric cancer
     - 70% after surviving 3 years without dying of gastric cancer
55chapter 4
3-year survivors (Table 2). The added feature of the nomogram will be useful for patient 
counseling, as it is now possible to give a patient an accurate estimation of the improved 
survival probability as time after surgery goes by, and for the timing of surveillance, 
clinical assessments, and diagnostic tests. For example, patients for whom the CPS after 
a certain period is nearly a 100% might consider to reduce the follow-up frequency, while 
patients with a relatively low CPS might have more frequent follow-up visits.
The CPS for an individual patient can be calculated manually with Figure 2, simply by 
entering the values and reading from the correct DSS axis in the bottom of the figure. 
CPS can also be calculated with Figure 3b, using the 0-year survival prediction from 
Figure 2. For example, a patient’s 5-year DSS probability derived from the 0-year survival 
axis in Figure 2 is 0.4. By entering the 5-year DSS probability of 0.4 on the x-axis of 
Figure 3b, the probability of 5-year DSS conditional on the fact that the patient survives 
one, two or three years after surgery can be derived from the y-axis and is 0.47, 0.58 and 
0.73 respectively. The new nomogram can also be accessed on the internet,22 and can 
calculate CPS by entering patient variables and the time of follow-up.
Extending static nomograms to provide conditional survival estimates has been 
previously illustrated for both prostate cancer and renal cell carcinoma.23,24 Both studies 
use variables available directly after surgery. Unique to the approach of the current study 
Table 3. Introduction of follow-up variables into the nomogram. All patients are one-year 
disease-free survivors from the MSKCC group
Added variables No. of patients 
with available 
data
































































aNone of the differences in CI between step 1 and step 2 were significant
WL: weight loss, PS: performance status, HGB: hemoglobin, ALB: albumin, CCI: corrected concordance index, 
event: death of disease
Table 2. Increase of 5-year DSS from the day of surgery, when compared with the baseline 
prediction directly after surgery (0-year survival), using the new nomogram
Median increase (%) IQR (%)
1 year after surgery
2 years after surgery







IQR: inter quartile range
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is the use of variables available with follow-up, as it can be assumed that there are clinical 
markers representing the current status of the patient that ultimately become more 
important than baseline characteristics and surgical variables.
The third aim of the present study was to explore whether the introduction of clinical 
variables available at follow-up could improve the accuracy of the 5-year DSS nomogram. 
This objective was based on the assumption that as time goes by after diagnosis, clinical 
factors other than surgical and pathological variables available only at the time of surgery 
may become important in predicting survival in gastric cancer. This approach is entirely 
novel in the development of nomograms. Introduction of new variables for the nomogram, 
however, did not improve the CI, as can be seen in Table 3: for most ‘cohorts’ with a 
certain newly added variable available, the CI for the nomogram with original variables 
was essentially equal to the CI of the nomogram with follow-up variables. This might be 
explained by the limited availability of follow-up variables (weight loss, PS, HGB, ALB), 
which has led to a relatively low number of one-year survivors that could be included in 
these analyses. Clinical data on two- and three-year disease-free survivors was even more 
limited and no analyses on these patients could be performed. Secondly, with the very 
high CI of the nomogram based on baseline variables, newly added follow-up variables 
would need to be very strongly predictive in order to improve the CI, which might not 
be the case with the currently used new variables. In order to reassess this question in a 
more thorough way, follow-up data should be prospectively collected at fixed time points. 
The absence of an improvement in CI with the introduction of multimodality therapy use 
in the nomogram does not necessarily indicate that chemotherapy and/or radiotherapy 
did not affect survival in the current population. Rather, the predictive accuracy of the 
current nomogram can be considered very high by means of concordance, and despite 
a proven effect on survival, multimodality therapy use was simply unable to further 
improve this concordance.
In conclusion, decisions about postoperative adjuvant therapy, and intensity of follow-
up are based on our best risk assessments at the time of surgery. However, follow-up 
is a dynamic process, with the risk of cancer-related death decreasing over time. The 
current nomogram has the ability to estimate risk of cancer-related death at time points 
after initial treatment, and offers useful insight to the patient and clinician about what to 
expect in the years ahead.
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The internationally validated Memorial Sloan-Kettering Cancer Center (MSKCC) gastric 
cancer nomogram was based on patients who underwent curative (R0) gastrectomy, 
without any other therapy. The purpose of the current study was to assess the performance 
of this gastric cancer nomogram in patients who received chemoradiotherapy after an R0 
resection for gastric cancer.
patients and methods
In a combined dataset of 76 patients from the Netherlands Cancer Institute (NKI), and 
63 patients from MSKCC, who received postoperative chemoradiotherapy (CRT) after 
an R0 gastrectomy, the nomogram was validated by means of concordance index and a 
calibration plot.
results
The concordance index for the nomogram was 0.64, which was lower than the CI of 
the nomogram for patients who received no adjuvant therapy (0.80). In the calibration 
plot, observed survival was about 20% higher than the nomogram predicted survival for 
patients receiving postoperative CRT.
conclusions
The nomogram significantly underpredicted survival for patients in the current study, 
suggesting an impact of postoperative CRT on survival in patients who underwent an 
R0 resection for gastric cancer, which has been proved by randomized controlled trials. 




Until the late nineties, surgery was considered the only treatment option for resectable 
gastric cancer.1 While complete resection remains the only potentially curative treatment, 
several recent studies have demonstrated that combining surgery with other modalities 
can improve outcome. The British MAGIC trial showed improved overall survival after 
perioperative chemotherapy for resectable, advanced gastric and distal esophageal 
cancer.2 A Japanese randomized study found improved overall survival after postoperative 
administration of S-1 (an oral fluoropyrimidine).3 The US Intergroup 0116 study 
demonstrated that postoperative chemoradiotherapy (CRT) improves overall survival 
among patients who have undergone an R0 resection for advanced gastric cancer.4 As 
a result of the Intergroup 0116 trial, postoperative CRT is now considered a standard 
treatment option for patients receiving surgery without preoperative chemotherapy for 
locally advanced gastric cancer.5,6 
The identification of patients who should undergo postoperative treatment can be done 
by postoperative AJCC tumor stage, but also with the use of nomograms. Nomograms 
are prediction tools that calculate survival probability for individual patients based on 
patient, tumor and treatment characteristics. These statistically based tools not only use 
the factors included in a clinical staging system but also incorporate additional factors 
suspected to have an effect on outcome. The internationally validated MSKCC gastric 
cancer nomogram predicts disease-specific survival (DSS) after an R0 resection for gastric 
cancer (Figure 1).7 Patients included to develop the nomogram underwent surgery only, 
and did not receive any other therapy. Therefore, the nomogram can be used to identify 
high-risk patients who underwent surgery only and might be candidates for postoperative 
therapy. However, it is unknown how well the nomogram will predict survival for patients 
who underwent surgery followed by postoperative chemoradiotherapy. Based on the 
survival benefit for postoperative chemoradiotherapy that was shown in the Intergroup 
0116 study, it is suspected that the nomogram will underpredict survival for patients 
receiving postoperative chemoradiotherapy. Therefore, the purpose of the current study 
was to assess the performance of the gastric cancer nomogram in patients who received 
postoperative chemoradiotherapy after an R0 resection for gastric cancer.
Patients and methods
A combined dataset with patients treated at the Netherlands Cancer Institute and patients 
treated at Memorial Sloan-Kettering Cancer Center was used for this analysis.
netherlands cancer institute phase i/ii studies
From 2000 to 2008, 113 patients with locally advanced adenocarcinoma of the stomach 
or gastroesophageal junction, stage Ib-IV according to the 6th edition of the American 
Joint Committee on Cancer (AJCC),8 underwent gastric resection followed by CRT at the 
Netherlands Cancer Institute. No patients received preoperative therapy. Patients who 
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did not undergo an R0 resection (N = 29), and patients for whom not all the nomogram 
variables were available (N = 8) were excluded, leaving 76 patients for analysis.
All patients underwent R0 gastrectomy with at least a D1 lymph node dissection, 
without routine splenectomy or pancreatic tail resection. After satisfactory recovery from 
surgery, patients were offered participation in one of the phase I-II trials of postoperative 
chemoradiotherapy.
Patients were treated with 25 fractions of 1.8 Gy of radiotherapy to a total dose of 45 Gy 
(5 fractions/week). The clinical target volume consisted of the gastric bed (with stomach 
remnant, when present), anastomoses, and draining lymph nodes. Radiotherapy was 
combined with escalating doses of capecitabine and cisplatin (N = 39),9 capecitabine 
(N = 33),10 or with fluorouracil (5-FU) and leucovorin, according to the Intergroup 0116 
scheme (N = 4) (Figure 2). The design of these studies is described in more detail in the 
original publications.9,10
Figure 1. Previously published nomogram predicting disease-specific survival (DSS) after an R0 
resection for gastric cancer
Instructions
Locate the patient’s sex on the Sex axis. Draw a line straight upwards to the Points axis to determine how many points towards 
gastric cancer-specific death the patient receives for his or her sex. Repeat this process for the other axes, each time drawing 
straight upward to the Points axis. Sum the points achieved for each predictor and locate this sum on the Total points axis. Draw 
a line straight down to the disease-specific survival axes to find the patient’s probability of surviving gastric cancer assuming he 
or she does not die of another cause first.
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memorial sloan-kettering cancer center
Patients treated at Memorial Sloan-Kettering Cancer Center (MSKCC) were selected 
from a prospectively maintained database containing information on 2590 patients who 
underwent a resection for an adenocarcinoma of the stomach between 1985 and 2009. 
Of these 2590 patients, 72 patients received postoperative chemoradiotherapy between 
2000 and 2009. Patients who received preoperative chemotherapy (N = 8) and patients 
who did not undergo an R0 resection (N = 2) were excluded, leaving 63 patients for 
analysis.
All patients underwent a gastrectomy, usually with D2 lymphadenectomy, without routine 
splenectomy or pancreatic tail resection. Postoperatively, all patients received 45 Gy of 
radiotherapy on the gastric bed (with stomach remnant, when present), anastomoses, 
and draining lymph nodes in 25 fractions of 1.8 Gy.
Radiotherapy was combined with one of several chemotherapy regimens. The majority 
of patients (N = 43) received 5-FU with leucovorin according to the Intergroup 0116 
protocol (Figure 2). The other patients received cisplatin combined with paclitaxel (N = 
10), cisplatin, paclitaxel and 5-FU (N = 2), epirubicin, cisplatin and 5-FU (N = 4) single-
agent 5-FU (N = 2), or single-agent capecitabine (N = 2). This study was approved by the 
Institutional Review Board of MSKCC.
Figure 2. Chemoradiotherapy regimens
Week 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
Intergroup 0116: 5-Fluorouracil + Leucovorin (N =  46)
5-Fluorouracil i.v.
Leucovorin i.v.  
Radiotherapy
Capecitabine (N = 33)
Capecitabine orally
Radiotherapy











Radiotherapy was administered in 5 fractions/week
i.v.: intravenous






Disease-specific survival (DSS) was calculated from the day of surgery until death of 
gastric cancer (event) or death of other causes, or alive at last follow-up (censored). The 
Cox proportional hazards model was used to compare DSS between NKI and MSKCC 
patients adjusted for factors present in the nomogram.
In agreement with our previous report, the following prognostic variables were used for 
the nomogram: age, gender, primary site (distal one-third, middle one-third, proximal 
one-third, and gastroesophageal junction), Lauren histologic type (diffuse, intestinal, 
mixed), number of positive lymph nodes resected, number of negative lymph nodes 
resected, and invasion depth. For each of the patients, the nomogram 5-year DSS 
probability was computed.
Table 1. Patient characteristics (N = 139)
Total (N = 139) NKI (N = 76) MSKCC (N = 63)
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  median (IQR) 5 (2.9-6.5) 5.0 (3.5-6.8) 4.5 (2.8-6.5)
Positive lymph nodes
  median (IQR) 4 (2-10) 4 (3-11) 5 (2-9)
Negative lymph nodes
  median (IQR) 11 (4-20) 4 (2-11) 17 (13-26)



















































Nomogram validation comprised two activities. First, discrimination was quantified with 
the concordance index (CI).11 The concordance index is similar to the area under the 
receiver operating characteristic curve, but appropriate for censored data, and ranges 
from 0.5 (no discrimination) to 1.0 (perfect discrimination). Given a randomly selected 
pair of patients, the concordance index is the probability that the patient who dies first had 
the worst predicted outcome by the nomogram. Secondly, calibration was assessed. This 
was done by grouping patients with respect to their nomogram predicted probabilities 
and then comparing the mean of the group with the observed Kaplan-Meier estimate of 
DSS. All analyses were performed using R statistical software package (version 2.11.0).
results
Table 1 depicts patient characteristics of the 139 patients that were included in the current 
study. Most patients (69.1%) were male. The median age in the NKI group (57 years) was 
lower as compared to the median age in MSKCC patients (65 years). In both groups, the 
majority of patients had a tumor in the middle (33.8%) or distal stomach (42.5%). As 
suspected, most patients (78.4%) had pathology stage III gastric cancer; this proportion 
being slightly higher for the NKI group (84.2%) than for the MSKCC group (71.4%).
With a median follow-up of 51 months, 62 patients (44.6%) had died of disease. Median 
survival was almost 6 years (71 months). On multivariate Cox regression, adjusting for the 
prediction based on all variables present in the nomogram, no significant difference in 
DSS was detected between NKI and MSKCC patients (HR 0.996, P = 0.989), indicating 
the feasibility of combining both datasets to assess the performance of the nomogram.
The nomogram performance in the current patient cohort was tested in two ways. First, 
discrimination between individual patients was assessed with the concordance index 
(CI). The CI for the nomogram was 0.64, which can be considered moderately predictive. 
Figure 3. Calibration plot of the nomogram validated in patients who received postoperative 
chemoradiotherapy (N = 139)


















However, this is lower than the CI for patients who received no adjuvant therapy, which 
was 0.80.7 Secondly, the observed and the predicted survival were compared with a 
calibration plot (Figure 3), which showed that the nomogram significantly underpredicted 
the 5-year DSS probability in the current patient cohort with about 20%.
discussion
In the current study, the performance of the existing gastric cancer nomogram was 
evaluated for patients who received postoperative chemoradiotherapy after an R0 
resection for gastric cancer. In the current patient cohort, discriminative ability, which 
was tested by means of the CI, was lower than the CI for patients who received no adjuvant 
therapy.7 As expected based on results from the Intergroup 0116 study, the nomogram 
significantly underpredicted 5-year DSS in the current patient cohort, indicating the need 
for updating nomograms with the incorporation of (neo)adjuvant strategies.
Postoperative CRT has proven to improve outcomes for patients with resectable gastric 
cancer in several early randomized trials in the eighties and nineties.12-15 However, 
patient numbers in these studies were small (below 200), limiting the value of 
this observation. The key trial supporting the use of postoperative CRT in advanced, 
resectable gastric cancer is the Intergroup 0116 trial.4 In this study, 556 patients were 
randomized after surgery for postoperative CRT with 5-FU and leucovorin, or no further 
treatment. The 5-year overall survival rate was significantly higher in patients receiving 
chemoradiotherapy (40% vs 28%), which was confirmed in a recent update with follow-
up of over 10 years.16 This trial was criticized because of the low number of D2 dissections 
(10%), the fact that patients were highly selected (only R0 resections with adequate 
postoperative recovery), the treatment compliance of 64%, and the complexity of the 
chemoradiotherapy protocol. Despite this critique, since publication of the Intergroup 
0116 results in 2001, postoperative CRT has become a standard treatment option in both 
Europe and the United States for patients undergoing curative resection of stage Ib-IV 
gastric cancer who did not receive neoadjuvant therapy.5,6 This might also be caused by 
the high number of patients who first receive surgery, after which their postoperative 
treatment plan is discussed in a multidisciplinary team. A SEER database analysis 
showed that postoperative radiotherapy use in the United States increased from 6.5% 
to 13.3% before and after 2000, likely reflecting an increased use of postoperative CRT.17 
During the past years, the concept of concurrent postoperative CRT has further evolved, 
with newer, potentially less toxic CRT schedules that have been tested in several studies. 
A study from Germany in which patients were treated with 45 Gy of radiotherapy plus 
folinic acid, 5-FU, paclitaxel and cisplatin, showed that this four-drug regimen has an 
acceptable toxicity profile.18 In a US Phase II study, a combination of cisplatin, paclitaxel, 
and radiotherapy showed an acceptable toxicity profile, but failed show a favourable 
disease-free survival rate.19 Several phase I/II studies from the Netherlands combining 
capecitabine with or without cisplatin with radiotherapy revealed feasibility of these 
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regimens.9,10,20 A regimen with daily capecitabine and weekly cisplatin that emerged from 
these studies is currently tested in a phase III randomized trial (CRITICS, clinicaltrials.
gov NCT00407186).
Other new regimens that have been tested include irinotecan,21 docetaxel,22 and 
liposomal cisplatin.23 A US Intergroup trial comparing the Intergroup 0116 regimen 
with postoperative CRT with epiribicin, cisplatin, and 5-FU (ECF) showed that the ECF 
regimen has an acceptable toxicity profile, without an improvement in survival compared 
to 5-FU and leucovorin.24 In the Korean ARTIST trial, 458 patients were randomized after 
gastrectomy with a D2 lymphadenectomy for postoperative chemotherapy with cisplatin 
and capecitabine with or without 45 Gy radiotherapy. Compliance for the postoperative 
schedule in both arms was high (75% and 82%), but no difference in disease free survival 
was shown.25
The currently available gastric cancer nomogram can be used to estimate 5-year and 
9-year DSS after an R0 resection for gastric cancer.7 The nomogram shows a high 
predictive accuracy with internal validation, and with external validation in several 
European datasets.26-28 This nomogram has two distinct purposes: risk stratification 
and informing patients. With risk stratification, the survival probability of an individual 
patient that is predicted by the nomogram can be used to determine if a patient is at 
high risk of recurrence, and should consider postoperative therapy. Secondly, patients 
can be informed on their risk of DSS. Because none of the patients from the datasets in 
which the nomogram was developed received any form of preoperative or postoperative 
chemotherapy or radiation, the nomogram can very well be used to stratify patients who 
underwent surgery into a high-risk and a low-risk category. This risk stratification gives 
a recommendation about postoperative therapy use. As it is expected that postoperative 
chemoradiotherapy will improve survival, it can be hypothesized that the nomogram will 
underpredict survival in patients receiving postoperative chemoradiotherapy.
In the current study, the performance of the gastric cancer nomogram was assessed 
in a cohort of 139 patients who received postoperative CRT after an R0 resection for 
gastric cancer, without receiving preoperative therapy. Different CRT schedules were 
used reflecting the ongoing search for better and less toxic CRT regimens over the years. 
Most patients in the current study had stage III disease based on postoperative pathology, 
which is expected since these patients are candidates for adjuvant therapy. Neither of 
the populations (NKI or MSKCC) was significantly associated with better survival after 
correcting for variables present in the nomogram. 
The number of events in this dataset was too small to create a new nomogram specifically 
for patients who received postoperative CRT. However, the number of events was 
sufficient to assess the performance of the existing nomogram in this dataset. The 
concordance index, which indicates discriminative ability, was moderately high in this 
population. The calibration plot at 5-years, however, showed significant underprediction 
of the nomogram in this patient cohort of about 20%. Since postoperative CRT has 
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shown to improve survival compared to surgery alone in a randomized setting, and the 
nomogram is based on surgery only patients, this was an expected finding. Therefore, 
the nomogram provided DSS probability should not directly be used in patients who 
received postoperative CRT. Since it is unlikely that a large group of patients who received 
chemoradiation and who are sufficiently followed can be assembled to construct a 
separate nomogram, we recommend that, as a rule of thumb, approximately 20% should 
be added to the nomogram-predicted 5-year DSS probability.
In conclusion, while the gastric cancer nomogram accurately risk-stratifies patients who 
received an R0 resection alone for gastric cancer, it significantly underpredicts 5-year 
DSS for patients who receive postoperative CRT after an R0 resection for gastric cancer. 
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abstract
Stomach cancer is one of the most common cancers worldwide, despite its declining overall 
incidence. Although there are differences in incidence, etiology and pathological factors, 
most studies do not separately analyze cardia and non-cardia gastric cancer. Surgery is 
the only potentially curative treatment for advanced, resectable gastric cancer, but the 
locoregional relapse rate is high with a consequently poor prognosis. To improve survival, 
several preoperative and postoperative treatment strategies have been investigated. 
Whereas perioperative chemotherapy and postoperative chemoradiation are considered 
standard therapy in the Western world, in Asia postoperative monochemotherapy with S-1 
is often used. Several other therapeutic options, though generally not accepted as standard 
treatment are postoperative combination chemotherapy, hyperthermic intraperitoneal 
chemotherapy and preoperative radiotherapy and chemoradiotherapy. Postoperative 
combination chemotherapy does show a statistically significant but clinically equivocal 
survival advantage in several meta-analyses. Hyperthermic intraperitoneal chemotherapy 
is mainly performed in Asia and is associated with a higher postoperative complication 
rate. Based on the currently available data, the use of postoperative radiotherapy alone and 
the use of intraoperative radiotherapy should not be advised in the treatment of resectable 
gastric cancer. Western randomized trials on gastric cancer are often hampered by slow 
or incomplete accrual. Reduction of toxicity for preoperative and especially postoperative 




Gastric cancer is a major problem worldwide: it is the second leading cause of cancer 
death, affecting approximately one million new individuals per year.1 Whereas the 
incidence in males is twice as high as in females, there is also a marked geographic 
variation. Highest incidence rates occur in north-east Asia (up to 70 per 100,000), 
Eastern Europe and much of the east part of South-America, while lowest incidence rates 
are seen in North America (8 per 100,000), Africa and South and West Asia.2 Stomach 
cancers can anatomically be classified as non-cardia (fundus, corpus and antrum) and 
cardia cancers, with non-cardia cancers constituting the majority of all gastric cancers 
worldwide. Whereas the incidence of non-cardia gastric cancer has declined over the past 
decades,3,4 there has been a rapid increase in the incidence of cardia gastric cancer until 
the early nineties, which has not persisted in the current century.5-7
carcinogenesis 
Two distinct histologic types of gastric cancer have been defined by Lauren: an intestinal 
type, which is characterized by irregular tubular structures in areas of mucosal 
inflammation, and a diffuse type, which can be characterized by discohesive cells 
and pools of mucus.8 Gastric carcinogenesis of the intestinal type is thought to be a 
multifactorial process involving irritation of the mucosa by environmental factors, acid 
secretion and bacterial nitrite and N-nitroso compounds production from dietary nitrates. 
The intestinal type gastric cancer is mostly found in the distal stomach and typically 
arises through the Correa’s cascade, progressing from the successive steps of normal 
gastric epithelium infected by Helicobacter pylori, leading to acute and chronic gastritis, 
atrophic gastritis, intestinal metaplasia, dysplasia and finally gastric carcinoma.9,10 Very 
little is known about the development of diffuse gastric cancer, although in the autosomal 
dominantly inherited syndrome of hereditary diffuse gastric cancer (HDGC), loss of 
polarity of gastric stem or progenitor cells has been suggested to lead to the formation of 
foci of signet ring cells that invade the lamina propria.11,12
etiology 
Childhood environment is an important factor in the risk of developing gastric cancer.13,14
Environmental risk factors for non-cardia gastric cancer include Helicobacter pylori 
infection,15-17 high intake of salt and salt-preserved foods,18,19 low intake of vegetables 
and fruits,20 tobacco smoking,21,22 and achlorhydria.23 Gastric atrophy has been positively 
associated with non-cardia gastric cancer.17,24 For cardia cancer, described risk factors are 
male sex, white race,25 smoking and obesity,26,27 and gastro-esophageal reflux disease.24
Of all cancers of the stomach about 10% arise in individuals with a family history of 
gastric cancer.28 HDGC develops in subjects with a germline mutation in one allele of 
the E-cadherin gene (CDH1).29 During a recent consensus meeting of the International 
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Gastric Cancer Linkage Consortium, updated results on carriers of 58 families with a 
CDH1 mutation showed a more than 80% life-time risk of developing diffuse gastric 
cancer.30 Familial preponderance has been described in other familial cancer syndromes, 
like Lynch syndrome,31 Li-Fraumeni syndrome,32 and Peutz-Jeghers syndrome.33,34 In 
these families the intestinal type of gastric cancer prevails.
staging
In the Western world, staging is performed according to the American Joint Committee 
on Cancer (AJCC) and the International Union Against Cancer (UICC).35 The Japanese 
Gastric Cancer Association has its own staging system of gastric carcinoma.36 Until 
recently, the Japanese staging of nodal status (N) was based on location of the positive 
nodes. Nowadays both Japanese and Western systems are based on the number of 
positive lymph nodes, which seems to be more reproducible, provided that a minimum 
number of 15 lymph nodes are removed and analyzed.37 
Tumors of the gastro-esophageal junction (GEJ) are often misclassified as either 
gastric when they should be esophageal, or vice-versa. In 2000, Siewert et al. proposed 
a classification based on anatomic location: type I (adenocarcinoma of the distal 
esophagus), type II (cardia carcinoma, arising from the GEJ), and type III: (subcardial 
gastric carcinoma infiltrating the GEJ and esophagus from below, Figure 1, page 18).38 
In the latest, 7th edition of the TNM classification, tumors of the GEJ are all classified as 
esophageal cancer based on the worse prognosis of cardia and GEJ tumors as compared 
to mid and distal gastric tumors.39 Differences in stage grouping between the 6th and 7th 
edition of the AJCC staging system for gastric cancer are shown in Table 1.40,41
survival
As more than half of the patients in the Western world present with stage III or IV gastric 
cancer, overall prognosis is poor.42 A recent survey shows that 5-year survival in all gastric 
cancer patients in Europe is only 24.1%.43 Survival for all patients in the US is comparable: 
in the period 1999-2005, survival was 26.5%. For patients with metastatic disease at 
initial presentation, 5-year survival is <5%.44 In patients treated with surgery in the US in 
the period 1985-1996, stage specific 5-year survival was 58% for stage IB, 34% for stage 
II, 20% for stage IIIA  and 8% for stage IIIB.42 In contrast, Japan has 5-year survival 
rates of approximately 60%.1 This difference has been addressed to mass screening 
programs using photofluorography,45 differences in tumor biology and location with 
more intestinal subtypes and distal locations, and stage migration due to higher lymph 
node yield in Japanese series.46 In a comparative analysis between a US and a Korean 
center, multivariate analysis applying different patient and tumor characteristics and the 
number of resected lymph nodes shows a higher disease-specific survival for Korean 
patients as compared to US patients (HR 1.3, P = 0.008), suggesting the possibility of an 
intrinsic biologic difference between gastric cancer in the US and Korea.47
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recurrence patterns
With increasing cancer stage, the risk of locoregional relapse increases, thus diminishing 
survival. In a combined analysis of several autopsies series, eventually 80-93% of all 
patients developed locoregional relapse.48 A retrospective study on 367 patients with 
clinically complete recurrence data in a single center revealed that 54% of recurrences 
were locoregional, whereas distant sites were involved in 51%. Of all recurrences, 79% 
developed within the first two years.49 In a single-center study performed during 1949-
1971, reoperations as second-look procedures in 107 previously resected gastric cancer 
patients - both symptomatic and asymptomatic – revealed locoregional failure in 23% 
as the only site of relapse.50 Data from a US randomized trial showed the highest 
relapse in locoregional sites, even after postoperative chemoradiation (CRT) had been 
administered.51 
surgical treatment
Resection is a prerequisite for the curative treatment of localized gastric cancer. It can be 
divided into three major approaches: endoscopic (sub)mucosal resection or dissection 
(EMR or ESD), minimally invasive surgery and open gastrectomy. Endoscopic mucosal 
Table 1. Stage grouping for gastric cancer according to the 6th (2002) and 7th (2010) edition of the 
AJCC staging system40,41
6th edition AJCC staging system 7th edition AJCC staging system
Stage T N M Stage T N M
0 Tis N0 M0 0 Tis N0 M0
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T: Tumor classification, N: Nodal status, M: Metastases status
Bold: No changes in TNM and stage groups
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resection is only used for the treatment of early gastric cancer (EGC), which is defined as 
a tumor of the stomach limited to the mucosa or submucosa regardless of lymph node 
metastases.52 This topic will not be further covered in this review.
laparoscopic surgery
Minimal invasive surgery for the treatment of gastric cancer is mainly performed in 
Korea and Japan, with the majority of patients treated for early and distal gastric cancer. 
But with increasing laparoscopic experience and improvement in instrumentation, more 
extensive procedures and treatment of more advanced gastric cancers is becoming more 
common. Although laparoscopic gastrectomy has been performed since 1991, only four, 
mostly single-center, randomized controlled trials comparing the technique with open 
gastrectomy have been reported.53-57 Laparoscopic gastrectomy has been discussed in 
two reviews which indicate oncologic equivalency and safety based on the current small 
patient numbers.58,59 Large multicenter randomized controlled trials are necessary to 
establish the role of laparoscopy in the treatment of gastric cancer. 
extent of gastric resection and margins
Total gastrectomy is the indicated treatment for tumors located in the proximal or middle 
third of the stomach.60 As compared to a total gastrectomy, a proximal gastrectomy for 
proximal gastric cancer is associated with a markedly higher rate of complications such 
as anastomotic stenosis and weight loss.61 For distal gastric cancer, a distal gastrectomy 
is the recommended therapy provided that an adequate margin can be obtained. Two 
randomized trials investigated the impact of total versus distal gastrectomy for distal 
gastric cancer, and showed no difference in postoperative morbidity, mortality, or overall 
survival with more extensive resection.62,63
Microscopically positive resection margins (R1) are associated with a significantly worse 
prognosis as compared to a microscopically radical (R0) resection, especially in patients 
with early stage disease.64,65 An Italian study investigated the minimal margin that should 
be obtained to ensure radical surgery in T3-4 tumors, and suggested a minimum margin 
of 6 cm.66 Dutch data show that survival in patients with an R1 resection is comparable 
with patients with positive cytology after abdominal washing,67 indicating that frozen-
section examination is mandatory for potentially curative resections of gastric cancer. 
lymph node dissection
As the primary tumor penetrates more deeply through the wall of the stomach, the risk 
of lymph-node metastases increases. The Japanese Classification of Gastric Carcinoma36 
defined 16 different lymph node stations surrounding the stomach (Figure 2, page 103), 
which are divided in three groups, each group further away from the primary tumor 
site. In a D1 dissection, the stomach (total or distal) plus the perigastric lymph nodes are 
removed. For a D2 dissection, additional removal of the nodes along the left gastric, the 
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common hepatic, the splenic and the left hepatoduodenal artery is performed as well 
as some stations that are different for proximal, middle and distal tumors. With a D3 
dissection, an even more extended lymphadenectomy is performed, including paraaortic 
and posterior hepatoduodenal nodes. For adequate staging a minimum of 15 lymph 
nodes should be evaluated.37
Three prospective randomized trials have been performed that compared D1 with D2 
lymph node dissection.68-70 In an early trial, 43 patients were randomized between a D1 
or D2 dissection, and with a median follow-up of 3.1 years no differences in survival were 
detected.68 A British trial that randomized 400 patients for D1 or D2 dissection showed 
equal 5-year survival rates (35% versus 33%), but increased postoperative mortality and 
morbidity in the D2 group (13% versus 7% and 46% versus 28%).69,71 In the Dutch Gastric 
Cancer Group Trial (DGCT), 711 patients underwent a D1 or D2 gastrectomy. Initial results 
showed an increased morbidity (25% versus 43%) and mortality (4% versus 10%) in the 
D2 group, which could be partially attributed to the higher number of splenectomies 
and pancreatectomies in this group,72 while there was no significant difference in 11-year 
survival rates (30% versus 35%).70 However, a recent update revealed that gastric cancer-
related death rate after a median follow-up of 15.2 years was significantly higher in the 
D1 group (48%) compared with the D2 group (37%),73 indicating that a D2 dissection is 
the recommended type of surgery in Western countries, especially when postoperative 
mortality can be avoided. 
In Japan, a D2 lymph node dissection is seen as standard treatment for curative resections.74 
Convinced of the benefits of extended lymph node dissection, Japanese surgeons 
consider it generally unethical towards patients to run a randomized trial including an 
arm with a D1 lymph node dissection. A Japanese trial randomizing 523 patients for D2 
alone or D2 combined with paraaortic node dissection showed no significant difference 
in 5-year survival while there was a trend towards more surgery-related complications in 
the paraaortic group (28% versus 21%).75,76 In a Taiwanese study with 221 patients, for the 
first time the benefit of a D3 over a D1 lymph node dissection was detected: 5 year overall 
survival was significantly higher in the D3 group (60% versus 54%).77
In conclusion, in Western countries there has been an extensive debate on the role of 
a D2 lymph node dissection, which can now be considered the recommended type of 
surgery for advanced gastric cancer, with removal of at least 15 lymph nodes for adequate 
staging. In Asian countries at least a D2 dissection is performed.
accePted adjuvant and neoadjuvant theraPies
Because adequate locoregional or systemic control is difficult to obtain with resection 
alone, surgery can be combined with adjuvant or neoadjuvant treatment. A distinction 
between accepted and non-standard adjuvant and neoadjuvant therapies is provided in 
Table 2. Randomized studies on adjuvant and neoadjuvant treatment of gastric cancer 
are summarized in Table 3 (page 82-83).
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postoperative chemotherapy
Adjuvant chemotherapy may eliminate occult residual locoregional or metastatic disease 
after surgery. More than 30 randomized trials have been performed evaluating adjuvant 
chemotherapy in gastric cancer over the past two decades. Although the earlier trials 
were small, during the last decade trials with up to 400 patients have been performed in 
Southern Europe. Most find a small survival benefit, which is mostly non-significant.78-82 
Different treatment regimens were tested, including 5-fluorouracil-based chemotherapy 
with or without anthracyclines, with or without mitomycin C, and platinum with etoposide. 
Most of these studies are included in several meta-analyses,83-89 which all except for one84 
show a small, significant increase in survival for adjuvant chemotherapy of 3-5 percent 
point (Table 4). However, the benefit of this increase in daily clinical practice is modest.
Sakuramoto et al. were the first to show a significant benefit in overall survival for 
postoperative chemotherapy in a large, adequately powered trial performed in an Asian 
patient population. In this study 1059 patients with stage II/III gastric cancer were 
randomized following at least D2 and R0 resection between surgery alone or surgery plus 
S-1 (oral fluoropyrimidine) for 12 months. Compliance after 12 months of chemotherapy 
was 66%. After 3 years, overall survival (80% versus 70%) and relapse-free survival (72% 
versus 60%) were significantly higher in the chemotherapy group.90 Experience with S-1 
in Western  populations is limited to a combination chemotherapy study in patients with 
advanced, untreated gastresophageal cancer.91 
Overall, many early trials showed no or little advantage of postoperative chemotherapy. 
However, meta-analyses indicate a statistically significant but clinically equivocal 
survival benefit for adjuvant chemotherapy. Whereas Western trials focus on multi-drug 
Table 2. Currently available treatment strategies for advanced, resectable gastric cancer
Therapy Supporting data Comments
Accepted 
therapy
postoperative chemotherapy Sakuramoto90 S-1 only in Asia
postoperative chemoradiotherapy MacDonald51, Kim99
perioperative chemotherapy Cunningham109, 
Boige111










Sun89 only positive in meta-analyses, 
absolute survival benefit ≤ 5%
hyperthermic intraperitoneal 
chemotherapy
Yan119 small studies, high 
morbidity, mainly in Asia
preoperative radiotherapy Fiorica101, Valentini123
preoperative chemoradiotherapy Ajani98,130,131 only phase II studies
No role or 
inadequate data
postoperative radiotherapy Valentini123 meta-analysis with limited 
number of studies, 
heterogeneous design




regimens, in Japan S-1 is considered to be of superior value. Compliance for postoperative 
chemotherapy remains a problem: in most Western studies 4-6 month of combination 
chemotherapy gives compliance rates from 87% to 43%, with hematological and 
gastrointestinal toxicities as the main reasons for not completing the treatment schedule. 
None of the randomized trials distinguished between cardia or non-cardia cancer.
postoperative chemoradiotherapy
Radiosensitizing drugs, such as 5-fluorouracil, have been added to radiotherapy with 
the intent to enhance the cytotoxic effect of radiotherapy on locoregional occult residual 
disease and to reduce locoregional relapse. Four early randomized trials showed the 
benefit of 5-fluorouracil-based CRT over surgery alone,92-95 while another early study was 
negative.96 However, patient numbers in these studies were small (N = 62-191), limiting 
the value of this observation. 
The key trial supporting the role of adjuvant CRT was the US Intergroup 0116 trial,51 in 
which 556 patients with stage Ib to IV gastric cancer who had received an R0 resection 
were randomized to no further treatment or postoperative CRT. Adjuvant treatment 
consisted of one cycle 5-fluorouracil, leucovorin and 45 Gy of radiation with 7 days of 
5-fluorouracil administered in 5 weeks, followed by two more cycles of 5-fluorouracil plus 
leucovorin. Treatment compliance in the CRT group was 64%; 17% stopped treatment 
because of mostly haematologic and gastrointestinal side effects. Major reasons for 
premature discontinuation in the other patients were early disease progression or 
patient’s request. Overall survival at 5 years was significantly higher in the CRT group 
(40% versus 28%), which was confirmed in a recent update with follow-up of over 10 
years.97 Because of this trial, postoperative CRT is currently a standard option in the 
United States for patients undergoing curative resection of stage Ib-IV gastric cancer 
who did not receive neoadjuvant therapy.98 However, the study has been criticized for 
the complexity of the CRT protocol, the limited interaction between chemotherapy 
and radiotherapy, the lack of surgical quality control, and because patients were highly 
selected (only R0 resections with adequate postoperative recovery). Furthermore, CRT 
Table 4. Meta-analyses on adjuvant chemotherapy
No. of trials No. of patients Mortality risk 95% CI West/East
Hermans 199384 11 2096 0.88 (OR) 0.72-1.08 both
Earle 199983 13 1990 0.80 (OR) 0.66-0.97 West
Mari 200087 20 3658 0.82 (RR) 0.75-0.89 both
Hu 200285 14 4543 0.56 (OR) 0.40-0.79 both
Panzini 200288 18 3118 0.72 (OR) 0.62-0.84 both
Janunger 200286 21 3962 0.84 (OR) 0.74-0.96 both
Sun 200989 12 3809 0.78 (OR) 0.71-0.85 both
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































might have compensated for the low number of extended lymph node dissections, with 
only 10% of the patients undergoing a D2 dissection and 54% receiving a D0 dissection.
At the same time, an observational study from South Korea compared 446 patients who 
underwent D2 gastrectomy with 544 patients who underwent D2 gastrectomy followed 
by CRT per the Intergroup 0116 protocol.99 After a median follow-up of 66 months, there 
was a significant benefit in survival in the CRT group (57% versus 51%), indicating the 
potentially beneficial role of postoperative CRT also after extended lymphadenectomy. 
A Dutch observational study comparing 694 patients who underwent D1 or D2 surgery 
with 91 patients who underwent postoperative fluoropyrimidine-based CRT showed 
improved local control in the CRT group after a D1 dissection, but not following a D2 
dissection.100 After an R1 resection, postoperative CRT was significantly associated with 
better survival.
In a meta-analysis of postoperative CRT, 5-year overall survival is significantly higher 
with CRT as compared to surgery alone (OR 0.45, 95% CI 0.32-0.64). Despite a higher 
frequency of severe and life-threatening toxicities in the CRT group, overall compliance 
for the CRT was 73%.  The majority of patients in this analysis are nonetheless derived 
from the Intergroup trial.101 
Several phase I/II studies on CRT with new types of chemotherapy have been performed to 
improve the interaction between chemotherapy and radiotherapy. A study from Germany 
in which patients were treated with 45 Gy of radiotherapy plus folinic acid, 5-fluorouracil, 
paclitaxel and cisplatin, showed that this four-drug regimen had an acceptable toxicity 
profile.102 Three studies from the Netherlands demonstrated the feasibility of radiotherapy 
combined with daily capecitabine and cisplatin.103-105 Radiotherapy fields contained the 
gastric bed and the anastomosis, with lymph node regions depending on the location 
of the primary tumor. A side-study on renal toxicity in 44 patients from these studies 
showed that there is a progressive relative functional impairment of the left kidney 
after postoperative CRT for gastric cancer, emphasizing that radiotherapy doses to the 
kidney should be minimized by using newer techniques such as intensity modulated 
radiotherapy (IMRT) in order to reduce toxicity while gaining the full benefit of survival 
of postoperative CRT.106
In conclusion, postoperative CRT shows an advantage in survival over surgery alone, but 
the question remains whether this effect persists after an extended lymphadenectomy 
and radical resection. New treatment regimens on CRT opting for equal or better efficacy 
and reduced toxicity are currently under investigation.
peri-operative chemotherapy
The most important limitation of postoperative therapy is the impaired patient 
performance status after a gastrectomy that can hamper or even prevent delivery of 
the planned adjuvant treatment.107 Part of this is caused by the nutritional status and 
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insufficient nutritional support that is given in this patient group prone to major weight 
loss.107,108 For this reason, the concept of neo-adjuvant treatment might be a valuable 
alternative, while the postoperative therapy still can be administered when tolerated. The 
main goal of giving neo-adjuvant chemotherapy is to treat micrometastatic disease at an 
early stage and to improve resectability by tumor downsizing and downstaging.109
In the beginning of the 1990s the concept of perioperative chemotherapy was tested 
for its feasibility in a small study, showing a compliance rate of 72% and an acceptable 
toxicity profile.110 The MRC Adjuvant Gastric Infusional Chemotherapy (MAGIC) 
trial, randomized 503 patients with advanced (more than submucosal), resectable 
adenocarcinoma of the stomach, esophagogastric junction, or lower esophagus for surgery 
and perioperative chemotherapy versus surgery alone. Chemotherapy consisted of three 
preoperative and three postoperative cycles of epirubicin, cisplatin and 5-fluorouracil. 
R0 resection rates were 66% and 69% for the two groups in favor of the chemotherapy 
group, and 40% of all resections were D2 lymph node dissections. Whereas 86% of 
the patients completed the preoperative chemotherapy schedule, only 55% started 
postoperative chemotherapy and subsequently 42% completed all six courses. The most 
important reasons for not starting or finishing postoperative chemotherapy were early 
progressive disease or death, patient’s request and postoperative complications. With a 
median follow-up of 48 months, 5-year overall survival was significantly higher in the 
chemotherapy group (36% versus 23%) with no differences according to tumor site. No 
differences in postoperative morbidity and mortality were observed between the two 
treatment groups.109
A French prospective trial randomized 224 patients with adenocarcinoma of the stomach 
(25%), the GEJ (64%) or lower esophagus (11%) between chemotherapy plus surgery (N 
= 113) or surgery alone (N = 111). Chemotherapy consisted of 2-3 cycles of preoperative 
5-fluorouracil and cisplatin and was continued after surgery in case of response to 
preoperative chemotherapy or stable disease with pN+. Compliance for the preoperative 
therapy was 87%, whereas 48% of the patients completed the total regimen. With a 
median follow-up of 5.7 years, 5-year overall and disease free survival were significantly 
higher in the chemotherapy group (38% versus 24% and 34% versus 21%).111 Although the 
final report of this initially in 2007 presented study has still to be awaited, the results are 
quite similar to the MAGIC study with better outcomes for peri-operative chemotherapy 
when compared to surgery alone.
Only a few studies have been performed on preoperative chemotherapy without 
postoperative treatment. In a Dutch randomized trial 59 patients were treated with 
surgery alone (N = 30) or chemotherapy with 5-fluorouracil, doxorubicin and methotrexate 
(FAMTX) followed by surgery (N = 29). This trial was discontinued before total accrual 
was achieved because of poor accrual and a low R0 resection rate in the neo-adjuvant 
group. With a median follow-up of 83 months, this study did not show a difference in 
overall survival.112 An EORTC study randomized 144 patients between surgery versus 
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surgery preceded by folinic acid, 5-fluorouracil and cisplatin. Again, due to poor accrual, 
the trial was closed early. Although the R0 resection rate was actually lower in the 
neoadjuvant chemotherapy group (82% versus 67%), there was no difference in overall 
survival.113 Based on these underpowered studies, it is difficult to draw conclusions about 
the role of preoperative chemotherapy without postoperative therapy. 
the choice between established treatment paradigms
Whereas adjuvant chemotherapy with S-1 is an established regimen in Japan, the 
Western debate currently focuses on the use of postoperative CRT versus perioperative 
chemotherapy. While the Intergroup 0116 study only included patients with an R0 
resection and adequate postoperative recovery, the MAGIC study included all patients 
that were eligible for curative surgery. Therefore, results of the Intergroup 0116 and 
MAGIC study are incomparable with regards to treatment adherence and survival.51,109 In 
both studies, most toxicities were hematological or gastrointestinal, but due to a different 
way of reporting on the number of adverse effects, toxicity profiles can not be compared 
either. But what these studies do indicate is that the toxicity profile of the chemotherapy 
and radiation regimen is critical for the individual patient to complete therapy, and 
consequently for trials to complete accrual.
To compare preoperative with postoperative chemotherapy, a Swiss/Italian study 
randomized 70 patients for docetaxel, cisplatin and 5-fluorouracil either before or after 
surgery. This trial closed early because of poor accrual. In the neoadjuvant group, 75% 
completed the whole treatment schedule, as compared to 34% in the postoperative group 
(66% started with postoperative chemotherapy). Neoadjuvant chemotherapy could be 
delivered with a higher dose intensity without decreasing the chances for radical surgery 
or an increase in perioperative mortality.114
Based on these results, preoperative chemotherapy should be considered standard 
treatment in patients with advanced (more than submucosal), resectable gastric cancer. 
With a significantly higher compliance rate as compared to postoperative therapy, it not 
only reduces tumor burden, but also increases the chance for an R0 resection. When 
tolerated, adjuvant therapy should also be administered, but no standard regimen for 
this has been established. Patients with (distant) micrometastases will benefit more from 
systemic chemotherapy, but so far there is no adequate diagnostic modality or molecular 
marker to identify distant micrometastases. A different approach on predicting the 
efficacy of postoperative chemotherapy is grading histological response in the resection 
specimen after preoperative chemotherapy. Such a response, however, has not proven to 
be associated with survival in a US study.115 Patients at high risk for a local recurrence, 
for example patients who undergo an R1 resection, may benefit most from postoperative 
CRT,100 although this has not been addressed in a prospective study yet.
Questions on the use of postoperative chemotherapy or CRT, after preoperative 
chemotherapy and surgery, are prospectively addressed in the Dutch CRITICS trial, 
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in which patients receive 3 cycles of preoperative ECC (epirubicin, cisplatin, and 
capecitabine), followed by D1+ surgery (D2 dissection without a splenectomy or 
pancreatectomy). Postoperative therapy consists of another three cycles of ECC, or CRT 
with capecitabine and cisplatin without epirubicine.116
non-standard adjuvant and neo-adjuvant theraPies
intraperitoneal chemotherapy
With a curative resection for gastric cancer, positive peritoneal washings occur in 7% of 
the patients,117 whereas more than 50% will develop a peritoneal carcinomatosis at some 
point during follow-up. Risk factors for positive cytology include serosal invasion and 
lymph node metastases.118 The concept of intraoperative intraperitoneal chemotherapy 
(IPC) has been tested in several trials on gastric cancer. IPC can be combined with 
hyperthermia (HIPC) and can also be administered directly after surgery (early 
postoperative intraperitoneal chemotherapy, EPIC).
Most trials on IPC are included in a meta-analysis, which reports on studies where 
patients received normothermic IPC, HIPC, or EPIC with or without postoperative 
systemic chemotherapy. Patient numbers of the ten included, and mostly Asian, studies 
varied from 67 to 268. This meta-analysis showed a significant improvement in survival 
with HIPC alone (Hazard Ratio (HR)=0.60, 95% CI 0.43-0.83) and HIPC combined 
with EPIC (HR=0.45, 95% CI 0.29-0.68). There was also a trend towards improved 
survival with IPC, but this was not significant in combination with either EPIC alone 
or delayed (after recovery from surgery) postoperative intraperitoneal chemotherapy. 
Intraperitoneal chemotherapy was associated with higher risks of neutropenia and intra-
abdominal abscess.119
A more recent large Korean study, that was reported in abstract form only and was 
not included in the meta-analysis, randomized 640 patients with serosa-positive M0 
resectable gastric cancer to adjuvant systemic mitomycin C and doxifluridine with or 
without IPC with cisplatin. With a median follow-up of 3.5 years, overall survival was 
significantly higher in the IPC group (71% versus 60%).120 This study can be criticized 
because of differences in the adjuvant chemotherapy schedule.121
Summarizing, HIPC in Asian trials is associated with a significant benefit in survival, 
at the cost of an increased postoperative complication rate. Therefore, this treatment 
modality is used with restraint in Western countries, and is considered an investigational 
strategy, not intended for standard daily practice.
postoperative and intraoperative radiotherapy
Several studies investigated the effect of postoperative and intraoperative radiotherapy. 
A British randomized study with 436 patients found no difference in 5-year survival 
between surgery alone, surgery plus radiotherapy (45-50Gy) or surgery plus chemotherapy 
(mitomycin C, doxorubicin, and 5-fluorouracil) postoperatively. Compliance for the 
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protocol-defined dose in the radiotherapy group was 66%, with poor patient condition 
and withdrawal of consent as the most important reasons for failure.122 A meta-analysis 
reporting on pre- and postoperative radiotherapy also revealed no significant difference 
for postoperative radiation.123
Intraoperative radiotherapy (IORT) has been tested in several relatively small trials. 
In an American randomized trial, 41 patients were treated with surgery (control arm: 
early stages) and postoperative radiotherapy (control arm: advanced stages), or with 
surgery and IORT (experimental arm: all stages). Locoregional recurrence rates were 
lower for the IORT group (44% versus 92%, P < 0.001), but this did not translate in 
a difference in survival. There were no differences in complication rates.124 A German 
study that randomized 115 patients for surgery or surgery plus IORT (1x 28Gy) also did 
not show a significant difference in overall survival.125 A Russian study, however, did 
show longer survival after IORT in a post-hoc subgroup analysis: 78 patients received 
either preoperative radiotherapy (5x4Gy) followed by surgery with 20Gy IORT, or surgery 
alone. Although there was no survival difference between the two groups, for patients 
with T3-4 disease or lymph node involvement a significant benefit in survival for the 
radiotherapy group was reported.126
Based on these underpowered studies, adjuvant radiotherapy as single modality following 
surgery has no role in routine daily clinical practice. IORT might be further investigated 
in patients with unfavorable tumor characteristics.
preoperative radiotherapy
In a Chinese prospective randomized trial, 370 patients with cardia gastric cancer were 
randomized for surgery alone or preoperative radiotherapy (20x 2Gy in 4 weeks) followed 
by surgery after 2-4 weeks. The 5-year survival rates were 30% for the RT group as 
compared to 20% for the surgery alone group (P < 0.01) with a higher R0 resection rate 
in the RT group and no statistical difference in postoperative mortality and morbidity. 
Increased pathologic response rate to radiotherapy correlated with increased survival.127
A Russian study randomized 102 patients with resectable gastric cancer to radiotherapy 
(5x4Gy in 1 week) plus surgery within 5 days or surgery only. Tolerance of the radiotherapy 
scheme was acceptable. The difference in 5-year overall survival between the two groups 
(39% versus 30%) did not reach statistical significance. Subgroup analysis showed a 
tendency towards better survival in the radiotherapy group in locally advanced gastric 
cancer (T4 and tumor positive lymph nodes).128 To investigate the effect of hyperthermia 
added to preoperative radiotherapy, an Ukrainian-American study randomized 293 
patients between surgery, surgery preceded by radiotherapy (4x5Gy), and surgery with 
a similar short course of preoperative radiotherapy and hyperthermia. Radiotherapy 
showed no significant benefit over surgery alone, but hyperthermia in combination with 
the radiotherapy significantly improved 5-year survival compared to surgery alone (51% 
versus 30%).129
89chapter 6
A meta-analysis based on the abovementioned three trials showed an advantage of neo-
adjuvant radiotherapy over surgery alone in 3- and 5-year survival (OR 0.57 and OR 
0.62).101 Another meta-analysis on pre,- intra-, and postoperative radiotherapy showed a 
significant increase in 3- and 5-year survival as well (RR 1.26) with most survival benefit 
using the preoperative approach.123
In summary, data on neo-adjuvant radiotherapy are still limited, but suggest an advantage 
in survival over surgery alone. The largest trial has been performed in patients from a 
high incidence area with exclusively cardia cancer.
preoperative chemoradiotherapy
Currently, most accruing randomized trials focus on peri-operative chemotherapy and 
postoperative chemo(radio)therapy. However, several phase I/II studies have combined 
the administration of neo-adjuvant chemotherapy with neo-adjuvant radiotherapy.130-133 
Although results are promising with different chemotherapy schedules all containing 
5-fluorouracil and cisplatin, multicenter phase III trials are necessary in order to evaluate 
whether this treatment strategy can improve survival.
conclusions and future PersPectives
Surgery remains the primary curative treatment for locally advanced gastric cancer. A 
D2 dissection is the recommended type of surgery in Western countries, while in the 
East at least a D2 dissection is performed. Despite the effort to improve surgical quality, 
locoregional relapse rate remains high with a consequent poor prognosis.
Currently accepted adjuvant and neoadjuvant therapies include adjuvant chemotherapy, 
postoperative CRT, and perioperative chemotherapy. Adjuvant chemotherapy is mainly 
given in Japan with S-1, but has not been evaluated in the West because of limited experience 
with S-1 in Western patients. The Western debate focuses on the use of postoperative CRT 
versus perioperative chemotherapy, but due to different inclusion criteria, the results 
of the Intergroup 0116 and MAGIC trials are incomparable with regards to treatment 
adherence and survival. These studies do indicate, however, that the toxicity profile of 
the chemotherapy and radiation regimen is critical for patient compliance and study 
accrual. Based on the superior compliance of preoperative chemotherapy as compared 
to postoperative chemotherapy or radiation, preoperative chemotherapy should be 
considered standard treatment in patients with advanced, resectable gastric cancer. 
When tolerated, postoperative treatment should also be administered, but no standard 
regimen for this has been established. After an R1 resection postoperative CRT might 
improve survival, but it has not been compared in a prospective randomized manner 
with postoperative chemotherapy.
Several currently accruing or yet unpublished trials focus on the choice of the optimal 
postoperative treatment (Table 5). In the Dutch CRITICS trial, patients receive 3 cycles 
of preoperative chemotherapy (ECC) followed by surgery, after which they receive 
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another 3 cycles of ECC, or postoperative CRT. The Korean ARTIST trial, which finished 
accrual, randomized patients who received a D2 dissection between postoperative 
chemotherapy (cisplatin and capecitabine) and postoperative CRT. No preoperative 
therapy was administered. Feasibility data of this study were reported at ASCO-GI 2009 
showing good toxicity profiles with compliance rates of 75% versus 82%, respectively. 
Survival data of this trial have to be awaited.134 With the low cure rates of the currently 
accepted therapies, several of the currently accruing Western trials focus on improved 
chemotherapy schedules: in the British MAGIC-B trial, bevacizumab is added to 
perioperative epirubicin, cisplatin, and capecitabine. A very recent protocol change has 
included another arm with panitumumab instead of bevacizumab. The US CALGB 
80101 compares the Intergroup regimen (radiation, 5-FU, leucovorin) with radiation, 
epirubicin, cisplatin and 5-FU and has finished accrual, but final outcomes of this study 
have to be awaited.
Western randomized controlled trials on gastric cancer are often hampered by slow or 
incomplete accrual. Reduction of toxicity for preoperative and especially postoperative 
treatment and adequate nutritional support are essential for the ongoing improvement 
of gastric cancer care. Currently accruing Asian trials mainly focus on improved adjuvant 
chemotherapy with or without immunotherapy. 
Most of the studies covered in the current review mention the rate of cardia cancer in 
the trial population. However, subgroup analyses for cardia versus non-cardia cancer 
are rarely performed. Because of the differences in epidemiological, etiological and 
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The Intergroup 0116 trial demonstrated that postoperative chemoradiotherapy (CRT) 
improves survival in gastric cancer. We retrospectively compared survival and recurrence 
patterns in two phase I-II studies evaluating more intensified postoperative CRT with 
those from the Dutch Gastric Cancer Group Trial (DGCT) that randomized patients 
between D1 and D2 lymphadenectomy.
patients and methods
Survival and recurrence patterns of 91 patients with adenocarcinoma of the stomach 
who had received surgery followed by radiotherapy combined with fluorouracil and 
leucovorin (N = 5), capecitabine (N = 39), or capecitabine and cisplatin (N = 47) were 
analyzed and compared with survival and recurrence patterns of 694 patients from the 
DGCT (369 D1, 325 D2). For both groups, the Maruyama Index of Unresected Disease 
(MI) was calculated and correlated with survival and recurrence patterns.
results
With a median follow-up of 19 months in the CRT group, local recurrence after 2 
years was significantly higher in the surgery only (DGCT) group (17% versus 5%, P 
= 0.0015). Separate analysis of CRT patients who underwent a D1 dissection (N = 39) 
versus DGCT-D1 (N = 369) showed fewer local recurrences after chemoradiation (2% 
versus 18%, P = 0.001), while comparison of CRT-D2 (N = 25) vs DGCT-D2 (N = 325) 
demonstrated no significant difference. CRT significantly improved survival after a 
microscopically irradical (R1) resection. The MI was found to be a strong independent 
predictor of survival.
conclusion
Following D1 surgery, the addition of postoperative CRT had a major impact on local 
recurrence in operable gastric cancer.
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introduction
Gastric cancer is the second leading cause of cancer death worldwide,1 and responsible for 
8.1% of all cancer deaths in Europe.2 Surgery is the only possible curative treatment, and 
results of gastrectomy with respect to survival, morbidity, and mortality have improved 
through the years.3 Despite these improvements, up to 80% of the patients who undergo 
a resection with curative intent develop locoregional recurrences.4 Although extended 
surgery has been associated with better staging and lower locoregional recurrence rates, 
randomized studies in the Western world have failed to show an improvement in survival 
with extended lymph node dissection.5-7 In one of these studies, the Dutch Gastric Cancer 
Group Trial (DGCT), 711 patients were randomized for gastrectomy between a D1 and 
D2 lymphadenectomy. Long-term results of this study showed no significant benefit in 
survival after a D2 lymphadenectomy, which was mainly due to increased postoperative 
morbidity and mortality.5 Only recently, a retrospective analysis on survival rates in the 
Netherlands before, during, and after the DGCT, showed that survival of patients with 
curatively resected non-cardia gastric cancer has improved over the last several years, 
which is most likely the result of standardization and surgical training.8
The high recurrence rate makes gastric cancer a disease difficult to cure by surgery alone, 
with 5-year survival rates after surgery of 34% to 70% for patients with stage I and II, and 
7% to 20% for stage III and IV disease.9 Recent data show that 5-year overall survival 
for all diagnosed patients in Europe is only 24.5%.10 Considering the recent advantages 
in survival that have been achieved with postoperative chemoradiotherapy (CRT)11 and 
perioperative chemotherapy,12 surgery alone is no longer the standard treatment for 
patients with resectable (more than T2N0) gastric cancer.13 
The Intergroup 0116 randomized study of 556 patients with resectable adenocarcinoma 
of the stomach or gastroesophageal junction demonstrated that postoperative CRT with 
fluorouracil and leucovorin improved 5-year overall survival (40% versus 22%), and 
local recurrence rate (19% versus 29%), compared to surgery alone.11 A recent update 
on this study confirmed these results with hazard ratios (HR) for survival (HR 1.32, P = 
0.004) and disease-free survival (HR 1.51, P < 0.001) favoring chemoradiation, after a 
median follow-up of more than ten years.14 Based on these results, postoperative CRT has 
become standard treatment for gastric cancer in the United States. In a side study, the 
investigators calculated the Maruyama Index of Unresected Disease (MI) for each patient 
to predict the likelihood that the remaining lymph nodes were tumor positive. The MI 
was found to be a powerful independent predictor of survival.15,16
From 2000 to 2008, several phase I/II trials with intensified postoperative CRT (as 
compared to the Intergroup 0116 trial) were performed in the Netherlands, and all these 
trials established the feasibility of these regimens.17-19 From these studies, a CRT regimen 
with daily capecitabine and weekly cisplatin has emerged, and is currently being tested 
in a phase III trial (CRITICS; clinicaltrials.gov NCT00407186). The objective of these 
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adjuvant strategies is to reduce the locoregional recurrence rate and improve survival. 
Therefore, in the current retrospective study, the patterns of recurrence and survival of 
patients in the phase I/II CRT studies were compared to patterns of recurrence and 
survival of patients in the DGCT, in which patients were treated with surgery only. In 
addition to these analyses, the correlation between MI and survival and recurrence 
patterns in these groups was investigated.
Patients and methods
phase i/ii chemoradiotherapy studies
From 2000 to 2008, 113 patients with histologically confirmed adenocarcinoma of the 
stomach or gastroesophageal junction, stage Ib-IV according to the American Joint 
Committee of Cancer,20 underwent gastric resection followed by CRT at the Netherlands 
Cancer Institute. For a detailed description of the study design, please refer to the original 
publications.17,18 
In summary, all patients underwent (partial) gastrectomy with preferably at least a 
D1 lymph node dissection, without routine splenectomy or pancreatic tail resection. 
After macroscopically radical gastric surgery, patients were asked to participate in the 
phase I-II studies. All patients were treated with 25 fractions of 1.8 Gy radiotherapy 
to a total dose of 45 Gy (5 fractions/week). The clinical target volume consisted of the 
gastric bed (with stomach remnant, when present), anastomoses, and draining lymph 
nodes. Radiotherapy was combined with escalating doses of fluorouracil and leucovorin 
(Intergroup 0116 scheme), capecitabine,18 or capecitabine and cisplatin17 (Figure 1). 
Follow-up after completion of treatment consisted of physical examination, lab tests 
including tumor markers every 3 months and computed tomography (CT) of the 
abdomen every 6 months.
Figure 1. Treatment design phase I/II studies
Week 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
Intergroup 0116: 5-Fluorouracil + Leucovorin (N = 5)
5-Fluorouracil i.v.
Leucovorin i.v.  
Radiotherapy
Capecitabine (N = 39)
Capecitabine orally
Radiotherapy











Radiotherapy was administered in 5 fractions/week
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dutch gastric cancer group trial, d1 versus d2
From 1989 to 1993, 1078 patients with histologically confirmed adenocarcinoma of the 
stomach without evidence of distant metastases were randomly assigned for D1 or D2 
lymph node dissection if, at laparotomy, no signs of distant lymph node, hepatic, or 
peritoneal metastases were found.5,21 D1 and D2 dissection were defined according to 
the guidelines of the Japanese Research Society for the Study of Gastric Cancer (JRSGC) 
(Figure 2).22 In D2 dissections, resection of the spleen and pancreatic tail were only 
performed in proximal tumors to achieve adequate removal of D2 lymph node stations 
10 and 11.
All patients were evaluated every 3 months during the first year and every 6 months 
thereafter. If history and physical examination were suspicious for the diagnosis of a 
relapse, this was considered sufficient. However, for the majority of patients, the 
diagnosis of recurrent disease was confirmed by radiology, endoscopy, and/or histology. 
For further details on study design, please refer to the original publications.5,21
definition of recurrence
Recurrences were categorized as local, regional or distant. Local recurrence was 
defined as recurrence in the gastric bed, regional gastric lymph nodes, or at the 
esophago/gastrojejunal anastomosis. This corresponds with the clinical target volume 
of radiotherapy. Peritoneal carcinomatosis was scored as regional recurrence. Distant 
recurrence was defined as liver or lung metastases or metastases in other organs (bone, 
brain, ovaries).
Figure 2. Lymph node stations as defined by the Japanese Research Society for Gastric Cancer24
N1 Lymph nodes (perigastric)
1 Right cardiac nodes
2 Left cardiac nodes
3 Nodes along the lesser curvature




12 Nodes at the hepatoduodenal ligament
13 Retropancreatic (perioduodenal) nodes
14 Nodes at the root of the mesentery
N2 Lymph nodes (branches coeliac axis)
7 Nodes along root left gastric artery
8 Nodes along common hepatic artery
9 Nodes around celiac axis
10 Nodes at splenic hilum
11 Nodes along splenic artery
15
N4 Lymph nodes
15 Nodes along the middle colic vein
16 Para-aortic nodes



















maruyama index of unresected disease
The MI was calculated using the Maruyama Computer Program,23 which contains data of 
4702 patients with gastric cancer treated at the National Cancer Center Hospital, Tokyo. 
The program matches a given case with the database in order to estimate the likelihood 
(percentage) of nodal disease for each of the 16 JRSGC-defined24 lymph node stations 
(Figure 2), using 7 variables: age, sex, Borrmann type of tumor, tumor size, location, 
depth, and histology. The program has shown to be highly accurate in Japanese, German, 
and Italian series.25-27  To quantify the likelihood of unresected nodal disease, the MI has 
been defined15 as the sum of nodal disease percentages for each of the regional node 
stations (1-12) not removed by the surgeon. For example, a given patient undergoes a 
gastrectomy with removal of lymph node stations 1-10. The MI of this patient is calculated 
by adding up the likelihood of disease percentages of station 11 and 12, which are left in 
situ. Previous publications have shown superior survival for patients with a MI < 5.15,16
For the DGCT, detailed lymphadenectomy data for each patient were reported. For the 
CRT group, however, only the type of lymph node dissection (D0, D1, D2) was registered. 
Therefore, we derived the resected lymph node stations from the Japanese Classification 
of Gastric Carcinoma,24 based on surgical and pathology reports.
statistical analysis
In order to account for intrinsic differences between populations, rather than 
matching, groups were adjusted for covariates in multivariate Cox proportional hazards 
models. Used covariates were: age (≥70/>70 years), sex, localization of tumor (proximal/
middle/distal/diffuse), Lauren classification (intestinal/diffuse/mixed) T-stage, N-stage, 
gastrectomy (total/subtotal), pancreatectomy, splenectomy, type of dissection (D0/D1/
D2), and radicality (R0/R1). Survival curves for the two populations are  model-based 
curves evaluated at the mean of the covariates used in the multivariate proportional 
hazards models. For the pooled MI survival analysis, Kaplan-Meier survival curves were 
calculated and the log-rank test was used to test for differences between high and low 
MI groups.
Patients from the DGCT were entered in this study if they had survived surgery, while 
patients from the phase I/II trials were only entered into this study if they had survived 
surgery and completed chemoradiotherapy. To account for the fact that patients in the 
phase I/II trials who died before entering the trial would not be present in the CRT 
group, delayed entry techniques were used for all survival and recurrence analyses.28 
For both groups, overall survival was calculated from surgery until death of any cause 
(event) or last follow-up contact (censored). Disease-free survival was calculated from 
surgery until recurrence or death (event) or the day of last follow-up without recurrence 
(censored). Times to recurrence (local, regional, distant) were calculated from surgery 
until recurrence (event) or the day of last follow-up without recurrence (censored). 




Ninety-one of 113 patients from the CRT group were suitable for analysis. Patients who 
underwent an esophageal-cardiac resection or patients with an adenocarcinoma of the 
gastroesophageal junction (N = 22) were excluded. Of the 711 patients of the DGCT 
(surgery only) who underwent a curative resection, 17 patients were excluded because 
Table 1. Patient characteristics
Chemoradiotherapy Surgery only P
N % N %
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they were classified as ‘T
0
’ or had metastatic disease, leaving 694 patients for comparative 
analysis.
Baseline characteristics are summarized in Table 1. D2 lymphadenectomy was performed 
in 46.8% of the surgery-only group compared to 27.5% in the CRT group. There were 
more microscopically irradical (R1) resections in the CRT group. Although Lauren 
classification was not available for all patients, in the CRT group there were less intestinal-
type and more diffuse-type tumors. Tumor and nodal stages were more advanced in the 
CRT group.
Figure 3. Multivariate analyses of local recurrence (LR) and overall survival (OS), 
(a) LR  all patients, (b) OS all patients, (c) LR D1 patients, (d) OS D1 patients, (e) LR D2 patients, 
(f ) OS D2 patients, HR = Hazard Ratio
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overall survival, recurrence-free survival, and recurrence rates
At time of analysis, median follow-up in the CRT group was 19 months, as compared to 
51 months in the surgery only group.
Survival and recurrence analyses revealed a significant decrease in local recurrence 
rate in the CRT group as compared to the surgery only group (HR 3.23, P = 0.0015, 
Figure 3a). Model-based local recurrence percentages after 2 years were 5% for the 
CRT group, and 17% for the surgery only group. This, however, did not translate into 
a significant difference in 2-year overall survival (71% versus 67%, HR 1.14, P = 0.51, 
Figure 3b) or recurrence-free survival (HR 0.86, P = 0.53, not shown). Analysis of the 
regional recurrence rate (peritoneal carcinomatosis) showed an advantage for the surgery 
only group (6% versus 3%, HR 0.48, P = 0.05, not shown). There was no significant 
difference in distant recurrence rate (HR 0.98, P = 0.95, not shown).
Subgroup analysis for the extent of lymphadenectomy revealed that the decrease in local 
recurrence rate was largest in patients who underwent a D1 lymphadenectomy. The rate 
of local recurrence after 2 years was significantly lower in the CRT-D1 group compared 
to the surgery-only-D1 group (2% versus 18%, HR 11.10, P = 0.001, Figure 3c). However, 
Figure 4. Kaplan-Meier survival curves for MI < 5 versus MI ≥ 5, pooled data from all 716 patients 
in which the Maruyama Index was calculated
Figure 5. Multivariate analysis with adjustment for Maruyama Index, 
(a) local recurrence, (b) overall survival
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overall survival again was not different between these two groups (80% versus 72%, HR 
1.46, P = 0.18, Figure 3d). There were no differences between patients who underwent 
a D2 resection followed by chemoradiation or a D2 resection alone with regards to local 
recurrence rate (12% versus 13%, HR 1.10, P = 0.84, Figure 3e) and overall survival (64% 
versus 63%, HR 1.05, P = 0.88, Figure 3f).
Subgroup analyses of radical (R0) and microscopically irradical (R1) gastrectomies 
demonstrated a significant improvement in 2-year overall survival in the CRT group 
following an R1 resection as compared to the surgery-only-R1 group (66% versus 29%, 
HR 2.91, P = 0.002). This coincided with a significant decrease in the local recurrence 
rate in the CRT-R1 group (6% versus 26%, HR 5.36, P = 0.02) and no significant 
differences in regional and distant recurrence rates. Although the local recurrence rate 
was significantly lower in the CRT-R0 group compared to the local recurrence rate for 
the surgery-only-R0 group (5% versus 13%, HR 2.53, P = 0.03), there was no significant 
difference in survival for patients in this subgroup.
maruyama index
The MI was calculated for 78 out of 91 patients in the CRT group, and for 638 out of 694 
patients in the surgery-only group. Median MI in the CRT group was 74.5 compared to 
25.5 in the surgery-only group. This difference is mainly explained by the low number 
of D2 dissections in the CRT group, in which only 6 patients had an MI < 5 (7.6%), 
compared to 153 (24.0%) with an MI < 5 in the surgery-only group.
Using pooled data from the CRT and the surgery-only group, comparison of patients 
with MI < 5 versus MI ≥ 5 shows that survival is superior for patients with an MI < 5 with 
2-year survival rates of 82% versus 59% (P < 0.001, Figure 4). In this analysis, only the 
predictive power of MI is tested. The number of patients in the CRT group was too low 
to test the predictive value of MI within this group.
To assess the probability that patients who receive postoperative chemoradiation benefit 
over patients with the same MI who receive only surgery, a multivariate analysis between 
the two groups, with only MI as a linear covariate, was performed. This analysis revealed 
a significant benefit in time to local recurrence for the CRT group (8% versus 22%, HR 
2.85, P = 0.003), and, again, no significant difference in 2-year overall survival between 
the groups (68% versus 65%, HR 1.13, P = 0.51) (Figure 5).
discussion
Extended lymph node dissection in resectable gastric cancer has never been indisputably 
proven to increase survival significantly in Western studies.5-7 Several (neo)adjuvant 
treatment strategies have been studied in order to improve outcome for patients with 
gastric cancer,29,30 but it was not until 2001, and again in 2006, that two studies revealed 
that patients with gastric cancer could actually benefit from such a treatment strategy.11,12 
The Intergroup 0116 trial, which now has a median follow-up of more than 10 years, 
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showed a significant benefit in overall survival and locoregional recurrence after 
postoperative CRT.11,14 This study has received major criticism because 54% of all patients 
underwent a D0 gastrectomy instead of the recommended D2 gastrectomy, leading to 
the hypothesis that postoperative CRT might have compensated for suboptimal surgery. 
Notwithstanding this, no significant differences in relapse-free survival or overall 
survival could be detected according to the extent of the dissection.31 Moreover, a Korean 
observational study did show an advantage in overall survival of 95.3 months versus 
62.6 months, respectively, in 990 patients who underwent a D2 lymphadenectomy plus 
postoperative chemoradiation (Intergroup 0116 scheme) or D2 dissection alone.32
In the present retrospective study, we demonstrate that postoperative chemoradiation 
leads to a reduction in the local recurrence rate (5% versus 17% after 2 years), without an 
advantage in regional or distant recurrence rate. This difference in recurrence does not 
lead to a significant decrease in 2-year overall survival. This may be due to the relatively 
short median follow-up period of 19 months. The effect on local recurrence persists when 
adjusting for MI, which has shown to be a strong independent predictive parameter for 
relapse-free and overall survival.15,16 The effect of CRT on local recurrence is especially 
strong in patients who received a D1 lymphadenectomy (2% versus 18% after 2 years), 
with possibly a trend towards longer overall survival.
In contrast to the benefit of chemoradiotherapy for patients receiving a D1 gastrectomy, 
subgroup analysis of patients who underwent a D2 lymph node dissection shows 
no advantage for postoperative CRT. Although the limited number of patients in the 
CRT-D2 group could have influenced this moderate effect of chemoradiation in the D2 
group, it suggests that, in the Western population, postoperative chemoradiotherapy has 
a higher impact following a D1 dissection than a D2 dissection. And consequently, one 
questions whether a limited D1 dissection combined with CRT is equal to an extended 
nodal resection and/or a more extensive gastric resection. 
Another subgroup that seems to particularly benefit from CRT is the subgroup of patients 
with an R1 resection. In this group, CRT improves both local recurrence rate and overall 
survival. 
Despite the benefit of CRT on local recurrence, the regional recurrence rate (peritoneal 
carcinomatosis) is higher in the CRT group. As the multivariate analyses were adjusted 
for Lauren classification, the higher number of diffuse tumors in the CRT group cannot 
explain this observation. A possible explanation might be the more intensive follow-
up with bi-annual CT scanning in the CRT group, which could have led to the earlier 
detection of asymptomatic ascites or peritoneal thickening. If this would be the case, 
this would underscore the power of local recurrence analyses as well, since the lowest 
local recurrence rates were found in a more intensively monitored group.17-19 There is no 
significant difference in the number of distant recurrences, which might be explained by 
the fact that the more aggressive locoregional treatment has limited effect on systemic 
recurrences.
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For the Intergroup 0116 study and the DGCT, MI has shown to be a strong independent 
predictor of survival and recurrence, whereas thus far the type of lymph node dissection 
has not. In the current study, MI shows to have a strong predictive value, as patients with 
an MI < 5 have superior 2-year overall survival rates. 
We emphasize that only a prospective randomized trial can provide definite answers 
to the question whether postoperative CRT has a clinical benefit over surgery with 
extended lymphadenectomy. Currently two such studies aim to answer this question. In 
a Korean trial, all patients will undergo D2 lymphadenectomy, followed by postoperative 
chemotherapy with or without concurrent radiotherapy (clinicaltrials.gov NCT00323830). 
In the second study, performed in the Netherlands and Sweden, patients will receive 3 
courses of ECC (epirubicin, cisplatin, capecitabine) followed by D2 lymphadenectomy 
without splenectomy and pancreatectomy, followed by either 3 additional courses 
of ECC or chemoradiation (capecitabine and cisplatin) (CRITICS, clinicaltrials.gov 
NCT00407186).
In conclusion, postoperative chemoradiation following surgery has a major impact on 
local recurrence in operable gastric cancer, while there seems to be no additional benefit 
on regional and distant recurrences. Especially patients with a limited D1 resection and 
patients with a microscopically irradical resection seem to benefit from CRT following 
surgery. Patients with a microscopically irradical (R1) resection also have a better overall 
survival following CRT.
111chapter 7
1 Kelley JR, Duggan JM. Gastric cancer epidemiol-
ogy and risk factors. J Clin Epidemiol 2003;56:1-
9.
2 Boyle P, Ferlay J. Cancer incidence and mortality 
in Europe, 2004. Ann Oncol 2005;16:481-488.
3 Akoh JA, Macintyre IM. Improving survival in 
gastric cancer: review of 5-year survival rates in 
English language publications from 1970. Br J 
Surg 1992;79:293-299.
4 Gunderson LL. Gastric cancer--patterns of re-
lapse after surgical resection. Semin Radiat Oncol 
2002;12:150-161.
5 Hartgrink HH, van de Velde CJ, Putter H, et al. 
Extended lymph node dissection for gastric cancer: 
who may benefit? Final results of the randomized 
Dutch gastric cancer group trial. J Clin Oncol 
2004;22:2069-2077.
6 Cuschieri A, Weeden S, Fielding J, et al. Pa-
tient survival after D1 and D2 resections for gastric 
cancer: long-term results of the MRC randomized 
surgical trial. Surgical Co-operative Group. Br J 
Cancer 1999;79:1522-1530.
7 Degiuli M, Calvo F. Survival of early gastric 
cancer in a specialized European center. Which 
lymphadenectomy is necessary? World J Surg 
2006;30:2193-2203.
8 Krijnen P, den Dulk M, Meershoek-Klein 
Kranenbarg E, Jansen-Landheer ML, van de 
Velde CJ. Improved survival after resectable non-
cardia gastric cancer in The Netherlands: the im-
portance of surgical training and quality control. 
Eur J Surg Oncol 2009;35:715-720.
9 Hundahl SA, Phillips JL, Menck HR. The 
National Cancer Data Base Report on poor sur-
vival of U.S. gastric carcinoma patients treated 
with gastrectomy: Fifth Edition American Joint 
Committee on Cancer staging, proximal disease, 
and the “different disease” hypothesis. Cancer 
2000;88:921-932.
10 Sant M, Allemani C, Santaquilani M, Knijn 
A, Marchesi F, Capocaccia R. EUROCARE-4. 
Survival of cancer patients diagnosed in 1995-
1999. Results and commentary. Eur J Cancer 
2009;45:931-991.
11 Macdonald JS, Smalley SR, Benedetti J, et al. 
Chemoradiotherapy after surgery compared with 
surgery alone for adenocarcinoma of the stom-
ach or gastroesophageal junction. N Engl J Med 
2001;345:725-730.
12 Cunningham D, Allum WH, Stenning SP, 
et al. Perioperative chemotherapy versus surgery 
alone for resectable gastroesophageal cancer. N 
Engl J Med 2006;355:11-20.
13 Cunningham D, Chua YJ. East meets west in 
the treatment of gastric cancer. N Engl J Med 
2007;357:1863-1865.
14 Macdonald JS, Benedetti J, Smalley S, et al. 
Chemoradiation of resected gastric cancer: A 
10-year follow-up of the phase III trial INT0116 
(SWOG 9008). In: 2009 ASCO Annual Meet-
ing; 2009: J Clin Oncol 27:15s, 2009 (suppl; 
abstr 4515); 2009.
15 Hundahl SA, Macdonald JS, Benedetti J, 
Fitzsimmons T. Surgical treatment variation in 
a prospective, randomized trial of chemoradiother-
apy in gastric cancer: the effect of undertreatment. 
Ann Surg Oncol 2002;9:278-286.
16 Peeters KC, Hundahl SA, Kranenbarg EK, Hart-
grink H, van de Velde CJ. Low Maruyama index 
surgery for gastric cancer: blinded reanalysis of the 
Dutch D1-D2 trial. World J Surg 2005;29:1576-
1584.
17 Jansen EP, Boot H, Dubbelman R, Bartelink 
H, Cats A, Verheij M. Postoperative chemora-
diotherapy in gastric cancer -- a Phase I/II dose-
finding study of radiotherapy with dose escalation 
of cisplatin and capecitabine chemotherapy. Br J 
Cancer 2007;97:712-716.
18 Jansen EP, Boot H, Saunders MP, et al. A phase 
I-II study of postoperative capecitabine-based 
chemoradiotherapy in gastric cancer. Int J Radiat 
Oncol Biol Phys 2007;69:1424-1428.
19 Jansen EP, Boot H, Dubbelman R, Verheij 
M, Cats A. Postoperative chemoradiotherapy in 
gastric cancer--a phase I-II study of radiothera-
py with dose escalation of weekly cisplatin and 
daily capecitabine chemotherapy. Ann Oncol 
2009;21:530-534.
20 Greene FL. AJCC Cancer Staging Manual. 6 
ed. New York: Springer-Verlag; 2002.
21 Bonenkamp JJ, Hermans J, Sasako M, et al. Ex-
tended lymph-node dissection for gastric cancer. N 
Engl J Med 1999;340:908-914.
22 Kajitani T. The general rules for the gastric cancer 
study in surgery and pathology. Part I. Clinical 
classification. Jpn J Surg 1981;11:127-139.
23 Siewert JR, Kelsen D, Maruyama K. Gastric 
Cancer Diagnosis and Treatment—an Interac-
tive Training Program. In. New York: Springer 
Electronic Media; 2000.
24 Japanese Research Society for Gastric Cancer, 
Japanese Classification of Gastric Carcinoma, 
First English Edition. Tokyo: Kanehara; 1995.
25 Bollschweiler E, Boettcher K, Hoelscher AH, 
et al. Preoperative assessment of lymph node me-
tastases in patients with gastric cancer: evaluation 
of the Maruyama computer program. Br J Surg 
1992;79:156-160.
26 Guadagni S, de Manzoni G, Catarci M, et al. 
Evaluation of the Maruyama computer program 
accuracy for preoperative estimation of lymph 
node metastases from gastric cancer. World J Surg 
2000;24:1550-1558.
27 Kampschoer GH, Maruyama K, van de Velde 
CJ, Sasako M, Kinoshita T, Okabayashi K. Com-
puter analysis in making preoperative decisions: a 
rational approach to lymph node dissection in gas-
tric cancer patients. Br J Surg 1989;76:905-908.
28 Klein JP, Moeschberger ML, NetLibrary Inc. 
Survival analysis techniques for censored and 
truncated data. In: Statistics for biology and 
health. 2nd ed. New York: Springer; 2003:xv, 
536 p.
29 Gianni L, Panzini I, Tassinari D, Mianulli AM, 
Desiderio F, Ravaioli A. Meta-analyses of ran-
domized trials of adjuvant chemotherapy in gas-
tric cancer. Ann Oncol 2001;12:1178-1180.
30 Mari E, Floriani I, Tinazzi A, et al. Efficacy of 
adjuvant chemotherapy after curative resection for 
gastric cancer: a meta-analysis of published ran-
domised trials. A study of the GISCAD (Gruppo 
Italiano per lo Studio dei Carcinomi dell’Apparato 
Digerente). Ann Oncol 2000;11:837-843.
references
112 part ii
31 Macdonald JS, Benedetti J, Estes N, et al. Post-
operative combined radiation and chemotherapy 
improves disease free survival (DFS) and overall 
survival (OS) in resected adenocarcinoma of the 
stomach and gastroesophageal junction: Update of 
the results of Intergroup Study INT-0116 (SWOG 
9008). . ASCO, Edition Journal of Clinical On-
cology 2004;6.
32 Kim S, Lim DH, Lee J, et al. An observational 
study suggesting clinical benefit for adjuvant post-
operative chemoradiation in a population of over 
500 cases after gastric resection with D2 nodal dis-
section for adenocarcinoma of the stomach. Int J 





preoperative chemotherapy does not influence the number of 
evaluable lymph nodes in resected gastric cancer
Johan L. Dikkena,b, Nicole C.T. van Griekenc, Pieta Krijnend, Mithat Gönene, Laura H. Tangf, 
Annemieke Catsg, Marcel Verheijh, Murray F. Brennana, Cornelis J.H. van de Veldeb, 
Daniel G. Coita
European Journal of Surgical Oncology 2012
Departments of Surgerya, Epidemiology and Biostatisticse, and Pathologyf, 
Memorial Sloan-Kettering Cancer Center, New York, USA
Department of Surgeryb, Leiden University Medical Center, Leiden, the Netherlands
Department of Pathologyc, VU University Medical Center, Amsterdam, the Netherlands
Comprehensive Cancer Center the Netherlandsd, Leiden, the Netherlands
Departments of Gastroenterology and Hepatologyg, and Radiotherapyh, the Netherlands Cancer Institute - 




While it is suggested that more than 15 lymph nodes (LNs) should be evaluated for 
accurate staging of gastric cancer, LN yield in western countries is generally low. The 
effect of preoperative chemotherapy on LN yield in gastric cancer is unknown. The aim 
of the present study is to determine whether preoperative chemotherapy is associated 
with any difference in the number of LNs obtained from specimens of patients who 
underwent curative surgery for gastric adenocarcinoma.
patients and methods 
In 1205 patients from Memorial Sloan-Kettering Cancer Center (MSKCC) and 1220 
patients from the Netherlands Cancer Registry (NCR) who underwent a gastrectomy with 
curative intent for gastric adenocarcinoma without receiving preoperative radiotherapy, 
LN yield was analyzed, comparing patients who received preoperative chemotherapy and 
patients who received no preoperative therapy.
results 
Of the 2425 patients who underwent a gastrectomy, 14% received preoperative 
chemotherapy. Median LN yields were 23 at MSKCC and 10 in the NCR. Despite this 
twofold difference in LN yield between the two populations, with multivariate Poisson 
regression, chemotherapy was not associated with LN yield of either population. Variables 
associated with increased LN yield were institution, female sex, lower age, total (versus 
distal) gastrectomy and increasing T-classification.
 
conclusions 
In this patient series, treatment at MSKCC, female sex, lower age, total gastrectomy 
and increasing primary tumor classification were associated with a higher number of 
evaluated LNs. Preoperative chemotherapy was not associated with a decrease in LN yield. 




In addition to the number of lymph node (LN) metastases,1,2 the total number of evaluated 
LNs is a strong predictor of survival after a curative resection for gastric cancer.3 In node-
negative patients a larger number of evaluated LNs is associated with better survival.4 
Although the minimum number of LNs that should be evaluated for definitive staging 
has not been defined,5 a LN yield of 15 or more has been associated with improved overall 
survival.6 More than 15 lymph nodes should be evaluated for accurate staging according 
to the American Joint Committee on Cancer (AJCC) staging manual.7,8 A lower number 
of evaluated nodes could lead to stage migration, i.e. the migration of patients into a 
less advanced nodal stage by investigating fewer lymph nodes. When fewer nodes are 
examined, lymph node metastases could be missed that would have been demonstrated 
when more lymph nodes would have been investigated.9 In Western countries, nodal 
yields are generally low. Studies report that only 29-32% of US patients who undergo a 
resection with curative intent have 15 or more nodes evaluated.6,10
With the increasing use of neoadjuvant therapy in the treatment of resectable gastric 
cancer,11-13 the question arises whether lymph node yield is influenced by the use of 
preoperative chemotherapy. If preoperative chemotherapy decreases the number 
of evaluable lymph nodes, retrieval of more than 15 nodes would be more difficult to 
achieve. Retrospective analysis of a series of patients who underwent a curative resection 
for gastric cancer prior to 1999 showed that preoperative chemotherapy (cisplatin, 
leucovorin, fluorouracil) had a marked effect on tumor cells in regional lymph nodes, 
and that the extent of this effect could be correlated with the degree of pathologic 
response of the primary tumor to chemotherapy.14 The MAGIC study, in which patients 
were randomized between surgery with preoperative and postoperative chemotherapy, or 
surgery alone, also showed that preoperative chemotherapy was associated with a lower 
number of tumor positive lymph nodes.11 Neither study reported on differences in total 
LN yield. 
In other malignancies, including rectal15-17 and breast cancer,18 preoperative therapy 
has been associated with a lower number of evaluated lymph nodes. For gastric cancer, 
data on this topic are not available. The aim of the present study was to determine if 
preoperative chemotherapy is associated with any change in the number of lymph nodes 
retrieved from surgical specimens of patients undergoing resection with curative intent 
for gastric cancer.
Patients and methods
memorial sloan-kettering cancer center
From a prospectively maintained database, 1921 patients were identified who underwent 
surgery for adenocarcinoma of the stomach (excluding tumors of the gastroesophageal 
junction) at Memorial Sloan-Kettering Cancer Center (MSKCC) between 1985 and 2009. 
Patients who underwent surgery other than total or distal gastrectomy (N = 516), patients 
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with metastatic (M1) disease identified before or during surgery (N = 161), patients 
without tumor identified on postoperative pathology (N = 26; group was too small to 
analyze separately) and patients who received preoperative radiotherapy (N = 9) were 
excluded from the analyses. Of the remaining 1209 patients, 1205 (99.7%) had available 
information on the number of evaluated LNs. Data on individual patient and tumor 
characteristics, treatment, and survival were entered into the database.
Neoadjuvant chemotherapy was administered according to hospital practice or active 
trial protocols. Patients were registered to have received preoperative chemotherapy 
if they received at least one cycle of treatment. All patients were scheduled for a D2 
lymphadenectomy with spleen preservation. Perigastric soft tissues were thoroughly 
examined in order to identify all possible lymph nodes, and multiple attempts were made 
in an effort to achieve more than 15 LNs in all specimens. The study was approved by the 
MSKCC Institutional Review Board.
netherlands cancer registry 
The Netherlands Cancer Registry (NCR) is a registry of all newly diagnosed malignancies 
in the Netherlands. Information in the NCR is routinely collected by trained registrars who 
extract this information from the hospital records. In the registry, information on patient 
and tumor characteristics is available as well as data on treatment and survival. Since 
the date of resection was not registered in the cancer registry, the date of histologically 
confirmed diagnosis was used to calculate patient’s age at operation. Before 2005, no 
data were collected on the type of gastrectomy. 
From the cancer registry, 1934 patients were selected who underwent resection for a 
primary adenocarcinoma of the stomach between 2005 and 2007. After exclusion 
of patients who underwent surgery other than total or distal gastrectomy (N = 460), 
patients with M1 disease (N = 107), patients without tumor identified on postoperative 
pathology (N = 16), patients without available data on the number of evaluated LNs (N = 
89), unknown T-stage and stage group (N = 13) and unknown tumor location (N = 29), 
1220 patients were available for analysis.
If a patient had received any preoperative chemotherapy, this was considered sufficient to 
register ‘preoperative chemotherapy’ use. Patients received surgery according to clinical 
guidelines for the treatment of gastric cancer in the Netherlands, advising at least a D1 
lymphadenectomy. TNM classification and stage group were recorded by the registrar 
based on the 6th edition (2002) of the AJCC staging system. Since data in the NCR could 
not be fully translated into the 7th edition (2010), in this study, the 6th edition is used.
In the Netherlands, an official pathology guideline has been approved only last year. 
Before that, no official Dutch guideline was available. However, in the Netherlands the 
6th edition of the AJCC staging manual was used in the study period, requiring more 




Differences between the MSKCC and NCR populations were analyzed with the Chi-
square test for categorical variables, and the Mann-Whitney U test for continuous 
variables. LN yields were expressed as the mean and standard deviation of the number of 
LNs evaluated. Because of a twofold difference in LN yield between the two populations, 
separate analyses were performed for the MSKCC and NCR groups. Differences in 
LN yield between groups were calculated with two-sample t-tests. When more than 
Table 1. Patient characteristics
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two subgroups were tested, for ordinal subgroups t-tests were performed between 
the consecutive groups, whereas for nominal variables the first subgroup was used as 
reference for the other groups. Multivariate Poisson regression was used to model the 
number of LNs retrieved as a function of demographic and clinical factors and to identify 
significant predictors of LN retrieval. Factors that were significant in univariate analysis 
were included in the multivariate model, except tumor location (which determined the 
type of surgery that was performed), nodal status (because it is dependent on the number 
of evaluated nodes), and stage group (because it is dependent on nodal status).
In the MSKCC group, patients with unknown differentiation grade (N = 18) were excluded 
from the multivariate analysis, because of overdispersion of the multivariate model with 
these patients included. Since preoperative chemotherapy might decrease the depth of 
invasion on postoperative pathology, a second multivariate analysis without tumor stage 
was also performed. All analyses were performed using SPSS (version 17.0.0).
results
A total of 2425 patients underwent a total or distal gastrectomy with curative intent for M0 
gastric adenocarcinoma between 1985 and 2009 at MSKCC (N = 1205) or between 2005 
and 2007 in the Netherlands (N = 1220). Patient characteristics are summarized in Table 
1. Fifty-nine percent of the patients were male and the mean age was 66.9 years. About 
two-thirds of the patients underwent a distal gastrectomy. Preoperative chemotherapy 
was administered in 15% of the MSKCC patients, and in 13% of the NCR patients (P = 
0.06). In the MSKCC population, 45% of the patients were node negative, and 55% had 
positive LNs. In the NCR population, 40% of all patients were node negative, and 60% 
of the patients had positive lymph nodes (P < 0.001). Large differences in LN yield were 
observed between MSKCC patients, with a median of 23 sampled nodes (Inter Quartile 
Range 16-32), and NCR patients, with a median number of 10 (IQR 6-16) sampled nodes 
(P < 0.001). The percentage of patients with more than 15 LNs examined was 77% in the 
MSKCC group, and 26% in the NCR group (P < 0.001). Stage group distributions were 
similar between MSKCC and NCR patients.
Table 2 summarizes differences in LN yield by patient, tumor, and treatment characteristics. 
Despite significant differences in nodal yield between the two populations, chemotherapy 
was associated with very little difference in the total number of nodes analyzed. The mean 
difference of two nodes in each population was significant in the NCR population, but 
not in the MSKCC group. Differences in LN yield per T-stage based on univariate analysis 
are depicted in Figure 1. Only in the NCR T2 tumor patient subgroup the number of 
evaluated lymph nodes was significantly higher after preoperative chemotherapy, likely 
a random observation. Figure 2 indicates a decrease in LN yield with increasing patient 
age, which is underscored for both groups in the multivariate analysis.
Despite wide variations in LN yield between the populations, on multivariate Poisson 
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regression (Table 3), preoperative chemotherapy was not associated with a significant 
difference in LN yield in either population. Factors that were associated with a significant 
increase in LN yield were the same for the MSKCC and NCR groups: female gender 
(+13.2% and +9.0%), decreasing age (+3.7% and +7.1% per 10 years), total gastrectomy 
(+17.4% and +20.8%) and increasing tumor stage. Excluding tumor stage from the 
multivariate model (not shown) only changed the effect of tumor grade in the NCR 
group: this became significant. 
Table 2. Univariate analysis on the number of evaluated lymph nodes for different patient 
characteristics, separately analyzed for the MSKCC and NCR population
                    MSKCC (N = 1205)                     NCR (N = 1220)
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discussion 
Although the use of preoperative chemotherapy has been associated with a decrease in 
tumor cells in regional lymph nodes in gastric cancer,14 and has been associated with 
nodal downstaging in one recent randomized study,11 there are no reports available on 
the association of preoperative chemotherapy on the total number of evaluated lymph 
nodes in gastric cancer.
In the present study, preoperative chemotherapy was not associated with any change 
in the number of evaluated lymph nodes in gastric cancer, either in a high-volume US 
center, or a population-based cancer registry. Performing this analysis in two entirely 
different populations increases the robustness of the results, given the comparable 
outcomes in both groups.
Comparing LN yield between the two populations reveals a large difference in the median 
number of evaluated nodes. Median LN yield is 23 in the MSKCC group and 10 in the 
NCR group. A US-population-based study on gastric cancer patients also found a median 
number of 10 evaluated nodes.10 While for adequate staging more than 15 LNs should 
be evaluated,7 in the current study, the percentage of patients with more than 15 LNs 
examined was 77% in the MSKCC group, but only 26% in the NCR group. These findings 
Figure 1. Univariate comparison of lymph node yield per T category, 
(a) MSKCC patients, (b) NCR patients
Figure 2. Univariate comparison of lymph node yield per age category



















MSKCC no chemotherapy (N = 1020)
MSKCC chemotherapy (N = 185)
NCR no chemotherapy (N = 1065)
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reflect the experience of gastric cancer surgery and specimen processing of a dedicated 
cancer hospital in comparison to a nationwide group of academic and general hospitals 
where gastric cancer surgery is not centralized and is performed in lower volumes. A 
recent survey in Denmark, where gastric cancer surgery was centralized from 37 to 5 
hospitals in 2003, showed an increase in the number of patients with at least 15 LNs 
evaluated from 19% to 75% in five consecutive years.19
In the current study, on univariate analysis, preoperative chemotherapy was associated 
with a statistically significant higher LN yield in the NCR (+2 nodes), but not in the 
MSKCC group. This is not a biologically significant difference, but a consequence of the 
smaller standard deviation in the NCR group. 
With multivariate analysis, which adjusts for the other demographic and tumor 
characteristics, preoperative chemotherapy was not associated with a change in LN yield 
in either the high-volume center or the population-based registry. The difference with 
the univariate analysis may be explained by the higher percentage of patients receiving 
chemotherapy in the younger age group (<50: 29%) as compared to the older groups (50-
69: 19% and ≥70: 6%), while the younger patients also have a higher LN yield. Adjusting 
for age group in the multivariate analysis offsets this effect. In the multivariate analysis, 
Table 3. Multivariate Poisson regression on the number of evaluated lymph nodes, separately 
analyzed for the MSKCC and NCR population
            MSKCC (N = 1187)              NCR (N = 1220)
RRa 95% CI P RRa 95% CI P
Sex






Age at diagnosisb 0.963 0.942-0.985 <0.01 0.929 0.900-0.959 <0.001
Type of surgery
  distal gastrectomy (ref)





















































a The RR (relative risk) of an increase in the lymph node yield for the covariate. For example, an RR of 1.132 
means that females in the MSKCC group had 1.132 times as many lymph nodes examined 
(ie, a 13.2% increase).
b Estimates the ratio of a 10-year incremental increase in age
c 18 patients were excluded because the multivariate model was unable to fit this small group
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female gender remained associated with an increase in LN yield in both groups, with 
13% more nodes in the MSKCC group and 9% more nodes in the NCR population. 
This has previously been reported for gastric10 and rectal cancer.20 It can be hypothesized 
that differences in immune system that exist between males and females21 might be 
responsible for this difference. Increased age was associated with a decrease in lymph 
node yield, also previously described for gastric,10,22 colorectal,15 and breast cancer.23 
This might be explained by a less aggressive lymph node dissection in elderly patients, 
or possibly a lower absolute number of lymph nodes present in the elderly, due to 
age-associated changes in the immune system.24 The increase in LN yield from total 
as compared to a distal gastrectomy is an expected finding given the more extended 
operation. Increasing T-stage was also associated with an increasing LN yield. It has been 
suggested that larger tumors may cause a more intense immune response within the 
regional LNs, making them more visible to pathologic examination and possibly leading 
to higher LN yields.25 
The relation between nodal status and LN yield is complex and is influenced by multiple 
factors. First, nodal status can have an effect on LN yield: LN metastases are often 
enlarged and easier to find during surgery and specimen processing by the pathologist. 
On the one hand, the presence of LN metastases could therefore lead to an increased LN 
yield; on the other hand, it could decrease LN yield if the surgeon or pathologist limits 
the search for extra nodes once positive nodes are identified.26 The relatively uniform D2 
dissection performed in the MSKCC dataset argues against this latter possibility. This 
problem might be overcome by using fat dissolving techniques to identify all LNs present 
in a specimen,27 but this very labor intensive technique was not regularly performed in 
either of our patient populations. Secondly, LN yield determines AJCC N status (instead 
of nodal status determining LN yield), because the number of positive nodes can never 
be higher than the total number of LNs. Therefore, nodal status was left out of the 
multivariate regression model.
Similar studies have been performed for other cancer types. One study has analyzed 
the effect of preoperative chemoradiotherapy on nodal yield in adenocarcinoma 
and squamous cell carcinoma of the esophagus. No differences were detected in the 
number of lymph nodes sampled.28 For rectal cancer, several studies report a lower 
total number of lymph nodes after preoperative (chemo)radiotherapy.15-17,20,29 For breast 
cancer, conflicting results are found: some studies report a decrease in nodal yield after 
preoperative chemotherapy,18,30 while others find no difference.31,32 Overall, no uniform 
relation between preoperative therapy and nodal yield can be defined for all cancer types. 
It can however be hypothesized that preoperative radiotherapy does have an effect on LN 
yield, while for preoperative chemotherapy this effect might be dependent on the type of 
chemotherapy administered. Furthermore, different surgical and specimen processing 
techniques might influence the effect of preoperative therapy on nodal yield for different 
cancer types.
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The number of evaluated LNs in a specimen is influenced by three main factors: First, 
patient and tumor-related factors contribute to LN yield. Age, gender, activity of the 
immune system all contribute to the absolute number of LNs present in a patient. 
Enlarged, tumor positive nodes will be found more easily, thereby increasing LN yield. 
Secondly, the surgeon determines the number of nodes that are dissected, by defining 
both the extent of gastrectomy, and the extent of the lymph node dissection performed. 
The third and potentially most important factor is the pathologist, who will find a certain 
number of LNs based on specimen processing protocols, and available resources. The 
only available pathologist related factor in the current series is the study population. By 
separately analyzing the two populations, an adjustment is made for high versus low 
volume center.
In conclusion, the increasing use of systemic therapy raises the question if preoperative 
chemotherapy reduces the number of evaluated lymph nodes in gastric cancer resection 
specimens. The current study was performed in two entirely different populations: a 
high-volume cancer center and a nationwide cancer registry. In both populations, the 
administration of preoperative chemotherapy was not associated with a difference in 
LN yield. Therefore the threshold of what is considered an adequate assessment of 
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Radical surgery is the cornerstone in the treatment of resectable gastric cancer.  The 
Intergroup 0116 and MAGIC trials have shown benefit of postoperative chemoradiation and 
perioperative chemotherapy, respectively. Since these trials cannot be compared directly, 
both regimens are evaluated prospectively in the CRITICS trial. This study aims to obtain 
an improved overall survival for patients treated with preoperative chemotherapy and 
surgery by incorporating radiotherapy concurrently with chemotherapy postoperatively.
methods and design
In this phase III multicenter study, patients with resectable gastric cancer are treated 
with three cycles of preoperative ECC (epirubicin, cisplatin and capecitabine), followed 
by surgery with adequate lymph node dissection, and then either another three cycles 
of ECC or concurrent chemoradiation (45 Gy, cisplatin and capecitabine). Surgical, 
pathological, and radiotherapeutic quality control is performed. The primary endpoint 
is overall survival, secondary endpoints are disease-free survival (DFS), toxicity, health-
related quality of life (HRQL), prediction of response, and recurrence risk assessed by 
genomic and expression profiling. Accrual for the CRITICS trial is from the Netherlands, 
Sweden, and Denmark, and more countries are invited to participate.
conclusion
Results of this study will demonstrate whether the combination of preoperative 
chemotherapy and postoperative chemoradiotherapy will improve the clinical outcome 
of the current European standard of perioperative chemotherapy, and will therefore play 
a key role in the future management of patients with resectable gastric cancer.
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background
In the Western world, most patients with gastric cancer present with advanced stages 
of disease, leading to a low 5-year survival of around 25%.1,2 After surgical resection, the 
majority of patients will develop a locoregional recurrence.3 Many different strategies 
have been evaluated to improve the outcome of gastric cancer surgery. Randomized trials 
investigating the role of a more extended lymph node dissection (D2) in comparison with 
the standard D1 lymphadenectomy found no difference in overall survival, while a D2 
dissection was associated with increased postoperative mortality and morbidity.4-7
Two Western studies have changed current clinical practice in the treatment of resectable 
gastric cancer. The Intergroup 0116 study showed a significant benefit in overall survival 
with adjuvant chemoradiotherapy (CRT) consisting of 45 Gy of radiotherapy combined 
with fluorouracil (5-FU) and leucovorin, compared to surgery alone.8 In the British 
MAGIC (Medical Research Council Adjuvant Gastric Infusional Chemotherapy) study, 
a significant overall survival benefit was found favoring perioperative chemotherapy 
(epirubicine, cisplatin, and continuous 5-FU infusion, ECF-regimen) versus surgery 
alone.9
Taken the abovementioned pivotal studies together, the important question that needs 
to be answered is whether postoperative chemoradiotherapy improves survival as 
compared to postoperative chemotherapy in patients who are treated with neoadjuvant 
chemotherapy followed by gastric resection. Due to differences in study design and 
eligibility criteria between the Intergroup 0116 and the MAGIC study, comparing results 
of these trials is intrinsically not possible (Table 1). Therefore, the two regimens should 
be compared in a prospective, randomized manner. This is performed in the currently 
accruing CRITICS trial (ChemoRadiotherapy after Induction chemoTherapy In Cancer 
of the Stomach). In the present manuscript, we describe the study protocol of this trial 
and reflect on the possible implications.
methods and design
study design and objectives
The CRITICS study is an international, multicenter, randomized phase III trial. 
The primary objective is to compare overall survival between patients treated with 
neoadjuvant chemotherapy followed by surgery and either postoperative chemotherapy 
or postoperative chemoradiotherapy for resectable gastric cancer (Figure 1). Secondary 
endpoints include disease-free survival, toxicity, health-related quality of life (HRQL), 
prediction of response and recurrence risk assessed by genomic and expression profiling. 
Randomization is performed directly after entering the study, before the administration 
of preoperative chemotherapy.
The study started in January 2007 and as of May 2011, 350 patients have been included, 
while a total of 788 is required to meet the H0 hypothesis that the experimental arm 
with adjuvant chemoradiotherapy improves overall survival by 10% or more. In the first 
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two years only a few centers in the Netherlands included patients in this trial. At current 
times, about 50 centers are collaborating, and, besides the Netherlands, Sweden and 
Denmark are participating countries (clinicaltrials.gov NCT00407186).
patient selection and preoperative staging
Patients with histologically proven stage Ib-IVa (UICC 6th edition) gastric adenocarcinoma 
Table 1. Comparison of Intergroup 0116, MAGIC and CRITICS trials
General Intergroup 01168 MAGIC9 CRITICS
Accrual 1991 – 1998 1994 - 2002 2007 - 
N 556 503 788 (needed)





Histology adenocarcinoma adenocarcinoma adenocarcinoma




Stage IB-IV (M0) II-IV (M0) IB-IV (M0)
Preoperative therapy
Schedule not applicable A: ECF (3 courses)
B: none
A: ECC/EOC (3 courses)
B: ECC/EOC (3 courses)
Compliance not applicable 86% ongoing
Surgery








R0 resection 100% 





Schedule A: 5-FU/LV/RT (45Gy)
B: none
A: ECF (3 courses)
B: none
A: CC/RT (45Gy)
B: ECC/EOC (3 courses)
Compliance 64% 42% ongoing
Quality Assurance
Surgery D2 recommended
postoperative analysis of 
extent of LN dissection
not reported D1+ resection
regular feedback to indi-
vidual surgeons and 
pathologists
Radiotherapy central review of RT plan
major deviations corrected
not applicable central review of at least 




Primary endpoint overall survival overall survival overall survival
Results A: 42% 5-year OS
B: 25% 5-year OS
A: 36% 5-year OS
B: 23% 5-year OS
ongoing
A: experimental arm, B: control arm, CTV: clinical target volume, GEJ: gastroesophageal junction, OS: overall 
survival
5-FU: 5-fluorouracil, LV: leucovorin, CC: capecitabine/cisplatin, ECC: epirubicin/cisplatin/capecitabine, 
EOC: epirubicin/oxaliplatin/capecitabine, RT: radiotherapy (always 25 x 1.8 Gy in 5 weeks)
D1+ resection: removal of stations 1-9 and 11, at least 15 lymph nodes, no routine splenectomy
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are eligible for this study. The gastroesophageal junction (GEJ) may be involved, but the 
bulk of the tumor has to be in the stomach. Patients should be at least 18 years old and 
WHO performance status should be 0 or 1. Patients must have adequate hematological, 
renal and liver functions as defined in the study protocol. Left ventricular ejection 
fraction should not be lower than 50%. Exclusion criteria include: previous malignancy, 
inoperability due to technical surgery-related factors or general condition, and a solitary 
functioning kidney within the potential radiation field.
Baseline investigations consist of blood tests, an esophagogastroduodenoscopy with 
tumor biopsy samples, computed tomography (CT) of the chest and abdomen, renography, 
cardiac ejection-fraction scan, electrocardiography, and when the preoperative CT-scan 
suggests peritoneal carcinomatosis, diagnostic laparoscopy. Endoscopic ultrasonography 
and a PET-scan are optional.
Randomization is performed with stratification for Lauren classification (intestinal, 
diffuse, or mixed type adenocarcinoma, or unknown), localization (GEJ, proximal, mid, 
or distal stomach) and hospital.
preoperative chemotherapy
Within two weeks after randomization, preoperative chemotherapy is started. All patients 
are treated with 3 cycles of epirubicin, cisplatin, and capecitabine (ECC). Epirubicin 50 
mg/m2 and cisplatin 60 mg/m2 are administered on day 1 intravenously every three 
weeks, with adequate hydration. Capecitabine is given orally on days 1-14 in a dose of 
1000 mg/m2 bid. In Sweden, oxaliplatin 130 mg/m2 is administered instead of cisplatin 
in order to facilitate chemotherapy administration in the outpatient clinic setting without 
the need for prehydration. At the start of the study no reimbursement was available for 
oxaliplatin in the treatment of gastric cancer in the Netherlands. Response evaluation 
with CT-scan after two cycles of chemotherapy is aimed primarily to identify patients 
with early progression.
Figure 1. Randomization scheme
R: randomization
























Surgery is planned 3-6 weeks after the last chemotherapy course. The definitive decision 
to proceed to surgery is taken based on the absence of signs of progressive disease and 
an ASA classification of 1 or 2.
Under general anaesthesia supported by epidural anaesthesia, a midline laparotomy 
is performed, followed by a complete exploration of the abdomen including peritoneal 
surfaces, liver, and in women, the ovaries. Any free abdominal fluid is aspirated for 
cytological examination. A curative resection is not possible in case of tumor infiltration 
into the head of the pancreas requiring a Whipple procedure, para-aortic lymph node 
metastases below the renal arteries, tumor positive cytology of free peritoneal fluid, or 
peritoneal metastases that cannot be included in the planned local resection. If curative 
resection is not possible, the best palliative surgical option is to be decided upon by the 
surgeon.
Principle of surgery is a wide resection of the tumor bearing part of the stomach (total, 
subtotal or distal gastrectomy) en bloc with the N1 and N2 lymph nodes (stations 1-9 and 
11, Figure 2, page 103) with a minimum of 15 lymph nodes, without  routine splenectomy 
and resection of the pancreatic tail (D1+ lymph node dissection).10 If possible, a 
macroscopic proximal and distal margin of 5 cm should be obtained. Adjacent organs are 
only removed when there is suspicion on tumor involvement. 
The continuity of the gastrointestinal tract is restored by a Billroth II reconstruction or 
with the use of a Roux-en-Y loop. Whether the anastomosis is hand-sutured or stapled is 
left up to the surgeon. A feeding jejunostomy is strongly advocated and is left in situ until 
postoperative treatment has been completed and oral intake is adequate.
pathology
The specimen is sent to the pathologist, preferably fresh and unopened to enable the 
collection of fresh frozen tissue, followed by processing and reporting of the specimen 
according to the study protocol. The pathology report includes a minimal dataset 
containing the following items: type of tumor, localization and size of tumor, invasion 
depth, surgical margins, and number of (tumor positive) lymph nodes. All specimens 
undergo additional central pathology review for grading of histological response.11
postoperative treatment
Between 4-12 weeks following surgery, patients in the control arm are given another 
3 courses of ECC. Patients in the experimental arm are treated with radiotherapy 
combined with capecitabine and cisplatin during five weeks. Capecitabine in this 
group is administered in a dose of 575 mg/m2 bid from Monday to Friday. Cisplatin is 
administered at a dose of 20 mg/m2 intravenously with pre- and posthydration weekly. 
The chemotherapy doses are based on previous dose-finding studies in The Netherlands 
Cancer Institute (see discussion).12,13
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Radiotherapy consists of 45 Gy in 25 fractions of 1.8 Gy with a frequency of five fractions 
a week. External beam therapy is used to irradiate the tumor bed, anastomoses and 
regional lymph nodes. The clinical target volume (CTV) has to be delineated on CT-images 
based on all diagnostic information available. In defining a planning target volume (PTV), 
the CTV has to be expanded in all directions with a margin of 10 mm, except towards 
the vertebrae and kidneys, where a margin of 5 mm is applied. All 3D conformal (or 
IMRT, intensity modulated radiotherapy) techniques are allowed to get a homogeneous 
dose distribution in the PTV. AP-PA techniques are judged to be suboptimal and are 
therefore not allowed. Target volume delineation manuals and workshops are offered to 
all participating radiation oncologists. A digital CTV contouring atlas is made available 
for all local investigators by the study coordinators. Furthermore, all centers are asked 
to provide CTV contouring and treatment plans of the first three included patients (or 
of consecutive patients if considered necessary) to the study coordinators before start of 
treatment, as interobserver variability in CTV delineation for postoperative radiotherapy 
after gastric resection is large.14
toxicity and adverse events
Toxicity is measured according to NCI Common Toxicity Criteria (CTC), version 3.0. 
When preoperative chemotherapy is postponed for more than two weeks consecutively, 
chemotherapy should be discontinued and the patient should proceed to surgery when 
possible. Dose modification rules are defined in the study protocol.15 Serious adverse 
events are defined according to the rules of good clinical practice and must be reported 
within one working day.
follow-up
After treatment, patients are followed by a medical oncologist or gastroenterologist (and 
radiation oncologist when they received radiotherapy) on a monthly basis during the first 
three months, followed by three-monthly visits during the rest of the first year and visits 
every six months until five years of follow-up. Beyond the initial postoperative period, 
follow-up by the surgeon is planned every 6 months. CT-scanning and renography are 
performed every 6 months, followed by yearly scans after 2 years of follow-up. 
statistics
Based on results from the Intergroup 01168 and MAGIC9 trials, it is estimated that 
5-year overall survival in the perioperative chemotherapy group is 40% and in the 
chemoradiotherapy group 50%. In order to detect a difference between 40% and 50% 
in 5-year overall survival with a power of 80% and a significance level of 0.05, about 430 
events are required, which corresponds to a total of 788 patients. Data analysis will be 
performed according to the intention to treat principle. An interim analysis is performed 
when half of the required number of events have been observed.
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ethics
All patients receive both oral and written information about the study. Randomization 
can only take place when patients have signed an informed consent. The study is 
carried out in agreement with the declaration of Helsinki. The study has been approved 
by the Medical Ethical Committee of the Netherlands Cancer Institute – Antoni van 
Leeuwenhoek Hospital. 
quality assurance
Local monitoring has been performed for the first three patients in the first ten participating 
centers and continuation of the monitoring will be performed. Furthermore, surgical 
and pathological quality is monitored for every patient, and feedback to the individual 
surgeons and pathologists on their own performance is used to improve surgical and 
pathological quality. 
side studies
Patients fill out quality of life questionnaires EORTC QLQ-C30 and STO22 five times 
after randomization: before treatment, after preoperative chemotherapy, after surgery, 
after postoperative therapy and during follow-up after 12 months. After finishing accrual 
and survival analysis, the value of the Maruyama Index of unresected disease16 and 
the Memorial Sloan-Kettering Cancer Center (MSKCC) predictive nomogram17 will be 
investigated. Furthermore, collected tumor tissue and serum will be used for genomic 




In both the British MRC trial4,5 and the Dutch Gastric Cancer Trial (DGCT)6,7 that 
randomized gastric cancer patients for a D1 or D2 lymph node dissection, overall 
survival was not statistically different between the two groups, while a D2 dissection 
was associated with increased postoperative mortality and morbidity. This might be 
partially attributed to the higher number of splenectomies and pancreatectomies with 
a D2 dissection. Another study showed that splenectomy is associated with a twofold 
risk of postoperative complications.18 Therefore, it is suggested that performing a 
gastrectomy with dissection of at least 15 (N1 and N2) lymph nodes, but without routine 
splenectomy and resection of the pancreatic tail, a so called D1+ resection, can result in 
a better outcome.19 The rationale for a minimum of 15 nodes has been the observation 
that patients with at least 15 nodes examined have superior survival compared to patients 
with fewer nodes examined.20,21
While the Intergroup 0116 study, which had no strict surgical quality protocol, was 
criticized for its low number of per protocol prescribed D2 dissections,16 in the MAGIC 
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study the percentage of D2 dissections was higher, although no surgical or pathological 
quality measurements were performed. In the CRITICS study, the Maruyama Index (MI) 
of unresected disease is used to estimate surgical quality.16 Also, feedback to individual 
surgeons and pathologists on their own performance is used to improve surgical and 
pathological quality.
postoperative chemoradiotherapy
The Intergroup 0116 study is the key trial supporting the use of postoperative 
chemoradiotherapy in the potentially curative treatment of gastric cancer.8 Because 
of this trial, postoperative CRT is currently a standard option in the United States for 
patients undergoing curative resection of stage Ib-IV gastric cancer.22 However, the 
study has been criticized because it had no strict surgery and pathology quality protocol, 
suboptimal surgery (with 54% D0 resections while at least a D1 resection should be 
recommended), a complex, toxic and nowadays outdated chemotherapy schedule with 
minimal room for interaction with the daily radiation sessions, and the fact that patients 
were highly selected (only R0 resections with adequate postoperative recovery). In 
addition, toxicity in the chemoradiotherapy arm was substantial, with only 64% of the 
patients completing the planned treatment. In a Dutch retrospective study, postoperative 
chemoradiation after a D2 dissection was not associated with improved survival,23 in 
contrast to the results of a large observational Korean study.24
Since the Intergroup 0116 study was initiated in the early 90s, the concept of concurrent 
chemoradiotherapy has nowadays been further developed. Capecitabine, an oral prodrug 
of 5-FU, mimics continuous infusion of 5-FU, and has proven its feasibility in combination 
with cisplatin and radiotherapy in several phase I/II studies in advanced, resectable 
gastric cancer,12,25 while its systemic exposure was not found to be compromised by the 
radiation treatment.26 In these studies, acute toxicity was low, and compliance to the 
treatment protocol was high (89-100%). The maximum tolerable doses that evolved from 
these studies are currently used in the CRITICS study. Renal toxicity was addressed in a 
prospective fashion, showing a reduction in contribution of the left kidney to total renal 
function in more than half of the patients, especially after 2D radiotherapy techniques.27 
This illustrates the need for precise modern radiotherapy techniques to minimize renal 
toxicity. 
chemotherapy 
Many studies have been performed with adjuvant chemotherapy in resectable gastric 
cancer. These studies have been part of several meta-analyses, which could demonstrate 
no, or at the most a modest survival benefit for adjuvant chemotherapy.28-33 Newer 
chemotherapy schedules, with capecitabine and oxaliplatin, have shown to be as least as 
effective as schedules with 5-FU and cisplatin, with respect to overall survival (REAL-2 
study).34
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The combination of adjuvant with neo-adjuvant chemotherapy has proven its value in 
two randomized studies. In the MAGIC study, perioperative chemotherapy resulted 
in a reduction of the tumor stage, a 10% higher resectability rate and a significant 
survival benefit of 13% at 5 years.9 It should be noted that only 55% started postoperative 
chemotherapy and 42% of the patients completed the entire treatment. The major reasons 
for a premature treatment stop were tumor progression, postoperative complications, 
patients’ refusal and toxicity. A French prospective trial showed comparable results with 
48% of the patients completing the total regimen.35 The final report of this study has to be 
awaited. A recent EORTC study comparing preoperative chemotherapy and D2 surgery 
with D2 surgery alone was stopped early because of poor accrual. A higher R0 resection 
rate was found in the chemotherapy arm, but no benefit in survival was detected in this 
underpowered study.36
Due to the strong position of perioperative chemotherapy with tumor downsizing and 
downstaging the CRITICS investigators were reluctant towards a randomization arm 
without preoperative chemotherapy. Therefore, both arms have the same preoperative 
chemotherapy schedule. This also leads to comparable resection rates thus eliminating 
the effect of surgery (and preoperative therapy) on a potential survival difference between 
the two treatment arms.
future perspectives
With the CRITICS trial, several other studies on the treatment of resectable gastric cancer 
are ongoing or have just finished. In the currently accruing MAGIC-B study, patients 
are randomized between perioperative ECC courses with or without bevacizumab. In 
the Korean ARTIST trial, which finalized accrual, patients were randomized between 
postoperative chemotherapy with cisplatin and capecitabine versus chemoradiotherapy 
after a D2 gastric resection. No preoperative therapy was administered. Feasibility 
data of this study were reported at ASCO-GI 2009 showing good toxicity profiles with 
compliance rates of 75% versus 82% respectively. Survival data of this trial have to be 
awaited.37
An interesting development is the use of trastuzumab for Her2 positive tumors, which 
has shown an impressive survival benefit in metastatic gastric cancer.38 This raises 
the question if trastuzumab is a valuable addition to the currently used chemotherapy 
regimens for Her2 positive, resectable gastric cancer. But so far, no such trials have been 
initiated.
final remarks
Accrual for the CRITICS study has been expanded to Sweden and Denmark and more 
countries are invited to participate. It is expected that the results of this study will play a 
key role in the future treatment of patients with resectable gastric cancer.39 
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Quality assurance is increasingly acknowledged as a crucial factor in the (surgical) 
treatment of gastric cancer. The aim of the current study was to define a minimum set 
of evidence-based quality of care indicators for the surgical treatment of locally advanced 
gastric cancer. 
methods
A systematic review of the literature published between January 1990 and May 2011 was 
performed, using search terms on gastric cancer, treatment, and quality of care. Studies 
were selected based on predefined selection criteria. Potential quality of care indicators 
were assessed based on their level of evidence, and were grouped into structure, process, 
and outcome indicators.
results
A total of 173 articles were included in the current study. For structural measures, 
evidence was found for the inverse relationship between hospital volume and 
postoperative mortality as well as overall survival. Regarding process measures, the most 
common indicators concerned surgical technique, perioperative care and multimodality 
treatment. The only outcome indicator with supporting evidence was a microscopically 
radical resection. 
conclusions
Although specific literature on quality of care indicators for the surgical treatment of 
gastric cancer is limited, several quality of care indicators could be identified. These 
indicators can be used in clinical audits and other quality assurance programs.
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introduction
Quality assurance is increasingly acknowledged as a crucial factor in the (surgical) 
treatment of gastric cancer, mainly because outcomes between different providers 
and different countries vary considerably.1-3 In Europe, mortality rates after gastric 
cancer resections range from below 2% in specialized centers,4 to above 10% in certain 
nationwide registries,2 while in Japan mortality rates below 1% are achieved in specialized 
centers.5 Also, long term survival rates in Asian centers are superior to those in Western 
centers, and even within Europe long-term survival shows substantial differences.3,6,7 
In an attempt to reduce these variations in outcomes and to pursue delivery of high 
quality oncologic care, the European Organisation for Research and Treatment of Cancer 
(EORTC) has advocated quality assurance programs for radiotherapy and medical 
oncology.8,9 More recently, surgical audits for gastric cancer treatment were initiated in 
the United Kingdom, Denmark, and the Netherlands.10-12 
Evidence-based treatment guidelines provide a framework for clinical decision making, 
but seldom incorporate all available quality indicators. Donabedian has proposed a model 
to evaluate patient care in terms of structure, process, and outcome measures.13 With this 
model, quality of care indicators can be assessed in a structural and uniform way. This 
has been performed for esophageal cancer and breast cancer.14,15 As yet, no systematic 
assessment of quality of care indicators for gastric cancer treatment has been performed.
The aims of the present study were to identify evidence-based standards for the surgical 
treatment of locally advanced gastric cancer, based on a systematic review of the 
literature, and to construct a minimum set of quality of care indicators for registration 
and benchmarking in gastric cancer surgery.
methods
search strategy
Literature that was published between January 1990 and May 2011 was assessed through 
Pubmed, Embase, and the Cochrane library, using a search strategy that was constructed 
by a specialized librarian (Appendix). Search terms on gastric neoplasms were combined 
with treatment-related search terms (surgery, chemotherapy, and radiotherapy). Because 
there is no universal Medical Subject Headings (MeSH) term available to identify studies 
on quality of care, a variety of search terms related to this subject was used to select 
studies appropriate for this review.
selection of studies
Study selection criteria were created using a Delphi technique16 with four authors (JLD, 
JS, JWvS and MWJMW) and are shown in Table 1. Only comparative studies on locally 
advanced (at least T2), non-metastatic gastric cancer were selected. Treatment should 
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consist of a gastric resection, with or without chemotherapy and/or radiotherapy before 
and/or after the operation. Two investigators (JLD and JS) independently reviewed each 
title, abstract, and manuscript (Figure 1). Disagreements on selecting a study were solved 
by discussion, or by consulting a third reviewer (JWvS). Reference lists of the selected 
articles were then searched for additional studies.
Different levels of evidence were distinguished. A meta-analysis of at least 2 randomized 
controlled trials (RCTs) was considered the highest level of evidence. The next level of 
evidence consisted of one or more RCTs, and the lowest level of evidence comprised 
non-randomized studies (prospective or retrospective). When at least five meta-analyses 
were available for a certain indicator, RCTs on the same subject were not included in 
the current review. When at least one RCT with at least 100 patients was available for a 
certain indicator, non-randomized studies on the same subject were not included.
Figure 1. Selection process
Articles identified with search strategy (N = 5126)a
 Pubmed:  N = 2797
 Embase:  N = 1869
 The Cochrane Library: N = 460
Excluded (N = 1249)
Overlapping articles
Unique articles for review (N = 3877)
Excluded (N = 3629)
After reading title:  N = 2746
After reading abstract:  N = 743
After reading manuscript:  N = 140
Articles fulfilling selection criteria of Table 1 (N = 248)
Included (N = 44)
Extra articles from reference lists
Excluded (N = 119)b
Articles with the lowest level of available evidence
Articles with the highest available evidence for 
potential quality of care indicators (N = 173)
a The used search strategy is outlined in the Appendix
b Levels of evidence are described in the Methods section (Selection of studies)
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quality of care indicators
Potential quality of care indicators were grouped into the three categories as defined by 
Donabedian: structure, process, and outcome.13 Structure indicators relate to the setting 
in which care takes place. Process indicators refer to the actual medical treatment that is 
applied to the patient. Outcome indicators reflect the outcome of healthcare. 
To be entered into a minimum set of evidence-based quality of care indicators for gastric 
cancer surgery, indicators needed support of at least one meta-analysis, two RCTs, or one 
RCT either with at least 100 patients or with an adequate power analysis supporting less 
than 100 included patients, or at least three non-randomized studies with multivariate 
analysis. In case of conflicting evidence for a certain indicator, RCTs were considered 
decisive over non-randomized studies. For conflicting studies with equal levels of 
evidence, the number of non-supporting studies was subtracted from the number of 
supporting studies.
results
A total of 3.877 unique articles published between January 1990 and May 2011 was 
identified with the literature search. These articles were reviewed, and 248 articles 
fulfilled the selection criteria shown in Table 1. In the reference lists of the selected 
articles, 44 studies matched with the selection criteria for this study. Articles were then 
grouped by subject and categorized based on their level of evidence. In the final selection 
step, articles with the highest level of evidence for a certain indicator were separated from 
Table 1. Inclusion and exclusion criteria
Included Excluded
Publication January 1990 - May 2011
English language
before 1990, after May 2011
non-English language
Study design In order of availability:
  meta-analysis
  RCT1
  non-randomized comparative study2
non-comparative study 
(including systematic reviews, 
non-systematic reviews, 
case reports, phase I/II studies)
Study population ≥50 gastric cancer patients 
at least T2 tumor
gastric cancer patients with: 
  T1 tumor
  metastatic disease
  recurrent disease
Treatment open or laparoscopic gastric cancer surgery 










RCT: Randomized Controlled Trial
1 when at least five meta-analyses were available for a certain indicator, RCTs on the same subject were not 
included in the current review
2 when at least one RCT with at least 100 included patients was available for a certain indicator, 
non-randomized studies on the same subject were not included in the current review
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those with lower levels of evidence on that subject. In total, 173 articles were included in 
the current review (Figure 1).
structure indicators (table 2)
Many studies have been performed analyzing possible volume-outcome relations in 
gastric cancer surgery (Table 2). In the majority of these studies, the effect of hospital 
volume on postoperative mortality was investigated, with variable results.12,17-33 Of note, 
in most large studies, a benefit for high annual hospital volume was found, while in 
smaller studies no difference between high volume and low volume hospitals was 
detected (Figure 2). In none of these studies, high hospital volume was associated with 
poor outcomes. In the studies that did find a relation between volume and outcomes, 
there was no uniform threshold for what should be considered high volume surgery, 
although it was most frequently set at 20 per year.
In a limited number of studies surgeon volume and surgeon experience were investigated, 
with a benefit for increasing surgeon volume,17,20,23,34,35 but no benefit for increasing 
surgeon experience.20,36 In two studies, outcomes between university/teaching and non-
university/non-teaching hospitals were compared, but no difference in survival was 
documented.26,37
process indicators – surgery (table 3)
extent of lymph node dissection
Numerous studies have been performed in which a limited lymph node dissection (D1) 
was compared with an extended lymph node dissection (D2), but only four of these 
studies were RCTs.4,38-40 None of these RCTs revealed a difference in overall survival, 
except for a small, early study.39
The increased postoperative mortality in the D2 group is likely the result of the high 
number of splenectomies and distal pancreatectomies, combined with a lack of 
experience with D2 lymph node dissections in Europe. As gastric-cancer specific survival 
in the Dutch D1D2 study was higher after a D2 dissection, it has been suggested that 
a D2 dissection without splenectomy, performed in an experienced center will lead to 
improved survival as compared to a D1 dissection.40 In a Taiwanese RCT performed in 
specialized centers, a D3 dissection led improved overall survival over a D1 dissection.41 
Combining an extended lymph node dissection with removal of the paraaortic nodes did 
not result in a survival benefit.5,42,43
laparoscopic resection
Laparoscopic resections for gastric cancer are mainly performed in Asia, where the 
incidence of early gastric cancer is high. In the majority of studies on laparoscopic 
surgery, only patients with early gastric cancer were included. There is one RCT 
comparing laparoscopic distal gastrectomy (LDG) with open distal gastrectomy in 
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patients with advanced gastric cancer.44 LDG was associated with less blood loss, earlier 
resumption of food intake and shorter hospital stay (postoperative recovery in Table 3), but 
postoperative mortality and morbidity, and overall survival were comparable between the 
two groups. Likewise, in most non-randomized comparative series, laparoscopic gastric 
cancer surgery was comparable to open surgery with respect to both short- and long-
term results.45-53 In several non-randomized studies, one should be aware of a significant 
difference in disease stage between the laparoscopic and open surgery group.
Table 2. Structure Measures
Legend to Tables 2-7







overall survival high volume
NA NA
5/0/2 17,28,31,33,138-140
postoperative mortality high volume 11/0/8 12,17-33
postoperative morbidity high volume 2/0/2 25,29,141,142
length of hospital stay high volume 0/0/1 29
number of lymph nodes high volume 2/0/0 12,143
Surgeon volume
(high versus low)
postoperative mortality high volume
NA NA
3/0/1 17,20,23,34
postoperative morbidity high volume 1/0/0 34







postoperative morbidity experienced 0/0/1 36







postoperative mortality NCI-NCCN Center
NA NA
1/0/0 143
number of lymph nodes NCI-NCCN Center 1/0/0 143
aonly in United States
+  number of studies indicating a positive effect of the indicator on the endpoint listed
-   number of studies indicating a negative effect of the indicator on the endpoint listed
























laparoscopic distal gastrectomy 
laparoscopic gastrectomy  





National Cancer Institute - National Comprehensive Cancer Network Center
non randomized study
open distal gastrectomy 
open gastrectomy








total gastrectomy + pancreaticosplenectomy
total gastrectomy + splenectomy
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Table 3. Process Measures - surgery





Extent of lymph node dissection






disease-specific survival NA 1/0/0 40
recurrence rate 1/0/0 0/0/1 40,144
postoperative mortality 0/2/0 0/2/1 4,40,144-146
postoperative morbidity 0/0/1 0/2/1 39,40,144,146
transfusion requirement NA 0/1/0 39






postoperative morbidity 0/1/0 147
operating time 0/1/0 147







postoperative mortality 0/0/1 0/0/2 42,149,150




functional outcomes 0/0/1 151
operating time 0/1/0 152
blood loss 0/1/0 152
Removal of celiac nodes long term complaints celiac node removal NA NA 0/1/0 153






postoperative mortality 0/0/1 0/0/5 44,47-49,52,53
postoperative morbidity 0/0/1 0/0/5 44,47-49,52,53
postoperative recovery 1/0/0 5/0/0 44,47-49,52,53





postoperative mortality 0/0/3 46,50,51
postoperative morbidity 0/1/3 45,46,50,51
postoperative recovery 2/0/0 46,51
number of lymph nodes 1/0/1 46,50
resection margins 0/0/2 46,50







postoperative mortality 0/0/1 0/0/6 55,156,159-163
postoperative morbidity 0/0/1 0/0/6 55,156,159-163
postgastrecomty symptoms 1/0/0 NA 164
weight NA 2/0/0 159,163







postoperative mortality 0/0/1 0/0/2 56,166,167
postoperative morbidity 0/0/1 0/1/1 56,166,167
number of harvested LNs 0/0/1 0/0/1 166,167
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Table 3 (continued)









postoperative mortality 0/0/1 0/1/2 57,58,168,169
postoperative morbidity 0/0/1 0/3/0 57,58,168,169
number of harvested LNs 0/0/1 1/0/0 57,168





postoperative mortality 0/0/3 59-61











multiorgan resection NA NA
0/1/2 170-172
postoperative mortality 0/0/2 171,172










postoperative morbidity 0/0/2 0/0/3 63,64,66,173,174
post gastrectomy symptoms 1/0/1 0/0/2 63,64,173,174
quality of life 2/0/0 2/0/1 63-66,174
weight 1/0/1 1/0/3 63-66,173,174





postoperative mortality 0/0/1 NA 67
postoperative morbidity 1/0/0 0/0/1 67,70
hospital stay NA 0/0/1 70





hospital stay 0/0/1 1/0/0 68,69
bile reflux 0/0/1 NA 68





postoperative morbidity 0/0/1 0/0/2 71-73
delayed gastric emptying NA 0/1/0 71









postoperative morbidity 0/0/1 175
operating time/blood loss 1/0/0 175
number of harvested LN 0/0/1 175







postoperative morbidity 0/0/1 176
small bowel obstruction 0/0/1 176
Duration of surgery surgical site infection shorter operation time NA NA 1/0/0 177
Ligation versus cauteriza-
tion of lymphatic vessels postoperative lymphorroea ligation NA NA 1/0/0
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intestinal obstruction 0/0/1 178
postoperative pain 0/0/1 178







postoperative mortality 0/0/1 180
analgesic use 1/0/0 179
hospital stay 1/0/1 179,180
Intra-operative blood loss peritoneal recurrence < 475 ml blood loss NA NA 1/0/0 181
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type of resection
In the largest RCT on subtotal versus total gastrectomy for distal gastric tumors, no 
difference was observed in overall survival or postoperative mortality or morbidity.54,55 
Routine (pancreatico)splenectomy has been advocated to obtain a more thorough lymph 
node dissection. However, a survival benefit has never been shown. In contrast, routine 
splenectomy increased the number of postoperative septic complications in a Chile 
RCT.56 The addition of a pancreatectomy also increased postoperative morbidity in a 
number of studies.57-61 A bursectomy did not result in increased postoperative morbidity 
and mortality, but a survival analysis is yet to be performed in the single RCT on this 
subject.62
type of reconstruction
A benefit of creating a reservoir or pouch after total gastrectomy was found in two meta-
analyses and two RCTs.63-66 Studies on reconstructive techniques after subtotal gastric 
resection have shown varying results, and no large RCTs are available on this subject.67-70 
In two studies comparing a stapled with a hand-sewn anastomosis, no difference was 
found in postoperative mortality or morbidity, while in one retrospective study, stapler 
use was associated with an increase in delayed gastric emptying.71-73
Several other subjects related to surgical technique are shown in Table 3. 
process indicators – perioperative care (table 4)
The administration of perioperative parenteral nutrition reduced postoperative morbidity 
in malnourished patients in one retrospective study.74 In another study, there was no 
significant difference between the groups with and without enteral and/or parenteral 
nutritional support.75 In three RCTs, immunonutrition was associated with less infectious 
complications and a shorter hospital stay.76-78 Due to its high costs, shorter hospital stay 
did not lead to less overall costs.77
In earlier days, nasogastric decompression has been used routinely to prevent 
anastomotic leakage, enhance bowel function and shorten hospital stay. However, in none 
of the studies, a benefit in postoperative morbidity or mortality of routine nasogastric or 
nasojejunal decompression was documented. In contrast, in three RCTs, hospital stay 
increased with the use of nasogastric decompression.79-81 
In both RCTs on fast-track gastric cancer surgery, fast-track care improved postoperative 
recovery (return to normal gastro-intestinal function, analgesic use, mobilization, and 
hospital stay) as compared to conventional care.82,83 Both RCTs were performed in China. 
One of the two studies also showed a significant decrease in medical costs with fast-track 
care.83 
Randomized studies on the prognostic impact of perioperative blood transfusions in 
gastric cancer surgery are not available, and non-randomized studies show conflicting 
results. In nine retrospective series, an association was found between no blood 
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transfusion and a better survival rate in univariate analysis.84-92 In four of these studies, 
this adverse effect remained significant in multivariate analysis considering other 
prognostic factors.85,88,90,91 
In one RCT on selective bowel decontamination, a decreased anastomotic leakage rate 
was found.93 In another study, the use of multiple dose antibiotics was associated with 
less surgical site infections than the use of single dose antibiotics.94 
process indicators – multimodality therapy (table 5)
neoadjuvant therapy
In several studies, the role of preoperative chemotherapy was assessed, but in none of 
these individual studies a benefit compared to surgery alone was found.95-97 However, 
in a recent meta-analysis on preoperative chemotherapy, a benefit in survival was 
documented.98 In the British MAGIC study, perioperative chemotherapy improved 
overall survival.99 In a study comparing preoperative with postoperative chemotherapy, a 
higher treatment compliance was observed in the preoperative chemotherapy group.100 
Preoperative radiotherapy has only been tested positive in a study with gastric cardia 
cancer patients.101
Table 4. Process Measures - perioperative care






support versus normal 
diet
postoperative mortality
nutritional support NA NA
0/0/2 74,75














postoperative morbidity 0/0/1 0/0/6 79-81,182-185
time to flatus/intake 0/1/0 0/3/3 79-81,182-185




early feeding NA NA
0/0/1 186
postoperative morbidity 0/0/1 186
postoperative recovery 1/0/0 186







postoperative morbidity 0/0/2 82,83




no transfusion NA NA
4/0/5 84-92
postoperative mortality 0/0/2 92,187
postoperative morbidity 0/0/2 92,187
LMWH prophylaxis vs no 
prophylaxis
postoperative morbidity
LMWH prophylaxis NA NA
0/1/0 188




decontamination NA 1/0/0 NA
93
Single versus 
multiple dose antibiotics surgical site infection
multiple dose 




Many studies have been performed on adjuvant chemotherapy after a gastric cancer 
resection, and most of these studies have been incorporated in several meta-analyses.102-111 
In all but one of the meta-analyses, a small, but significant benefit for the use of adjuvant 
chemotherapy was shown. Multi-drug regimens have been associated with better survival 
when compared to single-drug regimens.111 In the Intergroup 0116 study, overall survival 
was higher in the postoperative chemoradiotherapy group when compared to the surgery 
alone group.112 
outcome indicators (table 6)
In many studies, the prognostic benefit of a microscopically radical (R0) resection over 
microscopically irradical (R1) resection has been shown.35,113-128 Patients who have clear 
resection margins have a higher survival, and fewer local recurrences. In three studies, 
an association between an increasing number of removed lymph nodes and higher 
survival was reported.129-131
Table 5. Process Measures - multimodality treatment














R0 resection rate 1/0/0 1/0/1 95,96,98


















































overall survival postoperative chemoradiotherapy NA 0/0/2 Excl.
191,192
Postoperative D-galactose





hepatic metastases 1/0/0 193
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Table 6. Outcome Measures





R0 versus R1 resection
overall survival
R0 resection NA NA
15/0/1 35,113-128
local recurrence 1/0/0 113
Clear versus involved 
esophageal margin
overall survival
clear margin NA NA
0/0/1 114
local recurrence 1/0/0 114
postoperative morbidity 0/0/1 114
postoperative mortality 0/0/1 114
Number of lymph nodes 
evaluated
(<15 versus >15)
overall survival >15 nodes NA NA 2/0/0 129,130




>26 nodes NA NA
1/0/0 131
postoperative mortality 0/0/1 131
postoperative morbidity 0/0/1 131
minimum set of quality of care indicators
After applying the predefined selection rules as outlined in the Methods section 
(subheading Quality of care indicators), thirteen evidence-based quality of care indicators 
were identified (Table 7). Hospital volume was the only indicator on the structure of 
healthcare. As high annual hospital volume was defined as at least 20 resections per 
year in the majority of positive studies, this number has been added to the indicator. 
The majority of indicators in the set reflect the process of care. A microscopically radical 
resection was the only outcome indicator.
discussion
In this systematic review of the literature, evidence-based quality of care indicators for the 
surgical treatment of gastric cancer were identified. Possible indicators were evaluated in 
terms of structure, process and outcome measures as proposed by Donabedian.13 
structure indicators
High volume gastrectomy was associated with lower postoperative mortality in most 
large studies (>5,000 patients included), but not in the smaller studies (Figure 2). This 
indicates that sufficient patient numbers are needed in order to show a significant volume-
outcome relation. Limited evidence was found for surgeon volume as a quality indicator. 
This underlines the importance of the multidisciplinary and perioperative team in the 
(surgical) treatment of gastric cancer. Both findings are in concordance with a recent 
meta-analysis on hospital and surgeon volume in the surgical treatment of esophageal 
cancer.132 Nevertheless, results of volume – outcome analyses need to be interpreted with 
caution. Heterogeneity in patient population and treatment can introduce bias in such 
studies and ideally, outcome data are adjusted for case-mix factors. Nationwide registries 
in which patient and treatment characteristics are prospectively collected will give further 
insight in structure of care indicators in the future.
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process indicators
In the published literature on quality of gastric cancer surgery, a broad variety of process 
indicators has been analyzed. 
surgical technique
The extent of lymph node dissection has been the subject of many studies. In initial 
reports, a D2 lymph node dissection was associated with increased postoperative mortality 
without a survival benefit as compared to D1 surgery.38,133 Long term results from the 
Dutch D1D2 study, however, revealed an improved gastric cancer specific survival after 
a D2 dissection.40 From this, it can be concluded that, when postoperative mortality can 
be avoided, a D2 lymphadenectomy should be recommended. In experienced centers, 
postoperative mortality after a D2 lymph node dissection is low.4 Additional (pancreatico)
splenectomy has been associated with increased postoperative morbidity without any 
survival benefit.59-61
perioperative care
While fast-track surgery has proven its benefit in colorectal cancer surgery, the number 
of studies in gastric cancer is limited. In two recent RCTs, fast-track care was shown 
to be feasible (in China) and was associated with a shorter hospital stay, less medical 
costs, and improved quality of life at discharge when compared to conventional care.82,83 
The widespread introduction of fast-track surgery programs or clinical care pathways in 
the management of gastric cancer patients deserves further attention as it potentially 
contributes to a higher level of care.
Table 7. Minimum set of evidence-based quality of care indicators for gastric cancer surgery
Type Quality of care indicator Improved end points Level of  evidence
Structure high hospital volume (>20/year) overall survival
postoperative mortality
NRS
Process D2/3 lymph node dissectiona disease specific survival
overall survival
RCT
no routine (pancreatico)splenectomy postoperative morbidity NRS
pouch reconstruction quality of life MA
fast-track care postoperative recovery RCT
no perioperative blood transfusion overall survival NRS
selective bowel decontamination anastomotic leakage rate RCT
multiple dose antibiotics surgical wound infection rate RCT
preoperative chemotherapy overall survival MA
perioperative chemotherapy overall survival RCT
adjuvant (combination) chemotherapy overall survival MA
postoperative chemoradiotherapy overall survival RCT
Outcome R0 resection overall survival NRS
ain centers with low postoperative mortality
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A negative impact of perioperative blood transfusion on overall survival was seen in 
univariate analysis in nine studies. In only four studies, blood transfusion remained 
an adverse prognostic factor in multivariate analysis, and it should be avoided without 
jeopardizing best supportive care.85,88,90,91 Similar results have been observed in colorectal 
cancer surgery.134 Selective bowel decontamination emerged as a quality of care indicator 
as it decreased the risk of anastomotic leakage and its clinical sequelae in a large RCT.93 In 
a more recent RCT, preoperative intravenous administration of multiple dose antibiotics 
was associated with less surgical wound infections than the use of single dose antibiotics.94 
multimodality treatment
In a recent meta-analysis, preoperative chemotherapy was associated with improved 
survival.98 In this meta-analysis, patients from trials on perioperative chemotherapy were 
also included. Adjuvant chemotherapy has been administered for many years, and its 
survival benefit has been confirmed in several meta-analyses.102-111 In the Western world 
however, an optimal regimen for postoperative chemotherapy has not been yet established. 
In Japan, postoperative chemotherapy is standard of care. Following the results of the 
Intergroup 0116 study, postoperative chemoradiotherapy is currently standard of care 
in the United States.112,135 In Europe, perioperative chemotherapy has been advocated, 
according to the results of the MAGIC study.99 The international multicenter CRITICS 
study will give an answer to the question whether postoperative chemoradiotherapy 
improves survival as compared to postoperative chemotherapy in patients who undergo 
gastric cancer resection after preoperative chemotherapy.136
Figure 2. Studies on the relation between annual hospital volume and postoperative mortality, 
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No significant difference between high and low annual hospital volume
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outcome indicators
Radicality of the resection and the number of resected lymph nodes are frequently used 
as outcome parameters when measuring quality of oncologic surgery. In gastric cancer 
surgery, a large number of studies support a microscopically radical resection to be 
considered as a quality of care indicator.35,113-128 The number of studies on the number of 
evaluated lymph nodes in relation to outcomes was too small to identify this factor as an 
evidence-based quality of care indicator.129-131
conclusions
From the current review, it becomes clear that improving the quality of care in the 
treatment of gastric cancer is a multidisciplinary team effort in which surgical technique 
is only one of the contributing factors. High quality perioperative care asks for well 
trained nurses, experienced anesthesiologists, and ICU staff.137 Furthermore, outcome 
of gastric cancer surgery is obviously dependent on the experience of other specialists 
in the multidisciplinary team (i.e., medical oncologists, gastroenterologists, radiation 
oncologists).
The set of indicators that was derived from the current study can be used for registration 
and benchmarking in gastric cancer surgery. Most indicators in clinical audits, as 
established in the United Kingdom, Denmark, Sweden, and the Netherlands are derived 
from expert panel discussions. With the current review, the datasets in these audits 
may be supplemented with evidence-based quality of care indicators. Furthermore, the 
proposed minimum set of indicators can be used for uniform reporting in future studies 
on quality of gastric cancer surgery. 
A limitation of the current study is the absence of a MeSH search term for studies related 
to ‘quality of care’. Therefore, the search strategy included a variety of search terms for 
different aspects of care. This might have influenced the set of studies in the final selection. 
Furthermore, due to the large number of studies that emerged from the search strategy, 
stringent criteria for inclusion were used. Approximately 60% of included manuscripts 
in the current literature review are from Western countries, whereas approximately 
40% of the included manuscripts are from Asia. A large amount of literature from Asia 
was excluded from the current review because part of these studies are written in non-
English languages, while another large part focused on early gastric cancer, which was 
not the subject of the current review. Therefore, quality of care indicators derived from 
the current study are likely to be more applicable to Western countries than to Asian 
countries. Finally, although the identified quality of care indicators reflect best practice 
for gastric cancer surgery, none of the studies actually validated a best practice indicator 
as a tool to measure differences in quality of care between different providers.
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Appendix. Pubmed, Embase, and Cochrane search terms
Pubmed
Limits activated: English, Publication Date from 1990
(“stomach neoplasms”[mesh] OR (stomach[All Fields] OR gastric[all fields]) AND (neoplasms[all Fields] OR neoplasm[all 
fields] OR tumor[all fields] OR tumors[all fields] OR tumor[all fields] OR tumors[all fields] OR cancer[all fields] OR cancers[all 
fields] OR carcinoma[all fields] OR carcinomas[all fields])))
AND
(“gastrectomy”[mesh] OR “gastrectomy”[all fields] OR “gastrectomies”[all fields] OR “gastric resection”[all fields] OR “Stom-
ach Neoplasms/surgery”[mesh] OR “Lymph Node Excision”[mesh] OR “Surgical Procedures, Operative”[mesh:noexp] OR 
“Neoadjuvant Therapy”[mesh] OR “Chemotherapy, Adjuvant”[mesh] OR “Radiotherapy, Adjuvant”[mesh] OR adjuvant[tiab] 
OR neoadjuvant[tiab])
AND
(“quality indicators, health care”[mesh] OR (“quality”[all fields] AND (“indicators”[all fields] OR indicator[all fields])) OR “health 
care quality indicators”[all fields] OR “Quality Assurance, Health Care”[mesh] OR “health care quality assessment”[all fields] 
OR “benchmarking”[mesh] OR “benchmarking”[all fields] OR “Outcome and Process Assessment (Health Care)”[mesh:noexp] 
OR “outcome assessment”[all fields] OR “Process Assessment”[all fields] OR “Delivery of Health Care”[mesh] OR “Risk 
Adjustment”[mesh] OR “risk adjustment”[all fields] OR “Clinical Audit”[mesh] OR “audit”[all fields] OR “Quality of Health 
Care”[mesh:noexp] OR “Quality Control”[mesh] OR “Guideline Adherence”[mesh] OR “Clinical Competence”[mesh] OR 
“Hospital Mortality”[mesh] OR “Mortality”[mesh:noexp] OR “Mortality”[ti] OR “Morbidity”[mesh:noexp] OR “Postoperative 




Limits activated: English, Publication Date from 1990
(exp *”stomach tumor”/ OR ((stomach.ti. OR gastric.ti.) AND (neoplasms.mp. OR neoplasm.mp. OR tumor.mp. OR tumors.
mp. OR tumor.mp. OR tumors.mp. OR cancer.mp. OR cancers.mp. OR carcinoma.mp. OR carcinomas.mp.)))
AND 
(exp *gastrectomy/ OR “gastrectomy”.mp. OR “gastrectomies”.mp. OR “gastric resection”.mp. OR exp *stomach tumor/
su OR “Lymph Node Excision”.mp. OR exp *lymphadenectomy/ OR *surgery/ OR surgical.mp. OR adjuvant.ti,ab. OR exp 
*ADJUVANT CHEMOTHERAPY/ OR neoadjuvant.ti,ab. OR exp *adjuvant therapy/)
AND 
(exp *health care quality/ OR (quality.ti,ab. AND indicators*.ti,ab.) OR “quality assurance”.ti,ab. OR exp *quality control/ OR 
“health care quality assessment”.ti,ab. OR benchmark*.ti,ab. OR exp *outcome assessment/ OR “outcome assessment”.ti,ab. 
OR “Process Assessment”.ti,ab. OR  “delivery of health care”.ti,ab. OR exp *health care delivery/ OR exp *risk assessment/ 
OR  “risk adjustment”.ti,ab. OR exp *medical audit/ OR “audit”.ti,ab. OR “health care quality access evaluation”.ti,ab. OR exp 
*health care access/ OR exp *”evaluation and follow up”/ OR exp *clinical assessment/ OR exp *clinical evaluation/ OR exp 
*evaluation/ OR exp *evaluation research/ OR exp *outcome assessment/ OR “quality control”.ti,ab. OR exp *quality control/ 
OR “guideline adherence”.ti,ab. OR “guidelines as topic”.ti,ab. OR  “clinical coti,abetence”.ti,ab. OR exp *clinical competence/ 
OR “hospital mortality”.ti,ab. OR *mortality/ OR morbidity.ti,ab. OR *morbidity/ OR complication*.ti,ab. OR exp *postopera-




Limits activated: English, Publication Date from 1990
“stomach neoplasms” 
AND
(gastrectomy OR “lymph node excision” OR adjuvant OR neoadjuvant)
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A worldwide increasing incidence is seen for esophageal adenocarcinoma, but not for 
esophageal squamous cell carcinoma (SCC) and gastric cardia adenocarcinoma. Purposes 
of the current study were to evaluate the changing incidence rates of esophageal and 
gastric cardia cancer, and to assess survival trends.
patients and methods
Patients diagnosed with esophageal adenocarcinoma (N = 12,195) or SCC (N = 9,046), or 
gastric cardia adenocarcinoma (N = 9,900) between 1989 and 2008 in the Netherlands 
were included. Changes in European Standard Population (ESP) and relative survival 
over time were evaluated.
results
Incidence rates for esophageal adenocarcinoma increased in males (+7.5%, P < 0.001) 
and females (+5.2%, P < 0.001), while the incidence for esophageal SCC remained stable 
in males (-0.2%, P = 0.6) and slightly increased in females (+1.7%, P = 0.001). The 
incidence for gastric cardia cancer decreased in males (-1.2%, P < 0.006), and remained 
stable in females (-0.2%, P = 0.7). Five-year survival for both M0 and M1 esophageal 
carcinoma doubled over the last 20 years. No significant changes in survival were found 
for M0 and M1 gastric cardia carcinoma.
conclusions
In the Netherlands, a rising incidence is seen for esophageal adenocarcinoma, but not 
for gastric cardia adenocarcinoma. This finding most likely reflects true changes in 
disease burden, rather than being the result of changes in diagnosis or classification. 
The increased survival for esophageal carcinoma can be attributed to centralization of 




Esophageal and gastric cancer are, respectively, the sixth and second causes of cancer 
death worldwide, with an estimated 500,000 new cases of esophageal cancer and one 
million new cases of gastric cancer each year.1 
Esophageal cancer is primarily composed of two histological types, adenocarcinoma and 
squamous cell carcinoma (SCC), each with a distinct etiology and specific risk factors.2 
Subtypes of gastric cancer are often based on topology, distinguishing cardia and non-
cardia gastric cancer. Most gastric cancers are adenocarcinomas.
Worldwide, there has been a marked increase in the incidence of esophageal cancer 
over the last decades, which is mainly attributed to an increase in the incidence of 
adenocarcinoma of the esophagus in North America,3,4 Europe5 and Japan.6 The incidence 
of SCC of the esophagus has remained stable or is declining.3,5 For gastric cardia cancer, 
two studies have reported a rising incidence in the United States in the seventies and 
eighties, while the incidence since then has stabilized.4,7 In the Netherlands, a rising 
incidence of adenocarcinoma of the esophagus has been reported as well from 1989 to 
2003, while the incidence of esophageal SCC hardly increased, and gastric cardia cancer 
incidence rates were declining.8,9 However, these data did not include a comprehensive 
analysis of incidence and survival for esophageal adenocarcinoma, esophageal SCC, and 
gastric cardia adenocarcinoma. 
The first purpose of the current study was to give an update on incidence rates and stage 
distribution for esophageal adenocarcinoma and SCC, and gastric cardia adenocarcinoma 
in the Netherlands from 1989 to 2008. The second purpose was to evaluate survival 
patterns for these cancers during the same period.
Patients and methods
netherlands cancer registry
Data were obtained from the Netherlands Cancer Registry (NCR), in which data is 
collected on all newly diagnosed malignancies in the Netherlands, a country of 16.7 
million inhabitants. The NCR receives data from eight regional cancer registries, covering 
all hospitals in the Netherlands. Information on patient and tumor characteristics and 
treatment is routinely collected by trained registrars who extract this information from 
the hospital records 6-18 months after diagnosis. Topography and morphology are coded 
according to the International Classification of Diseases for Oncology (ICD-O)10, based 
on information from the medical files, including the pathology report. Tumors are staged 
according to the International Union Against Cancer (UICC) TNM classification. Until 
December 1996, the UICC 4th edition was used,11 from 1997 until 2001 the UICC 5th 
edition was used,12 and as of January 2002, all tumors were coded according to the UICC 
6th edition.13 For esophageal carcinoma, the 4th, 5th, and 6th UICC TNM classifications 
were not different, except for a minor modification in the 5th edition with the introduction 
of the M1a and M1b classification. For gastric cardia cancer, starting with the 5th edition, 
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nodal (N) status was based on the absolute number of positive lymph nodes, rather than 
the location of the lymph node metastases. Vital status in the NCR is extracted from 
the medical records or is obtained by record linkage with the Dutch Central Bureau of 
Statistics, which registers all deceased persons in the Netherlands. As the NCR does not 
capture the cause of death, mortality rates were extracted from the Dutch Central Bureau 
of Statistics, separately for esophageal and gastric cancer. The study was approved by the 
NCR Review Board.
patients
Between January 1989 and December 2008, 22,530 cases of primary invasive esophageal 
(C15.0-15.9) and 9,963 cases of primary invasive gastric cardia cancer (C16.0) were 
diagnosed in the Netherlands. For the current study, adenocarcinomas (ICD-O 
morphology codes 8140-8142, 8144, 8145, 8190, 8200, 8210, 8211, 8230, 8255, 8260-
8263, 8310, 8130, 8180, 8481, 8490, 8510, 8560, 8570, 8573-8576) of the esophagus 
or  gastric cardia, and SCCs (ICD-O morphology codes 8051, 8052, 8070- 8076, 8078) 
of the esophagus were selected. Tumors with other or unknown histology (including 
‘No Otherwise Specified’) of the esophagus (N = 1289) or gastric cardia (N = 63) were 
excluded, leaving 21,241 patients with esophageal cancer, and 9,900 patients with cardia 
cancer for analysis.
statistical analysis
Separate analyses were performed for esophageal adenocarcinoma (C15.0-15.9), 
esophageal SCC (C15.0-C15.9), and gastric cardia adenocarcinoma (C16.0). To evaluate 
trends over time, the study period was divided in four intervals of five years.
Incidence rates were calculated as the number of new patients per 100,000 inhabitants 
per year, and are age-standardized using the European Standardized Population (ESP).14 
The ESP reflects the incidence as if the population of the Netherlands would have the 
same age-composition as a hypothetical European population. Changes in incidence 
were evaluated with the estimated annual percentage change (EAPC), fitting a regression 
line to the natural logarithm of the rates using calendar year as a regressor variable.15
Differences in stage distribution between the various time-periods were calculated with 
a chi-square test. Stage IV gastric cardia adenocarcinoma comprises not only M1 disease 
but also locally advanced (T4N1-3, T1-3N3) M0 disease.13 Therefore, stage IV-M0 and 
stage IV-M1 gastric cardia adenocarcinomas were analyzed separately.
Follow-up was complete until December 31st, 2009. Survival was calculated from the 
date of diagnosis until death of any cause (event) or alive at last follow-up (censored) by 
using the life-table method. Then, relative survival was calculated correcting for age- and 
gender-specific background mortality.16 Mortality rates were obtained directly from the 
Dutch Central Bureau of Statistics as the absolute number of deaths per 100.000. All 
analyses were performed with SAS statistical software (version 9.2).
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results
Between January 1st, 1989 and December 31st, 2008, 12,195 patients with esophageal 
adenocarcinoma, 9,046 patients with esophageal SCC, and 9,900 patients with 
gastric cardia adenocarcinoma were diagnosed in the Netherlands. Patient and tumor 
characteristics are summarized in Table 1. The number of males exceeded the number of 
females in all three subgroups. Median age at diagnosis was 69.6 years for esophageal 
adenocarcinoma, 66.9 years for esophageal SCC and 69.3 years for gastric cardia 
adenocarcinoma. The majority (83.7%) of esophageal adenocarcinomas were located 
in the lower esophagus. Esophageal SCC was more evenly distributed throughout the 
esophagus. 
The incidence of esophageal adenocarcinoma increased in males in the period 1989-
2008 (Figure 1a): the ESP increased from 3.2 per 100,000 inhabitants per year in 1989 
to 9.9 in 2008 with an estimated annual percentage change (EAPC) of +7.5 (95% CI +6.8 
to +8.2, P < 0.001). In females, the ESP of esophageal adenocarcinoma also increased, 
but to a lesser extent: from 0.7 in 1989 to 1.7 in 2008, with an EAPC of +5.2 (95% 
CI +4.2 to +6.2, P < 0.001). For esophageal SCC, no significant change was detected 
in males (EAPC -0.2, 95% CI -1.0 to 0.6, P = 0.6), while in females the incidence 
slightly increased (EAPC +1.7, 95% CI +0.8 to +2.7, P = 0.001). The incidence of gastric 
cardia carcinoma decreased over the years in males but did not significantly change in 
females (Figure 1b): in males, the ESP decreased from 5.7 in 1989 to 4.4 in 2008, with 
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an EAPC of -1.2 (95% CI -2.0 to -0.4, P = 0.006), and in females, the ESP decreased 
from 1.2 in 1989 to 1.0 in 2008, with an EAPC of -0.2 (95% CI -0.9 to 1.2, P = 0.7). 
Differences in stage distribution were noted (all P < 0.001), but in all three tumor types 
about 40% of all tumors were diagnosed in a non-metastatic stage. The other 60% 
of tumors were either staged as M1 disease, or did not have a stage group assigned. 
Changes in stage distributions over the years for esophageal adenocarcinoma and SCC 
showed a similar pattern over time (Figures 2a and 2b). The percentage of patients with 
an unknown stage steadily decreased, with a corresponding increase in the proportion of 
stage IV patients. Comparing changes in tumor location for esophageal adenocarcinoma 
versus SCC, there was a relative increase in distally located tumors for adenocarcinoma 
(77.2% - 87.7%), without major changes in the distribution of SCCs (Figures 3a and 3b).
For gastric cardia adenocarcinoma (Figure 2c), the proportion of patients with no stage 
assigned also decreased, but this was less prominent (from 19.8% to 15.0%). With 
the incorporation of the absolute number of metastatic lymph nodes into the TNM 
classification as of 1997, differences in stage distribution for gastric tumors might very 
well reflect a staging difference rather than a true shift in stage distribution. 
Mortality rates per 100.000 inhabitants in the Netherlands increased for esophageal 
carcinoma, both for males (from 6.8 to 13.9) and females (3.1 to 5.1). Mortality rates 
for gastric cancer decreased for males (18.6 to 10.7) and females (11.5 to 6.6). Survival 
estimates for esophageal and gastric cardia carcinoma are shown in Table 2. Five-
year relative survival significantly increased from 12.2% to 25.3% for M0 esophageal 
adenocarcinoma and from 11.6% to 18.9% for M0 esophageal SCC. No significant 
increase in survival was detected for M0 gastric cardia carcinoma (19.0% to 20.6%). 
In the metastatic setting, 2-year relative survival significantly increased for esophageal 
carcinoma, but not for gastric cardia carcinoma. Survival curves are depicted in Figure 4.
Figure 1. Incidence of (a) esophageal carcinoma and (b) gastric cardia adenocarcinoma in the 
Netherlands, 1989-2008
ESP: European standardized population
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discussion
Worldwide, the incidence of esophageal cancer is increasing. In the United States, the 
incidence of esophageal cancer has shown a six-fold rise over the last three decades.4 This 
is entirely caused by a rise in the incidence of esophageal adenocarcinoma, primarily in 
white males.3 In Europe, mainly the Northern part, there has also been an increase in the 
incidence of esophageal adenocarcinoma in men, but not in women.5  The incidence of 
SCC has remained stable in Europe and the United States.3,5 In the current study, similar 
Figure 2. Stage distribution of (a) esophageal adenocarcinoma, (b) esophageal squamous cell 



























































Figure 3. Relative distribution of location for (a) esophageal adenocarcinoma and 







































patterns were found. The incidence of esophageal adenocarcinoma in males showed a 
three-fold increase over two decades (1989-2008), with a smaller increase in females. For 
SCC, the incidence remained constant in males, and slightly increased in females, who 
increased their smoking habits over the past decades.
For gastric adenocarcinoma, there has been a worldwide decrease in the incidence of 
non-cardia gastric cancer over the past decades.17,18 For gastric cardia cancer, early studies 
report an increasing incidence in the West Midlands (England),19 Connecticut (US),20 
and the SEER regions (US),21 but none of these studies report data after 1989. More 
recent studies from the United States,4,7 Sweden,22 and Spain23 confirmed this increase 
until the early nineties, after which the incidence for gastric cardia cancer reached a 
plateau followed by a slow decrease as of the late nineties. Other studies, including the 
current study, report a stable or decreasing incidence of gastric cardia cancer over the last 
decades.24,25 Therefore, the often cited17,26,27 increasing incidence of cardia gastric cancer 
in developed countries should be considered carefully, and be judged in the light of more 
recent observations.
In the current study, incidence rates significantly changed over time for adenocarcinoma 
of the esophagus in both males and females, for SCC in females, and for gastric cardia 
carcinoma in males.  Time trends in disease incidence should be interpreted cautiously, 
because they might reflect changes in diagnostics or reclassification of tumors, rather than 
representing a true change in disease burden. With the refinement of various diagnostic 
modalities in general, and the increased use of endoscopy in patients with reflux disease 
or Barret’s esophagus, improved diagnosis might be a reason for the increased incidence 
of esophageal adenocarcinoma in the Netherlands. However, improved diagnosis would 
be present in all disease entities, in both sexes and throughout the entire esophagus in 
a comparable way. Furthermore, improved diagnosis would mainly lead to an increased 
incidence of early stage tumors, but this is not observed in the current study.
Another explanation for changes in incidence is reclassification. Because there are no 
clear morphologic differences that distinguish adenocarcinomas of the lower esophagus 
from those of the cardia, tumors of the gastro-esophageal junction are vulnerable 
to reclassification. And although the registry’s topography classification rules have 
remained unchanged over the study period, clinical classification of tumors of the gastro-
esophageal junction might have shifted towards esophageal cancer. However, the six-fold 
increase in the incidence of esophageal adenocarcinoma is not fully compensated by 
the decrease in gastric cardia adenocarcinomas. Furthermore, reclassification would be 
equally present in males and females. Therefore, although reclassification might partly 
explain the increase in esophageal adenocarcinoma, it is likely that the greater part of the 
increase in esophageal adenocarcinoma is a true rise in disease burden. 
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All three studied cancers have their specific etiologic factors. Esophageal adenocarcinoma 
has been associated with obesity28, smoking21, reflux disease29, Barrett’s esophagus30, high 
meat consumption31, and a high fat consumption31, whereas esophageal SCC has been 
associated with alcohol consumption21, smoking21, and low fruit intake32. For gastric cardia 
adenocarcinoma, risk factors are male sex and white race,33 obesity28, reflux disease34, 
meat consumption31, and fat consumption31. These risk factors show a significant overlap 
with the risk factors for esophageal adenocarcinoma, making it difficult to explain why 
incidence changes for esophageal and gastric cardia adenocarcinoma are discordant. It 
has been suggested that these tumors consist of two different histopathological entities 
but evidence for this is limited35.
Others have favored the hypothesis that gastric cardia cancer consists of two distinct 
etiologies: one arising from H. pylori associated severe atrophic gastritis and being of 
intestinal or diffuse subtype similar to non-cardia cancer, and one related to reflux disease 
and intestinal in subtype, similar to esophageal adenocarcinoma.34 With a decreasing 
incidence of H. pylori, the first subtype might be responsible for the decreasing incidence 
of cardia carcinoma.9 Although this might be a plausible explanation, underlying 
mechanisms for the differences in incidence trends need further investigation before 
definite conclusions can be drawn.
For both M0 and M1 esophageal cancer, relative survival rates improved during the study 
period. For M0 tumors, this may be the result of centralization of esophageal cancer 
surgery in the Netherlands. Centralization improves patient selection, perioperative 
care, surgical experience, and decreases failure to rescue in case of complications. As of 
2006, a yearly minimum of ten esophagectomies per hospital was enforced by the Dutch 
Health Care Inspectorate. In two regions of the Netherlands, the minimum volume 
was introduced earlier, significantly improving survival.36  Secondly, the increased 
Table 2. Five-year relative survival of non-metastatic (M0) and metastatic (M1) esophageal and 
cardia carcinoma in the Netherlands, 1989-2008
Esophageal adenocarcinoma Esophageal SCC Cardia adenocarcinoma
% 95% CI % 95% CI % 95% CI
M0 disease
1989-1993 12.2 10.0-14.6 11.6 9.9-13.6 19.0 16.7-21.3
1994-1998 14.9 13.0-16.9 11.9 10.3-13.6 15.5 13.7-17.4
1999-2003 17.4 15.8-19.2 13.3 11.7-15.1 18.4 16.4-20.5
2004-2008 25.3 22.9-27.8 18.9 16.5-21.5 20.6 17.7-23.8
M1 disease
1989-1993 3.3 1.8-5.7 6.0 3.6-9.2 4.2 2.8-6.0
1994-1998 5.3 3.7-7.3 4.7 2.9-7.0 3.1 2.1-4.5
1999-2003 5.7 4.5-7.1 5.4 3.8-7.4 4.1 2.8-5.5
2004-2008 9.0 7.7-10.4 10.1 8.0-12.4 6.0 4.6-7.7
95% CI: 95% confidence interval, SCC: squamous cell carcinoma
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use of neoadjuvant chemotherapy or chemoradiation might have contributed to the 
better survival rates for M0 esophageal cancer.37,38 From 2004 to 2008, a large Dutch 
multicenter trial has explored the use of preoperative chemoradiation in esophageal 
cancer.39 All patients in this trial were included in the current analysis. For M1 tumors, 
the increase in survival can be attributed to stage migration due to improved detection 
of distant metastases.
A very recent study shows that esophagectomies were centralized to a great extent over 
the past 20 years in the Netherlands, while most gastrectomies are performed in low 
volume centers. High volume esophagectomies were associated with lower postoperative 
mortality, while there were hardly any high volume gastrectomies to conduct a properly 
Figure 4. Relative survival of patients with esophageal and gastric cardia carcinoma in the 
























































































































































powered volume-outcome analysis for gastrectomy.40 Furthermore, in the study period 
multimodality therapy has been administered more frequently in esophageal as compared 
to cardia carcinoma (results not shown). This might explain why for gastric cardia 
cancer, relative survival did not significantly increase, corresponding with earlier results 
from one region in the Netherlands.41 Because postoperative chemoradiotherapy and 
perioperative chemotherapy have emerged as adjuvant strategies that improve outcome 
in gastric cancer, it is expected that survival will increase over the coming decades.  
In conclusion, the current manuscript reveals an increase in the incidence of esophageal 
adenocarcinoma both in males and females, and a decrease in the incidence of gastric 
cardia adenocarcinoma in males. These are most likely true changes in disease burden, 
rather than being caused by either improved diagnosis or reclassification. The question 
why incidence trends for esophageal and cardia adenocarcinoma are different remains to 
be elucidated, but the existence of two different types of gastric cardia cancer is a possible 
explanation. 
The improved survival for M0 esophageal carcinoma reflects an increasing number of 
esophagectomies performed in high-volume centers and the increased use of modern 
multi-modality therapy. These two factors are poorly acknowledged in treating gastric 
cancer in the Netherlands, which might explain why no significant increase in survival 
was detected in this tumor type.
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Gastric cardia and non-cardia cancer exhibit differences in biological and epidemiological 
features. Aims of this study were to analyze trends in incidence, stage distribution, and 
survival over a 20-year period in the Netherlands, separately for both types of gastric 
cancer.
patients and methods
Data on all patients with a diagnosis of gastric cancer in the period 1989-2008 were 
obtained from the nationwide Netherlands Cancer Registry. Time trends in incidence 
(analyzed as European Standard Rate per 100,000 (ESR)) and relative survival were 
separately analyzed for cardia and non-cardia gastric cancer.
results
A total of 13,384 patients were included. Incidence rates per 100,000 for cardia cancer 
declined from 5.7 to 4.3 for males and remained stable for females (1.2). For non-cardia 
cancer, the incidence in males declined from 25 to 14 and in females from 10.4 to 6.9. 
Proportional incidence in stage IV cardia and non-cardia cancer increased in 2004-2008 
(cardia 32% to 42%, non-cardia 33% to 45%). Five-year survival rates for stage I-III and 
X (unknown) remained stable (cardia cancer: 20%, non-cardia gastric cancer: 31%). Five-
year survival for stage IV disease was 1.9% and 1.0% for cardia and non-cardia gastric 
cancer.
conclusions
The incidence of gastric cancer in the Netherlands strongly decreased over the 
past decades, in particular for non-cardia gastric cancer. Survival remained dismal. 




Gastric cancer can be subdivided in two distinct forms according to location: cardia cancer 
and non-cardia cancer. These two entities are reported to have a different epidemiological 
and biological behavior. The declining incidence in gastric cancer throughout the world 
is mostly attributed to a fall in incidence of non-cardia cancer.1-3 Helicobacter pylori 
infection is reported to be a risk factor for non-cardia cancer. It causes the formation 
of precancerous lesions.4,5 Eradication of Helicobacter pylori in the Western world is 
associated with a fall in incidence of non-cardia gastric cancer. Gastric cardia cancer on 
the other hand is associated with obesity and gastroesophageal reflux disease.6-8 The 
literature on incidence rates of cardia cancer is somewhat conflicting, with decreasing, 
stable and increasing incidence rates reported.1,6,9-14
Survival of gastric cancer remains dismal in the Western world, with reported 5-year 
survival rates of 10-20%,15,16 in contrast to Asian survival rates.17,18 This has been attributed 
to more aggressive surgery, differences in staging, and an intrinsic biological difference 
between Asian and Western gastric cancer patients.19,20 In both the Western and Asian 
world survival of cardia gastric cancer is lower compared to non-cardia cancer.10,18
In this study, the results of the first nation-wide population-based study on incidence and 
survival rates for gastric cancer in the Netherlands are presented. Trends in incidence, 
stage distribution, and survival rates for cardia and non-cardia gastric cancer were 
evaluated over a period of 20 years.  
methods
data collection
Data were obtained from the nationwide Netherlands Cancer Registry (NCR). This 
registry serves the total Dutch population of 16.6 million inhabitants. The NCR is based 
on notification of all newly diagnosed malignancies in the Netherlands by the automated 
pathological archive (PALGA). Additional sources are the national registry of hospital 
discharge, hematology departments and radiotherapy institutions. Completeness is 
estimated to be at least 95%.21 The information on vital status was initially obtained from 
municipal registries and from 1994 onwards from the nationwide population registries 
network. These registries provide complete coverage of all deceased Dutch citizens.
Patients diagnosed from 1989 to 2008 with a tumor of the stomach, classified as ICD-
9 151 and ICD-10 C16 according to the International Classification of Diseases (ICD), 
were included. Tumors were staged according to the International Union Against Cancer 
TNM classification that was used at the date of diagnosis. Between the 4th and 5th edition 
TNM classification, nodal staging was changed. Starting with the 5th edition, nodal status 
was based on the absolute number of positive lymph nodes, rather than the location of 
the lymph node metastases. There were no differences between the 5th and 6th edition 
TNM classification. Clinical stage was used in case of missing pathological stage.22-24 To 
evaluate trends over time, the study period was divided in four intervals of five years. 
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statistical analyses
Annual incidence rates were calculated per 100,000 person-years, using the annual mid-
year population size as obtained from Statistics Netherlands. Rates were age-standardized 
to European Standardized Rates (ESR). Changes were evaluated by calculating the 
estimated annual percentage change (EAPC) and the corresponding 95% confidence 
interval. To calculate this, a regression line was fitted to the natural logarithm of the 
rates, using the calendar year as regressor variable (i.e. y = ax + b where y = ln(rate) and 
x = calendar year, then EAPC = 100 * (ea – 1)). 
TNM stage group was calculated by using pathological T, N and M stage. If pathological 
confirmation was lacking, clinical T, N and/or M stage was used. Analyses were stratified 
for stage (stage I-III/X vs. stage IV). Differences in stage distribution between periods of 
diagnosis were tested by means of a Chi square test. 
Follow-up for vital status was complete until December 31st, 2009. Traditional cohort-
based relative survival analysis was performed; the number of days was calculated from 
the date of diagnosis until death of any cause (event) or alive at last follow-up (censored). 
Figure 1. Incidence rates of (a) cardia cancer and (b) non-cardia cancer in the Netherlands, 
1989-2008
ESR: European Standardized Rate per 100.000 inhabitants

























































































Then, relative survival was calculated correcting for age- and gender-specific background 
mortality, as a proxy of disease-specific survival. 
SAS software (SAS system 9.2, SAS Institute, Cary, NC) was used to perform the 
statistical analyses. For all analyses, a P-value < 0.05 was considered significant.
results
patient characteristics and incidence
A total of 13,384 patients diagnosed with gastric cancer were included (Table 1). The 
number of new cases of cardia cancer in males decreased from 2115 in 1989-1993 (annual 
average 423) to 2059 in 2004/2008 (annual average 412). The number of females with 
cardia cancer remained stable at about 133 patients per year. The number of new cases 
with non-cardia cancer decreased in males from 1257 to 927 per year (average of 5-year 
period), and from 863 to 655 in females. Median age for both cardia and non-cardia 
gastric cancer did not change over the years.
Age-standardised incidence rates (per 100,000 person-years) by gender are shown in 
Figure 1. The ESR in males decreased from 25/100,000 in 1989 to 14/100,000 in 2008, 
and decreased in females from 10.4/100,000 to 6.9/100,000. The estimated annual 
percentage change in incidence was -2.2 (95% CI -2.8 to -1.6) for males with cardia 
cancer, -0.94 (95% CI -1.9 to -0.02) for females, -3.8 (95%CI -4.1 to -3.6) for males with 
non-cardia cancer, and -2.9 (95% CI -3.2 to -2.5) for females. 

































































































Cardia cancer, stage I-III, X Cardia cancer, stage IV
Non-cardia cancer, stage IVNon-cardia cancer, stage I-III, X
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tumor stage
The proportion of patients with stage IV at diagnosis (pathological or clinical) increased 
for both cardia (from 32% in 1989-1993 to 45% in 2004-2008, P < 0.001) and non-cardia 
cancer (from 31% in 1989-1993 to 43% in 2004-2008, P <0.001), with a corresponding 
decrease in the percentage of patients with an unknown stage (Figures 2a and 2b).
survival
Five-year relative survival estimates for stage I-III and stage X gastric cancer remained 
low between 1989 and 2008 (Figures 3a and 3c). For cardia cancer stage I-III and X, 
5-year survival remained about 20%, and for non-cardia cancer stage I-III and X, 5-year 
survival remained about 31%. For stage IV cardia cancer, 5-year survival was 1.0%, for 
non-cardia cancer, this was 1.9% (Figures 3b and 3d). Changes in survival estimates 
between analyzed periods of diagnosis were not statistically significant.
discussion
In the Netherlands, survival of gastric cancer remains dismal and has not improved. The 
incidence of gastric cancer has markedly declined during the last century, a trend that 
has continued in the last decade. This decrease has also been reported in other parts 
of the world.25  It has mainly been attributed to a fall in incidence of non-cardia cancer, 
which is confirmed in the present study. The incidence of cardia cancer increased in 
the early 90’s, but since then it has been declining. The decline in incidence of non-
cardia cancer was however steeper compared to cardia cancer. This results in a somewhat 
higher proportional incidence of cardia cancer nowadays in both genders. Some studies 
report an increase in cardia cancer,2,13,26,27 although others report a stable or declining 
incidence.1,9,14,28 What should be taken into account is that in several studies the exact 
tumor location was unspecified, thereby biasing the results. Although the classification 
in the register’s topography rules have not changed, changes in diagnostic procedures 
and definitions could have caused a shift from cardia cancer to distal esophageal cancer. 
Previous studies conducted in the Netherlands showed a rise in the incidence of distal 
esophageal cancer.14,28 Although reclassification might partly explain the increase in 
esophageal adenocarcinoma, it is likely that the greater part of the increase in esophageal 
adenocarcinoma is a true rise in disease burden. Several factors are thought to affect the 
incidence of gastric cancer. Helicobacter pylori infection leads to superficial gastritis, which 
might progress to atrophic gastritis and loss of acid secretion. Eventually dysplasia and 
gastric cancer develop, especially in the distal stomach.4,12,29 As Helicobacter pylori seems to 
play a role in early carcinogenesis, eradication probably will not prevent the development 
of gastric cancer in patients with gastritis due to Helicobacter pylori. Due to changes in 
lifestyle and dietary pattern (improved sanitation) the prevalence of Helicobacter pylori 
infection has declined.30,31 Increased consumption of fruit and vegetables and lower salt 
consumption have also reduced the incidence of gastric cancer.32
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Cardia cancer differs from non-cardia cancer, biologically and epidemiologically. Two 
distinct etiologies have been described for cardia cancer. The first etiology is associated 
with an Helicobacter pylori infection. It causes atrophic gastritis and eventually develops 
to gastric cancer of the diffuse and intestinal tumor type (according to the Lauren 
classification)33, suggesting a similar pathway as for non-cardia cancer.12,34 The second 
etiology is associated with obesity and gastro-esophageal reflux disease which are 
independent risk factors for cardia cancer. However, the relative risk for cardia cancer is 
not as high as the risk for adenocarcinoma of the esophagus.6-8,12,34 In the current study, 
a difference in age distribution was found between cardia and non-cardia cancer. Non-
cardia cancer is diagnosed more often in people of an older age (73.1 versus 69.5 years). 
Cardia cancer prevalence is more equally divided between the age groups. The male-
female ratio is 3:1 for cardia cancer and 1.5:1 for non-cardia cancer. This is confirmed in 
other studies.9,11
For both types of gastric cancer, a rise in proportional incidence of stage IV cancer at 
the time of diagnosis was observed in the present study. In the period 2004-2008, at 
the time of diagnosis more than 40% of patients had developed stage IV gastric cancer 
in both cardia and non-cardia cancer. Due to late presentation of symptoms and lack of 
pathognomonic signs gastric cancer is more likely to be detected in a late stage. The rise 
in stage IV cancer in our study might be due to stage migration; because of improved 
imaging modalities distant metastases are seen at an earlier stage so more patients are 
classified in a more advanced stage group compared with earlier years when imaging 
 1989-1993 1994-1998 1999-2003 2004-2008






























































































































Table 1. Sex and age distribution for cardia and non-cardia cancer in the Netherlands, 1989-2008 
(N = 13,384)
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techniques were less effective. In countries where gastric cancer is endemic, such as 
Japan, screening programs have been developed, and gastric cancer is detected in a 
much earlier stage.35  In the Netherlands, this would not be cost-effective due to the lower 
incidence rates. Differences in race, age and sex distribution, histological distribution, 
staging (leading to stage migration), and treatment all may be of influence on the survival 
discrepancy between East and West.
During the study period, the prognosis of gastric cancer in the Netherlands remained 
dismal. Survival for patients with both cardia and non-cardia cancer did not improve 
over time. The prognosis for non-cardia cancer was better compared to cardia cancer, 
with five-year survival rates of 31% versus 20% for stage I-III and X. Stage IV cardia 
and non-cardia cancer both have a poor 5-year survival rate of 1-2%. The worse survival 
of cardia cancer can largely be explained by different histopathological characteristics. 
Cardia cancer is mostly detected in a more advanced stage, with a deeper penetration 
of the stomach wall and more tumor positive lymph nodes. Furthermore, it is more 
often poorly differentiated and has a greater diameter.18,36 In a study analyzing all types 
of gastric cancer, the presence of cardia cancer was an independent risk factor for lower 
survival, indicating this might be a more aggressive form of gastric cancer.18 As it is not 
cost-effective to perform a screening program for early detection of gastric cancer, it is 
imperative to improve treatment to increase survival. Centralization could be a solution 
and has been initiated in the Netherlands as of 2012. Improvement of the surgical and 
pathological technique as well as improvement of perioperative care are essential to 
improve survival.
Over the past 20 years, the age-adjusted incidence rate of gastric cancer in the Netherlands 
has declined for both males and females. Survival remained dismal, with 5-year survival 
rates of 20% for stage I-III and X cardia cancer and 31% for non-cardia cancer. Improving 
gastric cancer care on a nationwide level remains a challenge for the multidisciplinary 
team treating gastric cancer patients.
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Studies investigating perioperative chemotherapy and/or radiotherapy changed the 
treatment of curable gastric cancer in the Netherlands. These changes were evaluated 
including their influence on survival.
patients and methods
Data on patients diagnosed with gastric cancer from 1989-2009 were obtained from 
the Netherlands Cancer Registry. Changes over time in surgery and administration 
of perioperative chemotherapy, 30-day mortality, 5-year survival, and adjusted relative 
excess risk (RER) of dying were analyzed with multivariable regression for cardia and 
non-cardia gastric cancer. 
results
Most patients with stage I and II disease underwent surgery. Since 2005 more patients 
are treated with preoperative and/or postoperative chemotherapy. Postoperative mortality 
ranged from 1% to 7% and 0.4% to 12.2% in cardia and non-cardia cancer (<55 - >75 year). 
Five-year survival for cardia cancer and non-cardia cancer stage I-III and X (unknown 
stage) was 33% and 50% (2005-2008). The RER of dying was associated with period 
of diagnosis, age, gender, region, stage, (neo)adjuvant chemotherapy in case of cardia 
cancer, and type of gastric resection in case of non-cardia cancer.
conclusions
Administration of (neo)adjuvant chemotherapy has increased without improvement in 




Despite attempts to improve quality of care, survival rates for gastric cancer in the 
Netherlands remain dismal. For all stages cardia cancer, 5-year overall survival rates of 
10% are reported, while for non-cardia cancer 5-year survival is 14%.1 Other European 
studies report 5-year overall survival rates of 15-32%.2 Postoperative mortality rates vary 
from 5.2 to 12.1% in different countries in Europe.3,4
Over the past decades, many trials have been conducted to improve survival of patients 
with gastric cancer. In the Dutch D1-D2 trial, no benefit was found for a D2 resection 
after 5 years of follow-up, which was the result of a high postoperative mortality in 
the D2 group. However, after 15 years, cancer-specific mortality and the number of 
recurrences was lower in the D2 group.5 In other trials the role of preoperative and 
postoperative therapy in gastric cancer treatment was investigated. In the MAGIC trial, 
a benefit was proven for patients receiving perioperative chemotherapy consisting of 
epirubicin, cisplatin and 5-FU (ECF), although it is suggested that the survival benefit 
was mainly achieved by neoadjuvant chemotherapy.6 In the United States Intergroup 
0116 study that was conducted in the nineties, a survival benefit for patients receiving 
postoperative chemoradiotherapy was found. However, 54% of the patients received a 
D0 lymphadenectomy. It is therefore suggested that postoperative chemoradiotherapy 
mainly improves survival in patients with inadequate lymph node dissection.7 A 
retrospective study conducted in the Netherlands showed a decreased local recurrence 
rate and higher overall survival for patients who underwent a D1 resection followed by 
postoperative chemoradiotherapy, compared to D1 surgery alone. No difference was 
found for D2 surgery alone versus D2 surgery with postoperative chemoradiotherapy.8,9
In 2009, these studies led to the formation of the first official guideline for treatment of 
gastric cancer in the Netherlands. For stage II and III gastric cancer, it is recommended 
to offer neoadjuvant chemotherapy based on an ECF schedule. If a patient did not receive 
neoadjuvant chemotherapy and the resection margins were tumor-positive (R1), adjuvant 
chemoradiotherapy is recommended.10
The aims of the current study were to describe changes in the treatment of gastric cancer 
in the Netherlands, separately for cardia and non-cardia gastric cancer, and to analyze 




Data were obtained from the nationwide Netherlands Cancer Registry (NCR). This 
registry serves the total Dutch population of 16.6 million inhabitants. The NCR is 
based on notification of all newly diagnosed malignancies in the Netherlands by the 
national automated pathological archive (PALGA). Additional sources are the national 
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registry of hospital discharge, hematology departments and radiotherapy institutions. 
Completeness is estimated to be at least 95%.11 The information on vital status was 
initially obtained from municipal registries and from 1994 onwards from the nationwide 
population registries network, consisting of 8 regions during the study period. These 
registries provide complete coverage of all deceased Dutch citizens.
Patients diagnosed between January 1st 1989 and December 31st 2008 with a tumor of the 
stomach according to the International Classification of Diseases (ICD) were included 
in the current study. To evaluate trends over time, the study period was divided in five 
intervals of four years. Tumors were staged according to the International Union Against 
Cancer (UICC) TNM classification that was used in the year of diagnosis. Clinical stage 
group was used in case of missing pathological TNM stage group. If stage was not known, 
it was defined as X. Follow-up for vital status was complete until December 31st, 2010.
statistical analyses
All analyses were performed separately for cardia and non-cardia cancer. Differences 
in patient and tumor characteristics were analyzed with the Chi square test. Trends 
in treatment, including the use of preoperative and postoperative chemotherapy, and 
resection, were analyzed as proportional distributions.
The chance to undergo surgery and receive chemotherapy for patients with stage I-III and 
X (unknown stage) gastric cancer was analyzed with multivariable logistic regression. 
For chemotherapy, the analyses were restricted to patients diagnosed after 2004 because 
only a very small proportion of patients received chemotherapy before 2005. For patients 
diagnosed between 2005 and 2008, the chance of dying within 30 days after resection 
was calculated with multivariable logistic regression. Before 2005, date of resection was 
not registered by the NCR, and 30-day mortality could not be calculated. 
Traditional cohort-based relative survival analysis was calculated; the number of days 
was calculated from the date of diagnosis until death of any cause (event) or alive at 
last follow-up (censored). Then, relative survival was calculated correcting for age- and 
gender-specific background mortality, as a proxy of disease-specific survival. Only patients 
who underwent surgery were included.
The independent relative excess risk (RER) of dying for relevant patient and tumor 
characteristics was calculated by means of multivariable relative survival analysis with 
Poisson regression.
results
Between 1989 and 2008, 10,294 patients were diagnosed with cardia cancer, and 30,017 
patients were diagnosed with non-cardia cancer in the Netherlands. Patient and tumor 
characteristics are shown in Table 1. The age and gender distribution differed between 
cardia and non-cardia cancer: median age was 69.3 years for cardia cancer, and 72.9 
years for non-cardia cancer. Patients with cardia cancer were more often males compared 
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to patients with non-cardia cancer. 
Trends in treatment over time are depicted in Figure 1, separately for stage I, II, and III. 
Resection rates remained stable for stage I and II disease, but decreased for stage III 
cardia cancer with 20% (P < 0.001). The proportion of patients treated with chemotherapy 
increased significantly in every stage group (P < 0.001).
In Table 2, resection percentages and the adjusted chance to undergo a resection for 
patients with stage I-III and X gastric cancer diagnosed between 1989 and 2008 are 
shown. Elderly patients less often underwent a resection (<55 years old versus ≥75 years 
old: odds ratio (OR) 0.2 and 0.3 for respectively cardia and non-cardia cancer). Resection 
rates for stage I and II were similar, both for cardia and non-cardia gastric cancer, while 
Table 1. Patient characteristics, all diagnosed patients (1989-2008)
 Cardia cancer Non-cardia cancer
 N % N % P































































































































































resection rates for stage III cardia and non-cardia gastric cancer were significantly lower 
(OR cardia: 0.3, OR non-cardia: 0.2, P < 0.001). For non-cardia gastric cancer, the chance 
of undergoing surgery decreased over time (2005-2008 OR 0.6, P < 0.001). Resection 
rates significantly differed between regions, from 49% to 62% for cardia cancer and 
from 63 to 74% for non-cardia cancer.
In Table 3, the proportion of patients treated with chemotherapy and the adjusted chance 
to receive chemotherapy is shown for patients with stage I-III and X, resected for cardia 
and non-cardia cancer between 2005 and 2008. A younger age, diagnosis in a more 
recent time interval, and, for patients with non-cardia cancer, a more advanced stage 
were associated with a higher chance for receiving chemotherapy. Again, large regional 
Table 2. Multivariate logistic regression on the chance to undergo a resection, stage I-III and X, all 
diagnosed patients (1989-2008)
Cardia cancer Non-cardia cancer
 Resection rate (%) OR P Resection rate (%) OR P
Sex
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variations could be noted, ranging from 20% to 58% for cardia cancer and from 16% to 
25% for non-cardia cancer.
In Table 4, 30-day mortality is shown in percentages and as the adjusted risk after 
resection for gastric cardia and non-cardia cancer between 2005 and 2008. For cardia 
and non-cardia cancer combined, 30-day mortality after resection was 6.7%. The risk 
of dying postoperatively strongly increased with age, from 1% for patients younger than 
55 years to 8% among patients aged 65-74 years after resection for cardia cancer (P = 
0.043), and from 0.4% to 12% for patients aged 75 years or older after resection for non-
cardia cancer (P = 0.002) (Figure 2). Thirty-day mortality rates were lower for females 
compared to males after resection for non-cardia cancer. Statistically, there were no 
Table 3. Multivariate logistic regression on the chance to receive preoperative and/or postoperative 
chemotherapy, stage I-III and X, only resected patients (2005-2008)
Cardia cancer Non-cardia cancer
 Chemotherapy use (%) OR P Chemotherapy use (%) OR P
Total 29 21
Sex
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regional differences.
Five-year relative survival rates of patients who underwent a resection for stage I-III 
and X remained about 33% for patients with cardia cancer, and improved somewhat 
from 47 to 50% (not significant) for patients with non-cardia cancer (Figure 3). After 
adjustment for available patient and tumor characteristics, the risk of dying (RER) after 
being diagnosed with gastric cancer was lower in the period 2005-2008 compared to the 
period 1989-1992, both for cardia and non-cardia cancer. The risk of dying was higher 
for older patients and for males, and again regional variation was considerable (Table 5).
Figure 1. Patterns of care for patients with (a) stage I, (b) stage II, (c) stage III cardia and 
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Over the study period, resection rates for both cardia and non-cardia cancer remained 
relatively stable. The administration of preoperative and postoperative chemotherapy 
significantly increased from 2005 to 2008. Survival rates remained stable for both types 
of gastric cancer.
Resection rates were clearly lower for stage III compared to stage I and II gastric cancer. 
In cardia cancer, resection rates were lower compared to non-cardia cancer. Main factors 
adversely affecting resection rates were older age, higher tumor stage, a more recent 
period of diagnosis, interregional variation and unknown tumor differentiation grade. In 
non-cardia cancer the location of the tumor was a factor of influence as well.
Before the introduction of the national guideline for treatment of gastric cancer in 2009 the 
administration of preoperative and postoperative chemotherapy was not recommended. 
In 2006, the MAGIC trial was published which led to a change in treatment in the 
Netherlands as well as in the UK and the USA.12-14 In the latest period, after 2005, there 
was a significant increase in the number of patients treated with chemotherapy, both 
for cardia and non-cardia cancer. Even in stage I cardia and non-cardia cancer there was 
a remarkable increase in chemotherapy administration (59% and 36% respectively). 
As chemotherapy is administered based on clinical stage while the analyses for the 
current study were based on pathological stage, it is possible that due to downstaging 
after neoadjuvant chemotherapy, patients with a pathological stage I had a clinical stage 
II. Furthermore, it is quite difficult to assess the clinical stage. Non-invasive imaging 
modalities such as computed tomography (CT) and positron emission tomography 
(PET) do not have a high sensitivity for T-stage and lymph node metastases. Endoscopic 
ultrasonography (EUS) could determine T-stage although this is not implemented in 
the routine work-up of gastric cancer in the Netherlands.10,15-17 Therefore, preoperative 
chemotherapy might have been administered more liberally.
The majority of mortality rates reported in literature are derived from clinical trials. 
This can be subject to a selection or publication bias. The current epidemiological study 
Figure 3. Five-year relative survival after resection for stage I-III and X (a) cardia cancer, 




















































provides non-biased postoperative mortality rates in the Netherlands. Thirty-day mortality 
in the latest period (2005-2008) was 6.7% for cardia and non-cardia cancer combined. 
Although this leaves room for improvement, this is lower compared to the postoperative 
mortality rate in the nineties.3,4,18 Apart from surgical skills, postoperative mortality 
depends on selection of patients, anesthetic perioperative care and postoperative care 
at the ICU and the ward. It is imperative to improve treatment to prevent postoperative 
Table 4. Multivariate logistic regression on 30-day mortality (2005-2008)
Cardia cancer Non-cardia cancer
 30-day mortality (%) OR P 30-day mortality (%) OR P
Total 4 7
Sex
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deaths and to increase survival rates. Therefore, mortality rates could be improved by 
centralizing gastric cancer care to dedicated high volume hospitals. Although a recent 
study did not demonstrate a difference in survival rates between low- and high-volume 
hospitals for gastric cancer,19 as of 2012, centralization has been implemented with a 
minimum of 10 gastrectomies per hospital per year, and as of 2013 this minimal volume 
standard will be increased to 20 gastrectomies per hospital per year. Furthermore, 
Table 5. Relative excess risk (RER) of death, all diagnosed patients (1989-2008)
Cardia cancer Non-cardia cancer
 RER 95% CI RER 95% CI
Sex
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ref: reference category, RER: relative excess risk, 95% CI: 95% confidence interval
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multidisciplinary consultation should be implemented prior to and after surgery and 
knowledge of the national guidelines is imperative. With these new quality standards 
for gastric cancer treatment, endorsed by the Dutch Association for Surgical Oncology, 
adherence to the guidelines implemented in 2009 can be accomplished.
For both cardia and non-cardia there was no significant improvement in 5-year survival. 
In Europe, 5-year survival rates for resected gastric cancer are 23.8-35.8% compared to a 
survival rate of 33% in cardia and 50% in non-cardia cancer in the Netherlands.20 One of 
the most important factors influencing survival is lymph node (N) stage.21,22  A minimum 
of 15 lymph nodes is recommended for gastric cancer (UICC/AJCC).23 Studies performed 
in the Netherlands show that this criterion is still not met.22,24 A modified type of lymph 
node dissection with less morbidity and mortality rates compared to a D2 dissection, 
but with more lymph nodes retrieved than a D1 dissection could be a solution. First 
results of a study investigating the role of a D1-extra dissection (dissection of lymph 
node station 3-9, and depending on location 1, 2, 10, and 12a according to the Japanese 
classification)25 are promising; a mean lymph node yield of 30.8 (range 13-58) is achieved 
with acceptable morbidity and low postoperative mortality (unpublished results). The use 
of chemotherapy has only exponentially grown since 2007. This rise has not resulted in 
an increased survival rate yet. However, it is probably too early to see any differences in 
survival curves. 
This study has some limitations. In these analyses all patients receiving surgery with 
stage I, II and III were included. However, in the NCR it is not registered whether the 
intent of a resection was curative or palliative, which might lead to an underestimation of 
survival rates, especially in stage III. Cause of death is not registered; this might lead to a 
bias in the RER and survival rates especially in the older patient. On the other hand, our 
results are consistent with results found in literature.3,4
Despite a strong increase in the use of preoperative and postoperative chemotherapy 
for gastric cancer in the Netherlands, still many patients are treated with surgery alone. 
Mortality rates have declined in the last decade, but there is still room for improvement. 
Both for cardia and non-cardia gastric cancer, long-term survival rates have not 
significantly improved over the past 20 years. More studies are needed to investigate 
the effect of a (modified) extended lymphadenectomy, the use of chemotherapy and/or 
radiotherapy and the effect of centralization on mortality and survival for patients with 
resectable gastric cancer. 
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High hospital volume is associated with better outcomes after esophagectomy and 
gastrectomy. In the Netherlands, a minimal volume standard of 10 esophagectomies 
per year was introduced in 2006.  For gastrectomy, no minimal volume standard was 
set. Aims of this study were to describe changes in hospital volumes, mortality and 
survival, and to explore if high hospital volume is associated with better outcomes after 
esophagectomy and gastrectomy in the Netherlands.
methods
From 1989-2009, 24,246 patients underwent esophagectomy (N = 10,025) or gastrectomy 
(N = 14,221) in the Netherlands. Annual hospital volumes were defined as very low (1-5), 
low (6-10), medium (11-20), and high (≥21). Volume-outcome analyses were performed 
using Cox regression, adjusting for year of diagnosis, case-mix, and the use of multi-
modality treatment.
results
From 1989-2009, the percentage of patients treated in high-volume hospitals increased 
for esophagectomy (from 7% to 64%), but decreased for gastrectomy (from 8% to 5%). 
Six-month mortality (from 15% to 7%) and thee-year survival (from 41% to 52%) improved 
after esophagectomy, and to a lesser extent after gastrectomy (six-month mortality: 15%-
10%, three-year survival: 55-58%). High hospital volume was associated with lower 
6-month mortality (HR 0.48, P < 0.001) and longer 3-year survival (HR 0.77, P < 0.001) 
after esophagectomy, but not after gastrectomy.
 
conclusions
Esophagectomy was effectively centralized in the Netherlands, improving mortality and 
survival. Gastrectomies were mainly performed in low volumes, and outcomes after 
gastrectomy improved to a lesser extent, indicating an urgent need for improvement in 
quality of surgery and perioperative care for gastric cancer in the Netherlands. 
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introduction
Esophageal and gastric cancer are highly lethal malignancies.1 Despite surgery, which is 
the cornerstone of curative treatment for these diseases, survival is low, and compared 
to other surgical procedures, postoperative mortality is high. In the Western world, five-
year survival rates are below 25% for esophageal cancer,2,3 and do not exceed 40% for 
gastric cancer.2,4 Reported postoperative mortality after esophagectomy varies from 2% 
for specialized centers5 to 10% for certain nationwide registries.6 After gastrectomy, 
postoperative mortality varies between 3% to well above 10%.7,8 To reduce mortality 
and improve survival, it has been suggested that these high-risk operations should be 
performed in specialized centers with adequate annual volumes. Many studies have 
investigated volume-outcome relations after esophagectomy and gastrectomy, but the 
relative importance of volume after gastrectomy in particular is disputed.9,10 
In the Netherlands, a relation between high hospital volume and low postoperative 
mortality was demonstrated for esophagectomy in 2000.11 Despite extensive discussions 
within the Dutch Society of Surgery, this study did not lead to significant changes 
in referral patterns for esophagectomies on a national level. Therefore, as of 2006 a 
minimum volume of 10 esophagectomies per year was enforced by the Dutch Healthcare 
Inspectorate, and as of 2011 the Dutch Society of Surgery recommends a minimal volume 
of 20 esophagectomies per year. For gastrectomy, no minimum volume standard has 
been established in the Netherlands.
Aims of the present study were to describe changes in annual hospital volumes, 
postoperative mortality, survival, and lymph node yields for esophagectomy and 
gastrectomy in the Netherlands between 1989 and 2009, and to explore whether there 
is any association between annual hospital volume for esophagectomy and gastrectomy, 
and postoperative mortality, survival, and lymph node yield.
Patients and methods
netherlands cancer registry
Data were obtained from the Netherlands Cancer Registry (NCR), which covers all 
hospitals in the Netherlands, a country of 16.5 million inhabitants. Information on 
all newly diagnosed malignancies is routinely collected by trained registrars from the 
hospital records 6-18 months after diagnosis. Quality and completeness of the data is 
high.12 
Topography and morphology were coded according to the International Classification of 
Diseases for Oncology (ICD-O).13 ICD-O morphology codes were used to classify tumors 
as adenocarcinoma (8140-8145, 8190, 8201-8211, 8243, 8255-8401, 8453-8520, 8572, 
8573, 8576), squamous cell carcinoma (SCC) (8032, 8033, 8051-8074, 8076-8123) and 
other or unknown histology (8000-8022, 8041-8046, 8075, 8147, 8153, 8200, 8230-
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8242, 8244-8249, 8430, 8530, 8560, 8570, 8574, 8575). Tumors were staged according 
to the International Union Against Cancer (UICC) TNM classification in use in the year 
of diagnosis. Vital status was initially obtained from municipal registries, and from 1994 
onwards from the nationwide population registries network. These registries provide 
complete coverage of all deceased Dutch citizens. Follow-up was complete for all patients 
until December 31st, 2009. The study was approved by the NCR Review Board.
patients
Between January 1989 and December 2009, 71,090 patients with esophageal or gastric 
cancer were diagnosed in the Netherlands (Figure 1). Patients who did not undergo 
surgical treatment (N = 43,646) and patients without information on the hospital 
were the diagnosis was established, or where surgery was performed (N = 8), were 
excluded, leaving 27,436 resections available to calculate annual hospital volumes. After 
establishing annual hospital volumes, patients with in-situ carcinoma (N = 288), and 
patients with distant metastases (N = 2902) were excluded, leaving 24,246 patients with 
non-metastatic invasive carcinoma available for volume-outcome analyses. 
surgery
Since the NCR is a topography-based registry, and the type of surgery was not specified 
for every patient, the distinction between esophageal and gastric cancer surgery was 
based on tumor location. Esophagectomies were defined as resections for cancers of the 






Netherlands Cancer Registry 1989-2009
Diagnosis of esophageal or gastric cancer
N = 71,090
Excluded (N = 43,646)
No resection
Excluded (N = 8)
No hospital in registry
Resection for esophageal or gastric cancer
N = 27,436
Excluded (N = 3,190)
In-situ/metastatic disease
Resection for M0
esophageal or gastric cancer
N = 24,246
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esophagus (C15.0-15.9) and gastric cardia (C16.0), whereas gastrectomies were defined 
as resections for non-cardia gastric cancer (C16.1-16.9). To ensure this distinction did 
not influence the results, volume-outcome analyses were repeated with cardia cancer 
coded as gastric cancer. Yearly resection rates were calculated as the number of resections 
relative to the number of cancers diagnosed in a year.
hospital volumes
Annual hospital volumes were defined as the number of esophagectomies or 
gastrectomies per hospital per year. Clinically relevant volume categories were defined 
as very low (1-5 per year), low (6-10 per year), medium (11-20 per year), and high (≥21 per 
year). From 2005-2009, the hospital where surgery was performed was registered for 
all patients. Before 2005, the hospital were surgery was performed was only registered 
in 53% of the cases, and showed an 80% overlap with the hospital of diagnosis. For the 
remaining 47%, with an unknown surgical hospital, the hospital of diagnosis was used 
to calculate hospital volume.
statistical analysis
Esophagectomy and gastrectomy were analyzed separately. Resection rates and hospital 
volumes over time were analyzed with the Chi-square test. Changes in six-month 
mortality and three-year survival were analyzed with stratified Cox regression, adjusted 
for sex, age, socio-economic status,14 stage, morphology, preoperative therapy use, 
and postoperative therapy use (only for three-year survival). Overall survival (OS) was 
calculated from the day of diagnosis until death, because the date of surgery was not 
available before 2005. Six-month OS was calculated unconditionally, while 3-year OS was 
calculated conditionally on surviving the first six months after diagnosis. Lymph node 
yields over time were adjusted for sex, age, stage, and morphology.
For volume-outcome analyses, the patient was considered the unit of analysis, with 
hospital volume as the exposure factor. Differences in survival estimates were calculated 
with Cox regression, stratified for hospital volume and adjusted for the factors used to 
analyze changes over time, and for clustering of deaths within hospitals.15 Differences in 
lymph node yields were analyzed with generalized estimated equations, adjusted for the 
factors used to analyze changes over time, and for clustering within hospitals. 
Besides analyzing hospital volume in categories, annual volume was analyzed as a linear 
variable. Analyses were performed with SPSS (version 17.0.2) and R (version 2.12.2).
results
patient characteristics
Between 1989 and 2009, 24,246 patients with resectable, non-metastatic esophageal (N 
= 10,025) or gastric cancer (N = 14,221) underwent a resection in the Netherlands. Patient 
characteristics (Table 1 and 2) varied between the different volume categories. 
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For esophageal cancer, high-volume hospitals treated more patients with squamous cell 
carcinoma and more advanced tumor stages. For gastric cancer, patients treated in high-
volume hospitals were older and had more advanced tumors. 
hospital volumes over time
From 1989 to 2009, the annual number of esophagectomies doubled (from 352 to 723), 
and the annual number of gastrectomies steadily decreased (from 1107 to 495) (Figure 2). 
The percentage of esophagectomies performed in high-volume hospitals increased from 
7% to 64%, while the number of gastrectomies performed in high-volume hospitals 
decreased from 8% to 5%. 
In 2009, 44 of the 92 hospitals (48%) in the Netherlands performed esophagectomies, 
and 91 of the 92 hospitals performed gastrectomies.
Table 1. Patient characteristics for all surgically treated patients with non-metastatic invasive 
esophageal cancer in the Netherlands between 1989 and 2009 (N = 10,025)
Annual hospital volume 1-5 6-10 11-20 ≥21
N % N % N % N % P












































































































































































































SES: socio economic status, SCC: squamous cell carcinoma, preoperative/postoperative therapy: 
chemotherapy with/without radiotherapy
aT4N1-3M0 and T1-4N3M0 gastric cancers were assigned stage IV in the 6th edition TNM-classification
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resection rates, mortality, survival and lymph node yields over the years
Resection rates slightly decreased for esophageal cancer (from 1989-2009: 31% - 29%, 
P < 0.01), and strongly decreased for gastric cancer (56%-37%, P < 0.01). Adjusted six-
month mortality after esophagectomy decreased from 14.8% in 1989 to 7.1% in 2009 
(P < 0.001), while adjusted six-month mortality after gastrectomy decreased to a lesser 
extent: from 15.2% in 1989 to 9.9% in 2009 (P < 0.001) (Figure 3a). Adjusted three-year 
conditional survival significantly increased after esophagectomy: from 41.0% in 1989 to 
52.2% in 2009 (P < 0.001). Adjusted three-year conditional survival after gastrectomy 
increased to a lesser extent: from 55.0% in 1989 to 58.4% in 2009 (P < 0.01) (Figure 
3b). The improvement in six-month mortality and three-year survival over time was 
significantly stronger after esophagectomy, when compared to gastrectomy (both P < 
0.01)
Table 2. Patient characteristics for all surgically treated patients with non-metastatic invasive 
gastric cancer in the Netherlands between 1989 and 2009 (N = 14,221)
Annual hospital volume 1-5 6-10 11-20 ≥21
N % N % N % N % P



































































































































































































SES: socio economic status, preoperative/postoperative therapy: chemotherapy with/without radiotherapy
aT4N1-3M0 and T1-4N3M0 gastric cancers were assigned stage IV in the 6th edition TNM-classification
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Mean lymph node yield after esophagectomy increased from 10.1 in 1999 to 16.2 in 
2009 (P < 0.001), and mean lymph node yield after gastrectomy increased from 8.1 in 
1999 to 12.4 in 2009 (P < 0.001) (Figure 3c).
volume-outcome relations
Results from the multivariable analyses on volume-outcome relations are shown in Table 
3 and 4. After esophagectomy, medium and high volume hospitals were associated with 
lower six-month mortality and longer three-year conditional survival when compared 

















































Figure 3. Adjusted (a) 6-month mortality , (b) 3-year conditional survival, and (c) median lymph 



































































Difference between curves: P = 0.003 
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to very-low volume hospitals (Figures 4a, 4b). After gastrectomy, neither six-month 
mortality, or three-year conditional survival were associated with hospital volume category 
(Figures 4c, 4d). High hospital volume was associated with high lymph node yield both 
after esophagectomy and gastrectomy.
When analyzing hospital volume as a linear covariate, volume-survival results remained 
the same. No changes in the results were found when volume-outcome relations were 
analyzed with surgery for cardia cancer coded as gastrectomy (data not shown).
discussion
Over the study period, the number of esophagectomies performed in high volume 
hospitals considerably increased, while in 2009 most gastrectomies were performed in 
low volume hospitals. Both six-month mortality and three-year survival improved after 
esophagectomy, but to a lesser extent after gastrectomy. In the current dataset, a volume-
survival relation was revealed for esophagectomy, but not for gastrectomy.
Since Luft et al. published the first study on volume-outcome relations for surgery,16 
many studies have emerged investigating the effect of hospital and surgeons volume 
on short term and long term outcomes for a variety of diseases, including resections for 
Figure 4. Adjusted relation between annual hospital volume and (a) 6-month mortality and (b) 
3-year conditional survival after esophagectomy, and relation between annual hospital volume and 




























































































esophageal and gastric cancer. Several large studies have shown an association between 
high hospital volume and low postoperative mortality both for esophagectomy,17-20 and 
gastrectomy17,20-22, but other studies did not find an association23-25. In a meta-analysis 
exploring volume-outcome relations, high volume surgery was associated with lower 
postoperative mortality after both esophagectomy and gastrectomy.9 A limited number 
of studies investigate the relation between hospital volume and long-term survival after 
esophagectomy and gastrectomy, with conflicting results.7,24,26,27
Table 3. Volume-outcome relations for esophagectomy (1989-2009)
6-month mortality 3-year survivala LN yieldb







































































































































































aconditional on surviving the first six months, b1999-2009
HR: hazard ratio, OR: odds ratio, SES: socio economic status, SCC: squamous cell carcinoma, 
95% CI: 95% confidence interval, Bold: significant (P < 0.05)
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Over the past two decades, the number of esophagectomies in the Netherlands has 
increased, corresponding with an increasing incidence of esophageal cancer.28 The 
decreasing incidence of gastric cancer explains the low number of gastrectomies 
currently performed in the Netherlands.29 Furthermore, the resection rate for gastric 
cancer dropped significantly, most likely the result of improved preoperative staging. 
Combined with the almost complete disappearance of surgery for reflux disease and 
ulcers, surgeons are decreasingly exposed to gastrectomies. This might partly be 
Table 4. Volume-outcome relations for gastrectomy (1989-2009)
6-month mortality 3-year survivala LN yieldb



























































































































































aconditional on surviving the first six months, b1999-2009
HR: hazard ratio, OR: odds ratio, SES: socio economic status, 95% CI: 95% confidence interval
Bold: significant (P < 0.05)
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compensated by increasing volumes of bariatric surgery for obesity, but the surgical 
techniques used differ significantly.
In the current study, increasing hospital volume was associated with lower mortality 
and increased long-term survival after esophagectomy, but not after gastrectomy. This 
observation for gastrectomies might be explained by the low number of high-volume 
gastrectomies (2.5% of all gastrectomies in the current dataset), and the low threshold for 
what was considered high volume surgery. In other studies that did find an association 
between gastrectomy in high volumes and good outcomes, the lower limit of high-
volume surgery varied from 20/year up to 264/year.17,27
The current study covers an extensive period of two decades of esophagogastric cancer 
surgery in the Netherlands, and analyzes a significant population of about 25,000 
patients. Unlike many of the large volume-outcome studies, the current study uses a 
clinical database with highly reliable data, providing complete coverage of all diagnosed 
cancers in the Netherlands. Furthermore, outcomes are case-mix adjusted, increasing 
reliability of the results.30 The absence of comorbidity in the current dataset was partly 
compensated by the use of SES, which can be considered a proxy for comorbidity.31
A potential bias when analyzing outcomes over a long period is that preoperative 
staging and (perioperative) care generally improve over time. For example, endoscopic 
ultrasound, multislice high resolution computed tomography, and PET computed 
tomography were introduced resulting in improvement of staging. Hospital volumes for 
esophagectomy significantly changed during the study period, with most high-volume 
resections performed in the more recent years. Therefore, high volume resections are 
intrinsically associated with better outcomes. However, adjusting for year of diagnosis 
offsets this effect. Another potential weakness is the unavailability of the surgery hospital 
for part of the patients treated before 2005. Instead, the hospital of diagnosis was used. 
However, this only happened in the first years of the study, when hospitals less frequently 
referred patients to another hospital for surgery. 
A point of discussion might be that volumes are analyzed on hospital level, rather than 
surgeon level.7,27,32 Quality of care, however, consists of more than an individual surgeon’s 
performance. Perioperative care, anesthesia, ICU staffing, experience of the nursery staff, 
and collaboration between different disciplines all contribute to outcomes associated 
with the performed procedure.33 The role of the surgeon is only one, yet important, factor 
contributing to outcome.
Initiatives to improve medical and especially surgical care are legion. Randomized 
trials improve care by selecting appropriate treatments for certain indications,3,34 and by 
educating surgeons participating in the trial.35,36 However, the majority of cancer patients 
are treated outside trials, and especially improvements in the process and structure of 
care on a nation-wide level will bring benefit to this group of patients. Many studies have 
advocated the centralization of low-volume, high-risk operations, thereby improving 
nationwide quality of care.11,27 Centralization of esophageal and gastric cancer is currently 
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performed in several European countries, whereas referral to high-volume centers is also 
advocated in the United States by the Leapfrog group.37 In Denmark, centralization of 
gastric cancer surgery from 37 to 5 hospitals leaded to a drop in postoperative mortality 
from 8.4% to 2.1% over a period of 5 years.38 
Unlike the Netherlands, which is a relatively small country with good infrastructure, 
centralization of care in countries with large rural areas might lead to unreasonable 
travel burdens and problems with continuity of care after surgery. Therefore, others have 
advocated implementing processes that are related to excellent outcomes in low volume 
hospitals, but identification of these processes remains challenging.39
Meanwhile, using hospital volume as the sole basis for referral to improve outcomes is 
criticized.17 Although hospital volume can reliably identify groups of hospitals with better 
results on average, individual low volume hospitals can have excellent outcomes and vice 
versa. In contrast to volume-based referral, outcome based-referral avoids this problem 
and has proven its value for esophagectomy in the Western part of the Netherlands. In this 
area, a prospective audit was conducted to identify hospitals with excellent performance 
in esophagectomy. During the five-year audit, a gradual concentration towards centers 
with excellent performance occurred, leading to a drop in postoperative mortality (12% to 
4%) and an improvement in survival.40
Combining centralization with auditing substantially adds to improvement of care.41 
With auditing, providers of care are monitored and their performance is benchmarked 
against their peers. Auditing is performed on a national level for esophagogastric cancer 
in Denmark,38 Sweden and the United Kingdom. A nationwide audit for both esophageal 
and gastric cancer surgery has started in the Netherlands as of 2011 aiming for complete 
coverage of all esophagectomies and gastrectomies.
In conclusion, enforcing centralization for esophagectomy in the Netherlands has 
resulted in a shift in annual hospital volumes: most resections are currently performed in 
high volume centers. For gastrectomy, no minimum number of resections was required, 
and the majority of gastric cancer resections were performed in low volume hospitals. 
However, as of 2012 gastrectomies in the Netherlands will be centralized to a minimum 
of 10/year, and as of 2013 to a minimum of 20/year. Esophagectomy in high volume 
hospitals is associated with improved outcomes. No such relation for gastric cancer could 
be established in the current dataset, but only a minority of patients was treated in high 
volume hospitals. Over the past two decades, short-term mortality and long-term survival 
after esophagectomy decreased significantly, while outcomes after gastrectomy improved 
to a lesser extent, indicating an urgent need for improvement in quality of surgery and 
perioperative care for gastric cancer in the Netherlands. 
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Outcomes after esophagectomy and gastrectomy vary considerably between hospitals. 
Possible explanations include differences in case mix, hospital volume and hospital type. 
The present study examined the distribution of esophagectomies and gastrectomies 
between hospital types in the Netherlands, and the relationship between hospital type 
and outcome.
patients and methods
Data were obtained from the nationwide Netherlands Cancer Registry. Hospitals were 
categorized as university hospitals (UH), teaching non-university hospitals (TNUH) and 
non-teaching hospitals (NTH). Hospital type-outcome relationships were analyzed by 
Cox regression, adjusting for case mix, hospital volume, year of diagnosis and use of 
multimodal therapies.
results
Between 1989 and 2009, 10,025 esophagectomies and 14,221 gastrectomies for 
cancer were performed in the Netherlands. The percentage of esophagectomies and 
gastrectomies performed in UH increased from 17.6% and 6.4% respectively in 1989 
to 44.1% and 12.9% in 2009. After esophagectomy, the 3-month mortality rate was 2.5% 
in UH, 4.4% in TNUH and 4.1% in NTH (P = 0.006 for UH versus TNUH). After 
gastrectomy, the 3-month mortality rate was 4.9% in UH, 8.9% in TNUH and 8.7% in 
NTH (P < 0.001 for UH versus TNUH). Three-year survival was also higher in UH than 
in TNUH and NTH.
conclusions
Esophagogastric resections performed in UH were associated with better outcomes but, 
owing to variation in outcomes within hospital types, centers of excellence cannot be 
designated solely on hospital type. Detailed information on case mix and outcomes is 
needed to identify centers of excellence.
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introduction
Long-term survival for patients with resectable esophageal and gastric cancer is low in 
the Western world. The 5-year overall survival rate is below 25% after esophagectomy and 
less than 40% after gastrectomy.1,2 Both are high-risk operations with correspondingly 
high postoperative mortality rates.3,4
Both postoperative mortality and long-term survival after esophagogastric cancer surgery 
can be improved by performing these complex procedures in centers with sufficient 
experience and high annual volumes.3,5 An exact cut-off value that defines high-volume 
surgery has not, however, been established. In a recent survey of all esophagectomies and 
gastrectomies performed in the Netherlands between 1989 and 2009, esophagectomies 
carried out in high-volume hospitals (more than 20 procedures per year) were associated 
with lower postoperative mortality and improved survival compared with those performed 
in low-volume hospitals. No such relationship was found after gastrectomy, but the 
number of high-volume hospitals was small.6
Although hospital volume can be used as a proxy for quality of care, another approach 
is to compare outcomes by type of hospital in which the surgery takes place.7 University 
hospitals have been associated with better outcomes than non-university hospitals for 
a variety of procedures and diseases, including radical prostatectomy,8 heart failure, 
myocardial infarction and stroke.9,10 In a previous study, no difference was found in 
survival after gastrectomy between university teaching, non-university teaching and non-
teaching hospitals, although the number of patients and hospitals was limited.11 The 
effect of hospital type on outcomes after esophagogastric resections remains unclear.
The present study aimed to describe the distribution of esophagectomies and gastrectomies 
between hospital types in the Netherlands between 1989 and 2009, and to analyze the 
effect of hospital type on short- and long-term outcomes after these operations.
methods
netherlands cancer registry
Data were obtained from the Netherlands Cancer Registry (NCR), in which information 
on all newly diagnosed malignancies in the Netherlands, a country of 16.5 million 
inhabitants, was collected. Patient, tumor and treatment characteristics were collected 
routinely by trained registrars from the hospital records 6-18 months after diagnosis. The 
quality and completeness of the data are known to be almost 100%.12
Topography and morphology were coded according to the International Classification of 
Diseases for Oncology (ICD-O).13 ICD-O morphology codes were used to classify tumors 
as adenocarcinoma (8140-8145, 8190, 8201-8211, 8243, 8255-8401, 8453-8520, 8572, 
8573, 8576), squamous cell carcinoma (8032, 8033, 8051-8074, 8076-8123) and other 
or unknown histology (8000-8022, 8041-8046, 8075, 8147, 8153, 8200, 8230-8242, 
8244-8249, 8430, 8530, 8560, 8570, 8574, 8575). Tumors were staged according to the 
International Union Against Cancer tumor node metastasis (TNM) classification in use 
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in the year of diagnosis. Vital status was obtained initially from municipal registries, and 
from 1994 onwards from the nationwide population registries network. These registries 
provide complete coverage of all deceased Dutch citizens. Follow-up was complete for all 
patients until 31 December 2009. The study was approved by the NCR Review Board.
Esophagectomy and gastrectomy were analyzed separately. As the NCR is a topography-
based registry, esophagectomies were defined as resections for cancers of the esophagus 
(C15.0-15.9) and gastric cardia (C16.0), whereas gastrectomies were defined as resections 
for non-cardia gastric cancer (C16.1-16.9).
If the hospital of surgery was not registered, the hospital of diagnosis was assumed 
to be the hospital of surgery. Annual hospital volumes were defined as the number of 
esophagectomies or gastrectomies per hospital per year. Volume categories were defined 
as very low (1-5 per year), low (6-10 per year), medium (11-20 per year) and high (at least 
21 per year). Hospital types were defined as university hospitals, teaching non-university 
hospitals and non-teaching hospitals. University hospitals are attached to one of the 
eight universities in the Netherlands, and these hospitals collaborate closely with the 
corresponding medical faculty. A hospital was considered a teaching hospital if it offered 
(part of) a surgical residency programme.
statistical analysis
Changes in the distribution of operations between hospital types over time and 
differences in patient characteristics between hospital types were analyzed by means of 
the χ2 test. Overall survival was calculated from the day of the histological diagnosis until 
death, because the date of surgery was not available before 2005. Three-month overall 
survival was calculated unconditionally, whereas 3-year overall survival was calculated 
conditionally on surviving the first 3 months after diagnosis. Possible relationships 
between hospital type and outcomes were analyzed by stratified Cox regression, adjusted 
for annual hospital volume, year of diagnosis, sex, age, socioeconomic status,14 tumor 
stage, morphology, preoperative therapy use, postoperative therapy use (only for 3-year 
survival) and for clustering of deaths within hospitals.15 A separate analysis was performed 
including only patients diagnosed between 2005 and 2009. To assess potential referral 
bias, analyses were repeated for hospital of diagnosis instead of hospital of surgery. 
Analyses were performed with SPSS® version 17.0.2 (SPSS, Chicago, Illinois, USA) and 
R version 2.12.2 (R Project for Statistical Computing, Vienna, Austria). 
results
Between January 1989 and December 2009, 71,090 patients with esophageal or gastric 
cancer were diagnosed (Figure 1). Some 43,646 patients who did not undergo surgical 
treatment and eight without information on the hospital of diagnosis or surgery were 
excluded, leaving 27,436 resections for analysis. 
Before 2005, the hospital where the resection was performed was registered in 53.3% 
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of cases, showing a match with the hospital of diagnosis in 79.8% of patients. For the 
remaining 46.7% of cases, the hospital of diagnosis was considered the hospital of 
surgery. 
After analyzing hospital type distributions and their relation with annual hospital volume, 
288 patients with carcinoma in situ and 2902 with distant metastases were excluded, 
leaving 24,246 patients with non-metastatic invasive carcinoma available for hospital 
type-outcome analyses. 
hospital types over time
There are eight university hospitals in the Netherlands and one specialized cancer center 
that was analyzed as a university hospital. The number of non-university hospitals where 
esophagectomies and gastrectomies were performed decreased, from 120 in 1989 to 82 
in 2009. 
The annual number of esophagectomies increased over the years, from 352 in 1989 to 
723 in 2009 (Figure 2a). The percentage of esophagectomies performed in university 
hospitals increased from 17.6% (62/352) in 1989 to 44.1% (319/723) in 2009 (P < 0.001). 
The annual number of gastrectomies decreased from 1107 in 1989 to 495 in 2009 
(Figure 2b). The percentage of gastrectomies performed in university hospitals increased 
from 6.4% (71/1107) in 1989 to 12.9% (64/495) in 2009 (P < 0.001). Most gastrectomies 
are currently performed in teaching non-university hospitals.






Netherlands Cancer Registry 1989-2009
Diagnosis of esophageal or gastric cancer
N = 71,090
Excluded (N = 43,646)
No resection
Excluded (N = 8)
No hospital in registry
Resection for esophageal or gastric cancer
N = 27,436
Excluded (N = 3,190)
In-situ/metastatic disease
Resection for M0
esophageal or gastric cancer
N = 24,246
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patient, tumor and treatment characteristics
Between 1989 and 2009, 10,025 patients underwent esophagectomy and 14,221 
underwent gastrectomy for cancer (Tables 1 and 2). The median age of patients who 
underwent esophagectomy in university hospitals was 63 years, compared with 64 and 
65 in teaching non-university and non-teaching hospitals respectively. They were more 
likely to have a squamous cell carcinoma (26.1% in university hospitals versus 20.9% 
and 19.9% in teaching non-university and non-teaching hospitals respectively) and had 
higher tumor stages (stage III disease in 39.0% (1388/3559),  33.4% (1306/3905) and 
Table 1. Characteristics for all patients with resected non-metastatic esophageal cancer in the 
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SES: socio economic status, SCC: squamous cell carcinoma, preoperative/postoperative therapy: 
chemotherapy with/without radiotherapy
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34.4% (881/2561) respectively). A higher proportion of patients in university hospitals 
received multimodal therapy. Annual hospital volumes were higher in university 
hospitals: 69.9% of esophagectomies (2488/3559) in such hospitals were performed in 
centers with an annual volume of at least 21, compared with 11.1% (434/3905) in teaching 
non-university hospitals and no esophagectomies in non-teaching hospitals. 
Patients who underwent a gastrectomy in university hospitals had a median age of 
67 years, compared with 71 years in both types of non-university hospital. Patients in 
university hospitals also received more preoperative and postoperative multimodal 
Table 2. Characteristics for all patients with resected non-metastatic gastric cancer in the 
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therapy. Annual hospital volumes were highest in non-university teaching hospitals: 
43.9% of gastrectomies (2503/5702) in teaching non-university hospitals were performed 
in centers with an annual volume of ≥11, compared with 34.1% (386/1132) in university 
hospitals and 24.7% (1822/7387) in non-teaching hospitals.
relationship between hospital type and outcomes
In multivariable regression analysis adjusting for case mix, annual hospital volume, year 
of diagnosis and use of multimodal therapy, both esophagectomies and gastrectomies 
in university hospitals were associated with lower 3-month mortality and higher 3-year 
survival (Table 3). 
The adjusted 3-month mortality rate after esophagectomy was 2.5% (95% confidence 
interval 1.8-3.2%) in university hospitals, 4.4% (3.5-5.2%) in teaching non-university 
hospitals and 4.1% (3.2-5.0%) in non-teaching hospitals (Figure 3a). Corresponding 
3-year survival rates were 46% (44-49%), 42% (40-44%) and 43% (40-59%) (Figure 3b). 
Adjusted 3-month mortality rates after gastrectomy were 4.9% (3.7-6.1%) in university 
hospitals, 8.9% (8.1-9.7%) in teaching non-university hospitals and 8.7% (8.0-9.4%) in 
non-teaching hospitals (Figure 3c). Respective 3-year survival rates were 58% (55-61%), 
52% (51-54%) and 52% (51-54%) (Figure 3d). 
Hospital type-outcome analyses including only patients diagnosed between 2005 and 
2009 produced no major changes in the results, except that the difference in 3-year 
survival after gastrectomies between hospital types became non-significant (not shown). 
When analyses for 1989-2009 were repeated with the hospital of diagnosis instead of 
the hospital of surgery, again no major changes were found, although 3-month mortality 
after esophagectomy lost significance (not shown). When the analyses were repeated 
with university hospitals as the reference category, these hospitals were found to be 
associated with a significantly lower 3-month mortality rate after both esophagectomy 
and gastrectomy, and significantly better 3-year survival after gastrectomy, compared with 
non-teaching hospitals (not shown).
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performance of individual hospitals
Analysis of 3-month mortality rates at the level of individual hospitals indicated that 
most university hospitals had good outcomes (Figure 4). There were, nevertheless, 
non-university hospitals with outcomes similar to, or better than those of all university 
hospitals. There were also university hospitals with average outcomes. The number of 
patients per hospital was too small for statistical assessment of differences in outcomes 
between hospitals.
Figure 3. Relationship between hospital type and 3-month mortality and 3-year survival for (a, b) 






















































































































































The effect of hospital type on outcomes after esophagectomy or gastrectomy has been 
studied in a limited way before in the Netherlands.11,16 In a large American study, 
postoperative mortality after esophagectomy and gastrectomy in National Cancer Institute 
(NCI)-designated hospitals was lower than in non-NCI hospitals, even after adjustment 
for hospital volume.7 Most of these NCI centers are university hospitals.
In the present study, the increasing number of esophagectomies in the Netherlands 
reflects the increasing incidence of esophageal cancer. This increase has been taken 
up by university and teaching non-university hospitals. University hospitals have high 
annual volumes, whereas non-university hospitals operate in lower volumes.
In contrast, the incidence of gastric cancer is declining, leading to a smaller number 
of gastrectomies over the years.17 Although the absolute number of gastrectomies in 
university hospitals (approximately 100 per year) and teaching non-university hospitals 
(about 300 per year) has remained stable, the number performed in non-teaching 
hospitals has decreased. Most centers, even university hospitals, performed fewer than 
11 gastrectomies annually. In 2012, gastrectomy will be centralized in the Netherlands to 
hospitals with a minimum annual volume of 20 per year, mainly towards those centers 
currently performing esophagectomy.
In the present study, outcomes after esophagectomy and gastrectomy were better in 
university hospitals than in non-university hospitals, but there were no significant 
differences between teaching non-university hospitals and non-teaching hospitals. 
Despite differences of approximately 10% between university and non-university 
hospitals, 3-year survival rates after gastrectomy in the Netherlands remain low compared 
with Asian outcomes.18 This difference might be explained by differences in tumor stage 
at presentation, stage migration owing to more extended lymph node retrieval, and 
intrinsic biological differences between Western and Asian patients with gastric cancer.19 
Studies comparing outcomes between hospitals are vulnerable to various types of 
bias. The present methodology was chosen to limit some of these factors. Most 
esophagectomies performed in recent years were performed in university and teaching 
non-university hospitals. As quality of care in general is likely to have improved over 
the years, better outcomes for operations performed in university and teaching non-
university hospitals might reflect improvements in perioperative care over the years, 
rather than a true difference between hospital types. Adjustment for year of diagnosis 
was used to eliminate this effect. 
Adjustments were also made for annual hospital volume, reducing the effect of hospital 
volume on outcome when examining hospital types. Referral bias was assessed by 
repeating the analyses with the hospital of diagnosis instead of the hospital of surgery. 
No major differences in the results were found, indicating that the better outcomes in 
university hospitals were not the result of selective referral of healthier patients from 
non-university to university hospitals. A third of all esophagectomies were performed in 
239chapter 15
university hospitals, but only 8.0% of gastrectomies.  This tends to reduce the impact of 
the observation that university hospitals had better outcomes after gastrectomy.
The differences in outcomes between university and non-university hospitals may not 
be simply explained by type of hospital, regardless of any other factors. Rather, hospital 
Table 3. Multivariate Cox regression analysis of the relationship between hospital type and 
outcomes after esophagectomy and gastrectomy, 1989-2009 
Esophagectomy Gastrectomy
3-month mortality 3-year survival 3-month mortality 3-year survival
HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Hospital type




















































































































































































































































HR: hazard ratio, 95% CI: 95% confidence interval, SCC: squamous cell carcinoma, Bold: significant (P < 0.05)
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type might act as a proxy for differences in infrastructure and processes of care between 
different types of hospitals. In the Netherlands, university hospitals have higher staff-
to-patient ratios, more financial resources per patient, more specialized treatments,20 
and have higher-level intensive care units than non-university hospitals.21 Furthermore, 
individual hospitals may differ in quality of the diagnostic process, patient selection, 
administration of multimodal therapy, perioperative care, quality of surgery and ability to 
deal with complications. Excellent performance in all parts of this multidisciplinary care 
pathway contributes to a high standard of care and favorable outcome.22 Identification of 
centers of excellence should be based on robust and case mix-adjusted data provided by 
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In several European countries, centralization of esophagogastric cancer surgery has been 
realized and clinical audits have been initiated. Aims of the present study were to evaluate 
differences in resection rates, outcomes, and annual hospital volumes between these 
countries, and to analyze the relation between annual hospital volume and outcomes.
patients and methods
National data were obtained from cancer registries or clinical audits in the Netherlands, 
Sweden, Denmark, and England. Differences in outcomes were analyzed between 
countries and between hospital volume categories, adjusting for available case-mix 
factors.
results
Between 2004 and 2009, 10,854 esophagectomies and 9,010 gastrectomies were 
registered. Resection rates in England were 18.2% and 21.6% for esophageal and gastric 
cancer, compared with 28.5-29.9% and 41.4-41.9% in the Netherlands and Denmark (P 
< 0.001). Adjusted 30-day mortality after esophagectomy was lowest in Sweden (1.9%). 
After gastrectomy, adjusted 30-day mortality was significantly higher in the Netherlands 
(6.9%) compared with Sweden (3.5%) and Denmark (4.3%) (P < 0.05). Increasing 
hospital volume was associated with lower 30-day mortality after esophagectomy (odds 
ratio 0.55 for ≥41/year versus 1-10/year, 95%CI 0.42-0.72) and gastrectomy (odds ratio 
0.64 for ≥21/year versus 1-10/year, 95%CI 0.41-0.99)
conclusions
The present results demonstrate a lower 30-day mortality in hospitals performing 
higher numbers of esophagogastric cancer resections. However, differences in outcomes 
between several European countries could not be explained by existing differences in 
hospital volumes. To understand these differences in outcomes and resection rates, and 
to provide more reliable case-mix adjustments, a uniform European Upper GI Cancer 
Audit recording standardized data is warranted.
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introduction
Quality assurance is increasingly acknowledged as a crucial factor for improvement of care 
for patients with esophageal and gastric cancer. In Europe, the average five-year survival 
rate is 11% for esophageal cancer, and 25% for gastric cancer, but variation between and 
within countries is considerable.1 The reasons for these inter and intra country variations 
are difficult to assess. In some countries there are nationally sponsored cancer registries 
whereas others have established clinical audits. Furthermore the data recorded is variable 
and there are differences in data interpretation. Thus comparison of outcomes can be 
limited.  One of the key elements to any comparison is the completeness of the recorded 
data in order to eliminate any bias as this would adversely affect any resultant change in 
service configuration and therefore outcome. 
In the Netherlands, Sweden, Denmark, and England programs and processes have 
been established which are designed to achieve as comprehensive data collection as 
possible with the aim of quality assuring treatment of esophageal and gastric cancer. 
The purposes of the current study are to evaluate differences in annual hospital volumes, 
resection rates and treatment outcomes in these four countries and to determine where 
improvements can be made to allow better inter country comparisons.
Patients and methods
National data were obtained from cancer registries in the Netherlands and England, 
and from clinical audits in Sweden and Denmark (Table 1). The Cancer Registries from 
the Netherlands and England, and the audit from Denmark, provide national coverage 
of all patients with a diagnosis of esophagogastric cancer. In the Swedish audit, only 
patients who underwent surgery were included, and therefore no resection rates could 
be calculated for Sweden. Furthermore, in several Swedish regions, not all patients 
who underwent surgical resection were registered. To reduce the chance of selection 
bias, only Swedish regions with a case ascertainment above 90% were included. These 
were Uppsala-Örebro (2006-2009), Norra (2006-2009), Sydöstra (2007-2009), and 
Stockholm-Gotland (2008-2009). 
Detailed data from patients included in the UK National Esophago-Gastric Cancer Audit 
(NOGCA) have not been included as the case ascertainment at 71% is lower than the 
population based English Cancer Registry data, which partly reflects the voluntary nature 
of the NOGCA.2 
Resection rates were calculated in the cohort of patients with a diagnosis of esophageal or 
gastric cancer between 2004 and 2009 (not all countries had data in each year, (Figure 
1). Postoperative mortality, survival, and annual hospital volumes were calculated in the 
cohort of patients who underwent surgical resection between 2004 and 2009.
246 part iii
data availability
Demographic data were available in all datasets, but comorbidity data were not uniformly 
registered and could therefore not be used for case-mix adjustments. Tumor location and 
histology based on the International Classification of Diseases for Oncology (ICD-O) were 
available in all datasets.3 Tumor location was defined as esophagus (ICD-O C15.0-16.0), 
or stomach (ICD-O C16.1-16.9). Staging was performed according to the 6th edition of the 
International Union Against Cancer (UICC) TNM classification.4 Information on TNM 
stage group was not available for the English data as stage was not routinely recorded 
during the study period by the English registries.
calculation of annual hospital volumes
The hospital (in England: trusts, some of which manage several hospitals) where the 
operation was performed was available in all datasets. Annual hospital volume was 
defined separately for esophagectomy and gastrectomy as the number of resections 
per hospital in each calendar year. Volume categories were defined according to the 
distribution of resection numbers among hospitals (Figure 2).
statistical analyses
Data regarding esophagectomies and gastrectomies were analyzed separately. Differences 
in patient characteristics, resection rates, and annual hospital volumes between countries 
were analyzed with the Chi-square test. 
Figure 1. Study profile
Calculation of resection rates
Resection for esophageal or gastric cancer
NL (2005-2009): N = 5,791
SW (2006-2009): N = 653a
DK (2004-2009): N = 1,420
EN (2004-2008): N = 12,000
Resection for non-metastatic esophageal 
or gastric cancer
NL (2005-2009): N = 5,153
SW (2006-2009): N = 606a
DK (2004-2009): N = 1,334
Calculation of adjusted 2-year survival
Excluded
NL/SW/DK M1 patients: N = 771
EN all patients:  N = 12,000b
Diagnosis of esophageal or gastric cancer
NL (2005-2009): N = 18,041
DK (2004-2009): N = 4,283
EN (2004-2008): N = 62,306
Calculation of hospital volumes,
adjusted 30-day mortality,
unadjusted 2-year survival
NL: Netherlands, SW: Sweden, DK: Denmark, EN: England
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Table 1. Characteristics of participating countries and available datasets
Country Netherlands Sweden Denmark England
inhabitants (x106) 16.7 9.4 5.5 52
incidence esophageal cancer (m/f)a 8.0 / 2.5 3.9 / 0.9 6.1 / 1.7 9.2 / 3.4
incidence gastric cancer (m/f)a 9.7 / 4.2 6.2 / 2.9 7.1 / 3.5 8.9 / 3.7
Centralization of surgery
centralization of esophagectomy 2006: 10/yearb no 2003: 5 centres
2008: 4 centres
2001: 40/yearb




registry used Netherlands 
Cancer Registry
National 














registry type cancer registry clinical audit clinical audit cancer registry
registry active since 1989 2006 2003 multiple years
data collection trained 
registrars





years of diagnosis in dataset 2005-2009 2006-2009 2004-2009 2004-2008
follow-up until January 2010 April 2011 January 2011 December 2009
case ascertainment nationwide partialc nationwide nationwide
Data availability




























































aincidence per 100,000 world standard ratio, Karim-Kos et al.39
bminimal annual hospital volume
cin certain regions in Sweden, case ascertainment was incomplete. Therefore, regions with a case ascertainment below 90% 
were excluded
E: esophagus, EGJ: esophagogastric junction, S: stomach, AC: adenocarcinoma, SCC: squamous cell carcinoma, 
+ yes, - no, ± sometimes
Figure 2. Distribution of (a) esophagectomy (N = 10,854), (b) gastrectomy (N = 9,010) 









































































Postoperative mortality was defined as death from any cause within 30 days after surgery. 
In-hospital mortality data was not available from all the four data sources. Differences in 
30-day mortality between countries were analyzed with generalized estimating equations, 
adjusting for available case-mix factors (sex, age, morphology) and clustering of patients 
within hospitals using a random hospital effect model.5 Two-year overall survival after 
surgery was chosen as the long term outcome because of the relatively short follow-up 
period due to the recent nature of the data, and was calculated from the day of surgery 
until death from any cause (event) or alive at last follow-up (censored). Detail of cause 
of death was not available. Unadjusted two-year overall survival for each country was 
calculated with Kaplan Meier analysis. Adjusted differences in two-year overall survival 
between countries were analyzed with Cox regression, adjusting for case-mix factors 
as categorical covariates (sex, age, morphology, stage group) and clustering of patients 
within hospitals. English patients were excluded from the adjusted two-year survival 
analyses as stage data were not available. 
Differences in outcomes between hospital volume categories were evaluated in the 
same way as differences in outcomes between countries, including the adjustment for 
clustering of patients within hospitals. An interaction analysis was performed between 
country and annual hospital volume. Annual hospital volume was analyzed as a 
categorical variable and also as a linear variable. Statistical analyses were performed with 
SPSS (version 17.0.2) and R (version 2.12.2).
results
resection rates
Between January 2004 and December 2009, 84,630 patients with a diagnosis of 
esophageal or gastric cancer were registered in the Netherlands, Denmark, or England 
(Figure 1). Resection rates were similar in the Netherlands and Denmark, approximately 
29% for esophageal cancer, and 41% for gastric cancer. Resection rates in England were 
significantly lower: 18% for esophageal cancer and 22% for gastric cancer (both P < 
0.001). 
patient characteristics of resected patients
Between 2004 and 2009 19,864 patients underwent esophagectomy or gastrectomy for 
cancer (Table 2). Median age was 64 years for all patients who underwent esophagectomy 
and 71 for all patients who underwent gastrectomy. The percentage of patients 
undergoing resection with an age above 75 years was lowest in Denmark: 7.1% (63/892) 
for esophagectomy, and 22.7% (120/528) for gastrectomy, compared with 9.9-10.8% 
for esophagectomy and 32.4-38.4% for gastrectomy in the other countries. The highest 
proportion of stage I patients (esophagectomy: 15.8%, [446/2819] and gastrectomy 
34.2%, [1015/2972]) and the highest proportion of stage IV patients (oesophagectomy: 
12.0% [339/2819] and gastrectomy 17.1% [508/2972]) were recorded in the Netherlands.
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Table 2. Patient characteristics for patients who underwent esophagectomy (N = 10,854) or 
gastrectomy (N = 9010) for cancer
Country Netherlands Sweden Denmark England
N % N % N % N % P
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Country Netherlands Sweden Denmark England
N % N % N % N % P
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a Majority of this group: in the 6th edition TNM classification for gastric cancer, T4N+M0 and T1-3N3 cancers 
were assigned stage IV. A smaller part of this group are palliative resections for gastric cancers.
bChi square test: England excluded
cCalculated by excluding unknown stage and considering stage group as continuous variable
SCC: squamous cell carcinoma
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differences in outcomes between countries
Median follow-up for all patients was 37 months. In all countries, postoperative 30-
day mortality was lower after esophagectomy (4.6%) than after gastrectomy (6.7%), 
but variation between countries was considerable. Adjusted 30-day mortality after 
esophagectomy was lowest in Sweden (1.9%), and highest in England (5.8%), (P = 
0.028) (Figure 3a, Table 3). Differences between other countries were not significant. 
After gastrectomy, adjusted 30-day mortality in the Netherlands (6.9%) was significantly 
higher when compared to Sweden (3.5%, P = 0.017), and Denmark (4.3%, P = 0.029), 
(Figure 3b). Unadjusted 2-year overall survival estimates were not significantly different 
between countries, except for 2-year survival after gastrectomies between the Netherlands 
and England (51.9% versus 56.3%, P < 0.001) (Table 3). Adjusted two-year survival rates 
were not significantly different between the Netherlands, Sweden, and Denmark, in 
either resection group (Figure 4, Table 3).
Figure 3. Postoperative 30-day mortality after (a) esophagectomy and (b) gastrectomy, 
adjusted for sex, age, and histology
Figure 4. Two-year survival after (a) esophagectomy and (b) gastrectomy, adjusted for sex, age, 
histology, and stage group
NL: Netherlands, SW: Sweden, DK: Denmark, EN: England
NL: Netherlands, SW: Sweden, DK: Denmark






















































































differences in outcomes in relation to hospital volume
Overall, annual hospital volumes for esophagectomies were higher than for gastrectomies 
(Figure 2). Variation between countries is shown in Figure 5. In Denmark, 65.6% of 
esophagectomies were performed in hospitals with an annual volume above 30 per year, 
while a similar proportion (63.6%) was performed in Sweden in hospitals with an annual 
volume of less than 11 per year. Fifty nine per cent of all gastrectomies for cancer were 
performed in Denmark in hospitals with an annual volume above 20 per year, whereas 
over 75% of gastric resections were performed in the Netherlands and in Sweden in 
Table 3. Differences in postoperative 30-day mortality and two-year survival between countries
Esophagectomy Gastrectomy
30-day mortality




(NL, SW, DK, EN)
two-year survival
(NL, SW, DK)
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NL: Netherlands, SW: Sweden, DK: Denmark, EN: England, 95%CI: 95% confidence interval, OR: odds ratio, 
HR: hazard ratio, ref.: reference category, SCC: squamous cell carcinoma, Bold: significant (P < 0.05)
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hospitals with an annual volume of less than 11 per year, and 68.9% of gastrectomies in 
England were performed in annual hospital volumes of less than 21 per year.
Increasing hospital volume was significantly associated with lower postoperative 
mortality, both after esophagectomy and gastrectomy (Figure 6, Table 4). Adjusted 30-day 
mortality after esophagectomy in hospitals with an annual volume of at least 41 per year 
was lower than in hospitals with an annual volume of less than 11 per year (4.3% versus 
7.2%; P < 0.001). Adjusted 30-day mortality after gastrectomy in hospitals with an annual 
volume of at least 21 per year was also lower at 4.4% than in hospitals with an annual 
volume of less than 11 per year (6.7%, P = 0.047). Testing for interaction between country 
and hospital volume category revealed a significant interaction regarding postoperative 
30-day mortality after esophagectomy, which was the result of a stronger volume-outcome 
relation in Denmark than in the other countries (not shown). No such interaction was 
found for gastrectomy. 
High hospital volume was also significantly associated with better two-year survival after 
esophagectomy, with a hazard ratio of 0.79 (95%CI 0.66-0.96) for the highest volume 
group (≥41 per year) compared with the lowest volume group (1-10 per year). There was 
no statistically significant association between hospital volume and two-year survival 
after gastrectomy (Table 4, Figure 7). No interaction was found between country and 
hospital volume category regarding two-year survival.
discussion
This study has shown variations in annual hospital volumes for esophagectomy and 
gastrectomy with highest volumes in Denmark. Resection rates were similar in the 
Netherlands and Denmark but considerably lower in England. Postoperative 30-day 
mortality was lowest in Sweden, both after esophagectomy and gastrectomy, and 30-day 
mortality after gastrectomy in the Netherlands was significantly higher compared with 
Sweden and Denmark. Higher numbers of stage I and stage IV esophageal and gastric 
cancers were resected in the Netherlands than in the other countries. Increasing hospital 
volume was associated with lower postoperative mortality after both esophagectomy and 
gastrectomy. Two year adjusted survival after surgery was similar in each country, with 
longer overall survival after esophagectomy.
sources of data
Studies on outcomes after cancer surgery are commonly based on data from clinical 
trials or on patient series from specialized surgical centers. Due to selection of patients, 
such series do not reflect the general practice and cannot be used to compare outcomes 
between countries. Population-based studies, as performed by EUROCARE, provide 
insight in differences in mortality and survival patterns between countries.1 In the 
EUROCARE framework, however, for some countries only part of the national cancer 
registries is covered, and no data from recent years are available. Furthermore, it is 
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intended for incidence and survival trend analyses, and not to monitor clinical practice 
or to provide feedback to individual health care providers. Nationwide clinical audits, as 
currently performed in the UK, Sweden, Denmark, and the Netherlands, provide detailed 
information on patient, tumor, treatment, and hospital characteristics, and data are 
quickly available for comparative analyses. However, a disadvantage of clinical audits is 
that data are reported by the health care provider and are therefore not always complete. 
In contrast, cancer registries mostly include all available patients, but the captured 
information is less detailed. For example, patient comorbidity was missing in the Dutch 
and English dataset, and tumor stage in the English dataset. The lack of this information 
may bias the outcome data and may even partly explain some of the differences.
resection rates
In the current study, resection rates for both esophageal and gastric cancer were lower 
in England than in the Netherlands and Denmark (and not available in Sweden). The 
UK NOGCA has confirmed a steady reduction in resection rates over the past decade 
describing rates of curative resection for esophageal junctional and gastric cancer 
respectively of 33% and 31% in 1998 decreasing to 24% and 23% in 2005,6 which has been 
attributed to improved preoperative staging and multidisciplinary management, thereby 
better selecting patients for surgery.7 Comparison of resection rates is also confounded 
by differences in clinical practice, but with the current datasets no conclusions can be 
drawn on which country has the optimal resection rate. This should be addressed in 
future studies with adequate information on preoperative staging.
differences in centralization of surgery
A Dutch study published in 2001 showed lower postoperative mortality after 
esophagectomies in high volume hospitals, and as of 2006 esophagectomies in the 
Netherlands were centralized with a minimum annual volume of 10/year.8 As of 2011, 
this was increased to 20/year. Over the study period, there was no minimum volume 
standard for gastrectomy, but gastrectomies will be centralized as of 2012. In addition 
in 2011, a national esophagogastric cancer audit has started.9 This may answer why 
the resection rate in stage IV disease is higher than elsewhere as it may reflect clinical 
practice in peripheral hospitals where preoperative assessment is less robust.
In Sweden, a national esophagogastric cancer audit was initiated in 2006. Both 
esophagectomies and gastrectomies were performed in low volumes, but very recently, 
also Sweden has started centralization of upper GI surgery. In Denmark, a nationwide 
esophagogastric cancer registry has been initiated, and upper GI surgery was restricted 
to five centers in 2003, and further to four centers in 2008.10 This was accompanied 
by a strongly reduced postoperative mortality after gastrectomy and an increase in the 
number of evaluated lymph nodes, which is often used as a quality indicator in gastric 
cancer surgery.11 In the current study, hospital volumes in Denmark were higher than 
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in any other country, with the majority of esophagectomies being performed in hospital 
volumes of over 40/year. In the UK, a National Health Services (NHS) Cancer Plan 
became effective in 2001.12 In this plan, recommendations were made to centralize 
esophagogastric cancer surgery, to establish specialist treatment teams, and to audit 
all steps in esophagogastric cancer care.13 Over the last 10 years, centralization of 
esophagogastric cancer surgery has occurred. In 2008 and 2009, 82% of esophageal and 
gastric cancer resections were done in 41 designated centers with 63% of esophagectomies 
and 65% of gastrectomies being performed in high-volume centers (at least 50 
resections per year).14 Centralization of surgery is not unique to Europe. A recent US 
study describes centralization of several surgical procedures including esophagectomy 
for cancer, resulting in a decrease in postoperative mortality over the past decade.15
differences in outcomes between countries
Due to its population-based nature, the present study provides an accurate comparison 
of postoperative mortality and long-term survival after esophagectomy and gastrectomy 
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NL: Netherlands, SW: Sweden, DK: Denmark, EN: England, OR: odds ratio, HR: hazard ratio, ref.: reference 
category, SCC: squamous cell carcinoma, Bold: significant (P < 0.05)
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between several countries in Europe. However, the variability in the recorded data and 
missing information on patient comorbidities, multimodality therapy, and cause-specific 
survival do not justify explaining the differences between countries simply on annual 
hospital volumes. Sweden has superior postoperative mortality rates when compared to 
Figure 5. Annual hospital volumes for (a) esophagectomy and (b) gastrectomy 







































Annual Hospital Volume      ≥41      31-40      21-30      11-20      1-10
a
Figure 6. Postoperative 30-day mortality after (a) esophagectomy and (b) gastrectomy, adjusted for 
sex, age, and histology, by annual hospital volume category 
Figure 7. Two-year survival after (a) esophagectomy and (b) gastrectomy, adjusted for sex, age, 
histology, and stage group, by annual hospital volume category.





























































































the other participating countries, even after adjustment for case-mix, without performing 
surgery in high annual volumes. It is known that Sweden in general has a high quality 
health care with nationwide quality assurance programs, which might have contributed 
to the current results.16 A second, hypothetical explanation might be differences in 
selecting patients for surgery between Sweden and the other countries. Furthermore the 
inclusion of only regions in Sweden with high case ascertainment may have excluded 
patients who did less well and hence bias the findings. Completeness of the data 
requires dedication of the surgical team to report all cases, which might be correlated to 
a high standard of care in these regions. On the contrary, postoperative mortality after 
gastrectomies in the Netherlands is high. This might be explained by the absence of a 
quality assurance program during the studied period for gastric cancer surgery in the 
Netherlands. A centralization program for gastrectomies has been initiated as of 2012. It 
should be noted that differences in unadjusted two-year survival rates between countries 
should be interpreted with care, as tumor stage distributions in the group of patients who 
underwent surgical resection might differ between countries.
differences in outcomes in relation to hospital volume
The relationship between annual hospital volume and postoperative mortality after 
esophagectomy and gastrectomy has been investigated extensively.15,17 In the majority 
of studies on esophagectomy, a benefit for high volume surgery was found.18 Results 
from studies on hospital volumes for gastrectomies are less uniform. In a significant 
number of studies, no effect of hospital volume on postoperative mortality was found.19-22 
However, patient numbers in these studies were relatively small (below 5,000) when 
compared to studies in which a benefit for high volume gastrectomies was found (up to 
56,000).23-26 The available evidence on hospital volume in relation to long term survival 
is more limited: two out of four available studies for esophagectomy were positive,27-30 
and five out of seven available studies on gastrectomy were positive.26,31-35 In the current 
study, a significant relation between annual hospital volume and postoperative mortality 
was found both for esophagectomy and gastrectomy. Furthermore, increasing hospital 
volume for esophagectomy was associated with improved long term survival. No such 
relation for gastrectomy was found, which might be explained by the low threshold of 
what was considered ‘high volume surgery’ (≥21/year).
It could be argued that in the current study, individual surgeon volumes should be 
analyzed as well as hospital volume. Quality of care and outcomes, however, are the result 
of collaboration between different professionals, including surgeons, anesthesiologists, 
ICU staff and nursing staff. All these disciplines contribute to outcomes.36 The role of the 
individual surgeon is one, yet important factor.
Using hospital volume as the only basis for determining outcome quality has been 
criticized.23 There can be low volume hospitals with excellent outcomes and vice versa. 
Outcome-based referral avoids this problem, by selecting centers of excellence based on 
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case-mix adjusted outcomes. It has been used to centralize esophagectomy in one part 
of the Netherlands, which led to a reduction in postoperative mortality from 12% to 3% 
over a ten-year period.37
conclusions
In the current study, considerable differences between European countries were 
documented regarding resection rates, postoperative 30-day mortality, and annual 
hospital volumes in esophagogastric cancer surgery. Increasing hospital volume was 
associated with better outcomes, but differences in outcomes between countries could 
not be explained by existing differences in annual hospital volumes. Nationwide clinical 
audits aim to identify centers of excellence based on case-mix adjusted outcomes. On 
an international level, these audits can be used to understand differences in outcomes 
between countries. This, however, requires uniform definitions and registration of data, 
which is currently not the case. The current study provides a first step towards recording 
standard clinical data for each country to facilitate intercountry comparisons, analogous 
to the EURECCA initiative for colorectal cancer.38 It is proposed to develop a European 
esophageal and Gastric Cancer Audit to provide further insight into differences between 
countries with the ultimate aim of improving quality of care for esophageal and gastric 
cancer patients throughout Europe. 
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Gastric cancer is the second leading cause of cancer death worldwide, affecting 
approximately one million new individuals per year.1 Highest incidence rates are described 
in Northeast Asia, Eastern Europe, and much of the east part of South America, while 
Europe and North America are low incidence areas.2 Survival in the Western world is 
dismal, with five-year survival rates for all patients with gastric cancer of approximately 
25%, both in Europe and the United States.3,4 In the Netherlands, approximately 1,800 
patients are diagnosed with gastric cancer each year, and five-year survival is 22%.5
staging
Cancer staging is one of the fundamental activities in oncology.6,7 For over 50 years, the 
TNM classification has been a standard in classifying the anatomic extent of disease.8 In 
order to maintain the staging system relevant, the International Union Against Cancer 
and the American Joint Committee on Cancer (AJCC) have collaborated on periodic 
revisions of this staging system, leading to the 7th edition in 2010.9 With each staging 
system revision, there is a tension between improving prognostic value of the staging 
system by adding subdivisions of existing stage groupings and introducing new predictive 
parameters, and the desire to keep the staging system simple. With an increasing 
number of categories for the 7th edition gastric cancer staging system, it has become 
more complex, while predictive accuracy has not improved. Increasing the number 
of categories of the staging system is not unique to gastric cancer.9 With the growing 
availability of pathologic and molecular data, there is a trend towards incorporating 
more and more information into newer staging systems. Although these new categories 
might better reflect the natural history and prognosis of these diseases, there is a limit 
to the improvement of prognostic accuracy achievable with a categorical anatomic-based 
staging system like the TNM-classification.10,11  At the same time, the goal of creating 
an intuitive, easy to use staging system disappears, and in daily clinical practice, cancer 
staging consists of using complex tables.
Meanwhile, tools for individual patient prognostication have been developed that 
significantly outperform the TNM-classification in prognostic accuracy.  For gastric 
cancer, a nomogram has been developed based on a single US-institution database,12,13 
and has been validated in several international patient cohorts.14-16 The question is if the 
TNM-classification should aspire to the same goal of highly accurate individual patient 
prognostication as these nomograms. Prognostication is only one of the five goals of 
the TNM-classification, and all other goals are directed towards a simple intuitive 
international language: to aid the clinician in planning and evaluating treatment, to 
facilitate the exchange of consistent information, and to contribute to research.6 
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surgery
Shortly after finishing accrual of the Dutch Gastric Cancer Group trial comparing D1 
(limited) with D2 (extended) lymphadenectomy, morbidity and mortality results were 
published indicating a significantly higher mortality after a D2 dissection (10% versus 
4%),17 similar to the Medical Research Council Gastric Cancer trial.18 The number of 
splenectomies and pancreatic tail resections, which have shown to increase postoperative 
mortality, was also higher in the D2 group. Analyses performed after 11 and 15 years 
of follow-up revealed no significant differences in overall survival.19,20 However, gastric-
cancer related death at 15 years was significantly lower after a D2 (37%) when compared 
to a D1 (48%) dissection (P = 0.01),20 suggesting that when postoperative mortality can 
be avoided, a D2 lymphadenectomy improves survival compared to a D1 lymph node 
dissection. In a more recent, Italian study, a D1 versus D2 lymphadenectomy was 
analyzed in 267 patients treated in five centers.21 Although long-term survival results 
have to be awaited, and the study population might be too small to detect differences in 
overall survival, postoperative mortality after a D2 dissection was only 2.2%. This taken 
together with the currently performed spleen-preserving gastrectomy indicates that a 
D2 lymph node dissection in experienced centers should be the recommended type of 
surgery in advanced gastric cancer, not only in Asia, but also in Europe and the United 
States.22,23 A routine pancreatic tail and spleen resection should be avoided.24 
Although laparoscopic surgery has been applied for gastric cancer for over two decades, 
only a limited number of randomized controlled trials on this subject have been 
reported.25-29 A recent review on these randomized studies indicates that laparoscopic 
gastrectomy is safe and feasible, and that short term outcomes are better than those of 
open gastrectomy in patients with early gastric cancer.30 Large multicenter randomized 
controlled trials are necessary to establish the role of laparoscopy in the treatment of 
gastric cancer. As the learning curve for laparoscopic gastrectomy takes at least 60 
operations, laparoscopic gastrectomy should not be performed in low-volume hospitals.31
surgical quality assurance
Improving quality of care for patients with resectable gastric cancer is a major challenge, 
especially when performed in lower volume centers like in many European countries. 
Whereas Japan has established national screening programs for gastric cancer, and has 
a two to seven-fold higher incidence rate as compared to European countries, in Europe 
incidence rates are relatively low leading to lower exposure of hospitals to patients with 
resectable gastric cancer.
Although randomized controlled trials provide important information on the optimal 
treatment strategy for gastric cancer, and trials in general can improve outcomes on 
a national level, the majority of patients are treated outside the framework of clinical 
trials. Especially improvements in the structure and process of care on a nationwide level 
will bring benefit to this group of patients. National quality assurance programs aim to 
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reduce variations between providers of care and to improve outcomes after gastric cancer 
surgery. The most frequently used quality assurance programs include centralization of 
care to high-volume or high-quality hospitals and clinical auditing.
Luft et al. were the first to publish on the relation between hospital volume and 
outcomes.32 More than 20 years later, Birkmeyer et al. published another landmark 
study showing a relation between increasing hospital volume and lower postoperative 
mortality for several surgical procedures.33 Ever since, a large number of studies on the 
effect of hospital volume on both short term and long term outcomes after gastrectomy 
has been published, and in the majority of these studies, a significant relation between 
high hospital volume and better outcomes was found.33-48 
In Denmark, the available evidence on a volume-outcome relationship has led to 
enforced centralization of gastric cancer surgery from 37 to 5 hospitals as of 2003, 
which has resulted in a significant decrease in postoperative mortality (8.2% in 2003 
to 2.4% in 2008, P < 0.05), and an increase in the number of patients with at least 
15 lymph nodes examined (19% - 67%).37 Centralization of gastric cancer surgery is 
currently implemented in the United Kingdom, Sweden, Finland, and as of 2012 in the 
Netherlands. As esophagectomies have already been centralized in the Netherlands, 
esophagogastric cancer surgery will be centralized towards centers currently performing 
esophagectomies, resulting in upper GI centers. This enables the formation of dedicated 
upper GI surgical and multidisciplinary teams, and eliminates the possibility that patients 
with incorrectly staged junctional tumors need to be transferred from an esophageal to a 
gastric cancer center or vice versa after first surgical inspection of the tumor.
Meanwhile, using hospital volume as the sole basis for referral to improve outcomes 
is criticized.33 Although hospital volume can be used to identify groups of hospitals 
with better outcomes on average, individual low volume hospitals can have excellent 
outcomes and vice versa. In contrast to volume-based referral, outcome based-referral 
avoids this problem, and has proven its value for esophagectomy in the Western part of 
the Netherlands. In this region, a prospective audit was conducted to identify hospitals 
with excellent performance in esophagectomy. During the five-year audit, a gradual 
concentration towards centers with excellent performance occurred, leading to a drop 
in postoperative mortality (12% to 4%) and an improvement in survival.49 Others have 
advocated the identification of processes associated with excellent outcomes, and to 
implement these in low volume hospitals, rather than to refer patients to centers of 
excellence. However, identification of these processes and determination of their impact 
on quality of care remains challenging.50
It has been suggested that centralization combined with auditing is more effective 
when compared to centralization alone.51 With auditing, providers of care are monitored 
and their performance is benchmarked against their peers. Data is usually entered by 
the providers of care and is centrally collected. A disadvantage of auditing is the effort 
needed to collect the data. Information technology solutions incorporated in electronic 
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medical record systems are needed to solve this problem. In the United Kingdom, a 
national esophagogastric cancer audit was initiated in 2002 by the Association of 
Upper Gastrointestinal Surgeons of Great Britain and Ireland.52 In the United States, 
the National Surgical Quality Improvement Program is used to audit many different 
surgical procedures, and several studies have shown a decrease in postoperative 
morbidity and mortality for vascular and general surgical procedures after introduction 
of this audit.53-55 Sweden also has a long tradition of clinical auditing, which started with 
the Swedish Rectal Cancer Registry, but is now extended to upper-GI surgery.56 In the 
Netherlands, as of 2011, the Dutch Upper-GI Cancer Audit has started, with the aim of 
capturing all esophageal and gastric cancer resections in the Netherlands, and to provide 
weekly feedback to participating surgeons. Surgeons from several European countries 
are currently collaborating on the development of a European Upper GI Cancer Audit 
(EURECCA Upper GI).
multimodality treatment
Whereas Asian patients mainly receive postoperative chemotherapy with S-1, in the 
Western world postoperative chemoradiotherapy or perioperative chemotherapy are 
administered. Due to differences in patient selection, it is not possible to compare 
results from the Intergroup 0116 study on postoperative chemoradiotherapy with results 
from the MAGIC study on perioperative chemotherapy.57,58 However, it becomes clear 
that the toxicity profile of the multimodality regimen is crucial for both the patient to 
complete therapy, and for the trial to finish accrual. As preoperative therapy is generally 
associated with improved compliance without compromising resectability,59 this should 
be the recommended therapy for patients with advanced, resectable gastric cancer. After 
radical surgery, postoperative therapy should be administered when tolerated by the 
patient, but no standard regimen for this has been established. In case of contaminated 
resection margins (R1 resection), locoregional disease is left behind and postoperative 
chemoradiotherapy should be the recommended therapy.60 Patients with distant 
micrometastases will benefit from postoperative chemotherapy, but no diagnostic 
modality can identify these metastases so far, and therefore, the regimen of choice remains 
unclear. To address this issue, the Dutch CRITICS study was initiated in 2008.61 In this 
study, all patients receive three cycles of preoperative ECC, followed by gastrectomy with 
D1+ surgery (i.e. an extended lymphadenectomy without the lymph nodes in the splenic 
hilus and without a spleen and pancreatic tail resection). Then patients in arm A receive 
another three cycles of ECC, while patients in arm B receive postoperative CRT with 
cisplatin, capecitabine, and 45 Gy radiotherapy. An estimated 788 patients are required 
for this study; currently over 400 patients from the Netherlands, Sweden, and Denmark 
are included.
Another, recent development is the use of the monoclonal antibody trastuzumab for 
HER2 positive gastric cancers, which account for approximately 30% of all gastric 
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cancers.62 In the large, international ToGA trial, a significant benefit in overall survival 
was found for patients with inoperable locally advanced or recurrent HER2 positive gastric 
cancer receiving trastuzumab versus conventional chemotherapy. Currently, in many 
trials the use of trastuzumab in HER2 positive resectable gastric cancer is investigated, 
but no results have been published so far. However, there is debate on the currently 
accepted diagnostic methods to detect HER2 positive tumors.63,64 In contrast to breast 
cancers, gastric cancers are highly heterogeneous, and HER2 expression is different 
throughout the tumor. Furthermore, a considerable number of tumors in the ToGA trial 
were negative by immunohistochemistry, which is the diagnostic modality used in daily 
clinical practice, but showed HER2 gene amplification with FISH, which is the gold 
standard. Therefore, more research is needed on the diagnosis of HER2 expression in 
gastric cancer in order to accurately interpret data from currently accruing clinical trials.
conclusions and future perspectives
Cancer staging represents a compromise in accounting for the most prognostically 
relevant factors to aim at a simple, intuitive, useful, common language to describe the 
natural history of a tumor. It should not be confused with more complex, multivariable 
prognostication models, which may be useful in defining groups of patients at 
homogenous risk of recurrence, regardless of anatomic TNM characteristics. Future 
TNM classifications for gastric cancer should aspire more simplicity and should aim for 
a clinically more useful staging system.
Surgery is the only potentially curative treatment for gastric cancer, and despite recent 
developments in multimodality therapy it remains the cornerstone of treatment. A 
gastrectomy with D2 lymphadenectomy without routine spleen and distal pancreatic 
resection is the recommended type of surgery for advanced, resectable gastric cancer. 
The current debate focuses on the question which multimodality treatment schedule 
should be administered to patients with resectable gastric cancer. Because of the higher 
compliance of preoperative therapy when compared to postoperative therapy, preoperative 
chemotherapy should be recommended for all patients with advanced gastric cancer, 
followed by either postoperative chemotherapy or chemoradiotherapy, an issue currently 
addressed in the international CRITICS trial.
Further tailoring of treatment based on a patient’s genetic profile has been pursued. 
However, HER2, which is the most promising genetic marker so far, has been subject 
to critique due to the intratumoral heterogeneity of HER2 expression in gastric cancers 
and discrepancies between IHC and FISH results for HER2 testing, thereby impeding 
an accurate assessment of HER2 status. Truly clinically useful genetic markers for gastric 
cancer remain to be awaited. 
Another approach to tailor made treatment is practiced in Japan. Due to the high 
caseload of patients, Japanese surgeons and gastroenterologists have the opportunity to 
differentiate treatment based on clinical tumor stage. More experience with endoscopic 
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techniques, including endoscopic (sub)mucosal dissection, high volume and laparoscopic 
surgery, and the use of a preoperative sentinel node procedure provide a level of care for 
gastric cancer patients far beyond that in most Western centers.
Because gastric cancer surgery in the Western world is associated with high postoperative 
mortality, and patients presenting with gastric cancer become older and have an increasing 
number of comorbidities, gastric cancer resections should be performed in centers with 
sufficient experience. Although in the Netherlands, several regional initiatives were 
started to centralize gastric cancer care, nationwide programs are needed to improve care 
for all gastric cancer patients. The proposed minimal hospital volume standards of 10 per 
year in 2012 and 20 per year as of 2013 for gastric cancer resections are a first step towards 
this improvement. With this centralization of surgery, it is expected that postoperative 
30-day mortality for the annual 500 gastric cancer resections in the Netherlands will 
decrease from the current 8% to below 5%, saving the lives of approximately 15 patients 
annually in the perioperative period. But the available evidence also confirms that long-
term survival will improve with referral of gastrectomies towards high volume centers. 
However, surgical excellence in the treatment of gastric cancer not only requires 
expertise in gastrectomies, but also in other upper gastrointestinal surgery, including 
esophagectomies. Only with the formation of ‘upper GI centers’ it is possible to 
adequately treat patients with junctional tumors and patients with complex gastric 
cancers. Furthermore, expertise should not be limited to the surgical treatment of these 
cancers. Rather, experience should be present in the whole multidisciplinary chain 
involved in treating gastric cancer, including diagnostic imaging, upper GI endoscopy and 
endoscopic ultrasound, surgery, perioperative care, intensive care, nutritional support, 
chemotherapy, and radiotherapy. Therefore, it should be encouraged that the Dutch 
Upper GI Cancer Audit (DUCA), which is currently a monodisciplinary surgical audit, 
will expand to all disciplines involved in esophagogastric cancer care, thus also capturing 
patients who are never considered for surgery. As the DUCA has started in 2011, and 
only 60% of all gastrectomies in the Netherlands were registered in the first registration 
year, comparing quality of care between participating hospitals is not yet possible. But 
when case ascertainment will increase over the years and centralization of gastrectomies 
will take place, in the near future the DUCA will be an instrument to identify centers of 
excellence which can share their best practice with other hospitals in the Netherlands. 
Collaboration with other upper GI audits in Europe, which is currently under way in 
the EURECCA Upper GI consortium, will provide the opportunity to share knowledge 
with other countries and define best practice throughout Europe. Bringing together this 
international high quality data will also enable the development of refined treatment 
algorithms for specific subgroups of patients, for example the elderly. Ultimately this will 
lead to the optimal choice of treatment for every gastric cancer patient in Europe.
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summary
Research described in this thesis focuses on several aspects of gastric cancer care: staging 
and prognostication, multimodality treatment, and surgical quality assurance.
part i - staging and prognostication
Cancer staging is one of the fundamental activities in oncology.6,7 For over 50 years, 
the TNM classification has been a standard in classifying the anatomic extent of 
disease.8 In order to maintain the staging system relevant, the International Union 
Against Cancer (UICC) and the American Joint Committee on Cancer (AJCC) have 
collaborated on periodic revisions of this staging system, leading to the 7th edition in 
2010.65 In chapter 2, differences between the 6th and 7th edition TNM classification for 
gastric cancer are described, and both staging systems are compared with regards to 
complexity and predictive accuracy. In the 7th edition TNM classification, nodal status 
cut-off values were changed, leading to a more even distribution for the redefined nodal 
classification groups. This increased the predictive accuracy of N-classification. Overall, 
the TNM staging system became more complex, with an increase in the number of TNM 
groupings from 56 to 80, which did not result in an increased predictive accuracy. Future 
refinements of the TNM-classification should consider whether increased complexity is 
balanced by improved prognostic accuracy. 
Another change that was incorporated in the 7th edition TNM classification was the 
addition of tumor grade as an independent determinant of stage grouping in early 
stage tumors. With the significantly lower prognosis of poorly differentiated early stage 
adenocarcinomas, these tumors might become candidate for neoadjuvant therapy, 
given an accurate identification of these tumors with preoperative staging. In chapter 
3, the accuracy of preoperative histopathologic grading in adenocarcinomas of the 
gastroesophageal junction (GEJ) was evaluated. The overall accuracy of tumor grade 
assessment was 73%. However, in early stage tumors the sensitivity to detect a poorly 
differentiated tumor was only 43%, and 21% of patients with an early stage GEJ tumor 
were assigned to an incorrect stage/prognostic group based on preoperative tumor 
grading. Caution should therefore be exhibited in staging patients with esophageal 
adenocarcinoma based on preoperative biopsy data.
Although the TNM classification can be used to assess a patient’s prognosis, tools for 
individual patient prognostication have been developed that significantly outperform 
the TNM-classification in prognostic accuracy. For gastric cancer, a nomogram has 
been developed based on a single US-institution database,12,13 and has been validated in 
several international patient cohorts.14-16 chapter 4 describes the development of a new 
gastric cancer nomogram that not only can predict survival for patients directly after an 
R0 gastrectomy, but also for patients alive at time points after surgery. This conditional 
probability of survival nomogram was highly discriminating (concordance index: 0.772), 
and surviving one, two, or three years from surgery showed a median improvement of 
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5-year disease-specific survival of 7.2%, 19.1%, and 31.6%, as compared to the baseline 
prediction directly after surgery. This nomogram was based on variables available 
directly after surgery, while variables available with follow-up (such as weight loss and 
performance status) did not further improve the predictive accuracy of this nomogram.
In chapter 5, the performance of the original gastric cancer nomogram, which was 
based on patients who underwent surgery without multimodality therapy, was assessed 
in a group of patients who received postoperative chemoradiotherapy after an R0 
resection for gastric cancer. The nomogram significantly underpredicted 5-year survival 
for patients who received postoperative chemoradiotherapy, indicating a benefit in 
survival for patients who receive postoperative chemoradiation after an R0 resection for 
gastric cancer. Furthermore, this study stresses the need for updating nomograms that 
incorporate multimodality therapy use.
part ii - multimodality treatment
Over the past decade, many trials have been performed in which the effect of multimodality 
treatment on survival for resectable gastric cancer was evaluated. In chapter 6, an 
overview of the literature on the treatment of gastric cancer is presented, and the 
available multimodality strategies are discussed. Currently accepted regimens include 
postoperative monochemotherapy with S-1 in Asia,66 and perioperative chemotherapy 
and postoperative chemoradiotherapy in the Western world.57,58 
In chapter 7, patterns of recurrence and survival of patients who received postoperative 
chemoradiotherapy were compared to recurrence and survival patterns of patients 
who only underwent surgery. The local recurrence rate was significantly lower in the 
chemoradiotherapy group (5% versus 17%, P = 0.0015). Subgroup analysis revealed that 
this difference was even stronger in patients who underwent a gastrectomy with a limited 
(D1) lymph node dissection (2% versus 18%, P = 0.001), while no difference was found 
for patients who underwent an extended (D2) lymph node dissection. Additional analysis 
with prolonged follow-up showed a higher 2-year overall survival for patients who received 
postoperative chemoradiotherapy after a D1 lymphadenectomy compared to surgery 
alone, and no difference in overall survival for patients who received a D2 dissection. 
Postoperative chemoradiotherapy was also significantly associated with higher two-year 
overall survival for patients who underwent a microscopically irradical (R1) resection 
(66% versus 29%, P = 0.02). Results from this study indicate that, especially after a 
gastrectomy with a limited lymph node dissection, postoperative chemoradiotherapy has 
a major impact on local recurrence and overall survival. Postoperative chemoradiotherapy 
should be offered to patients who undergo a microscopically irradical (R1) resection.
In chapter 8, the results of a study on lymph node yield after gastric cancer resections are 
described. While it is suggested that more than 15 lymph nodes (LNs) should be evaluated 
for accurate staging of gastric cancer, LN yield in Western countries is generally low. The 
effect of preoperative chemotherapy on LN yield in gastric cancer is unknown. In this 
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study, LN yields of patients who received preoperative chemotherapy and patients who 
only underwent surgery were compared. Preoperative chemotherapy was not associated 
with a decrease in LN yield, indicating that evaluating more than 15 LNs after gastrectomy 
is feasible, also after administration of preoperative chemotherapy.
In chapter 9, the final chapter of part II of this thesis, the study protocol of the currently 
accruing Dutch-Swedish-Danish CRITICS trial is described. This trial was initiated to 
determine which of the two currently used standard regimens for the multimodality 
treatment of gastric cancer in the Western world, postoperative chemoradiotherapy, or 
perioperative chemotherapy, should be preferred. In this trial, all patients receive three 
cycles of preoperative ECC (epirubicin, cisplatin, and capecitabine), followed by D1+ 
surgery (D2 dissection without splenectomy or pancreatectomy). Postoperative therapy 
consists of another three cycles of ECC, or chemoradiotherapy with capecitabine and 
cisplatin without epirubicine. Results of this study will play a key role in the future 
management of patients with resectable gastric cancer.
part iii - surgical quality assurance
As an introduction to part III of this thesis, in chapter 10, the results of a systematic review 
of the literature on quality of care indicators for gastric cancer surgery are described. The 
availability of specific literature on quality of care indicators was limited, but several 
indicators could be identified in more general literature on gastric cancer surgery. High 
hospital volume was found to be strongly related to lower postoperative mortality and 
higher long-term survival. Several quality indicators regarding operative technique were 
identified, including the performance of an extended lymphadenectomy, avoiding a 
routine spleen and pancreatic tail resection, and the use of a pouch reconstruction. Free 
resection margins were also associated with improved long-term survival.
In chapter 11 and chapter 12, incidence and survival patterns for tumors of the esophagus, 
GEJ, and stomach in the Netherlands over the past 20 years are described. While the 
incidence of esophageal adenocarcinoma has doubled, the incidence of both tumors of 
the GEJ and stomach has decreased. These findings most likely reflect true changes in 
disease burden, rather than being the result of changes in diagnosis or reclassification. 
The increasing incidence of esophageal adenocarcinoma can be attributed to the 
increasing incidence of obesity and gastroesophageal reflux disease.67,68 Over the study 
period, five-year survival for non-metastatic esophageal cancer strongly improved (12% 
to 25% for adenocarcinoma, 12% to 19% for squamous cell carcinoma), while five-year 
survival for non-metastatic GEJ cancer (20%) and stomach cancer (32%) remained stable. 
In chapter 13, patterns of care for gastric cancer in the Netherlands over the past 20 years 
are described. Whereas resection rates for stage I-III gastric cancer have remained stable 
at about 85%, the use of preoperative and/or postoperative chemotherapy has strongly 
increased since 2005. In 2008, nearly 40% of the patients with stage I-III gastric cancer 
received preoperative or postoperative chemotherapy with curative intent, and it is likely 
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that since then, this percentage has further increased.
In chapter 14, the results of a study on hospital volumes, mortality, and long-term 
survival for esophagogastric cancer surgery in the Netherlands between 1989 and 2009 
are described. In the Netherlands, a minimum hospital volume standard of at least 10 
esophagectomies per year was introduced in 2006, while during the study period, no 
such standard was present for gastrectomies. During the study period, esophagectomy 
was effectively centralized in the Netherlands, and in 2009, 64% of all esophagectomies 
were performed in annual volumes of ≥21/year. Gastrectomy has not been centralized, 
and in 2009 only 5% of all gastrectomies were performed in annual volumes of ≥21/
year. Whereas short-term and long-term survival after esophagectomy and gastrectomy 
improved over the years, this improvement was significantly stronger for esophagectomy. 
High hospital volume was associated with lower 6-month mortality (HR 0.48, P < 
0.001) and longer 3-year survival (HR 0.77, P < 0.001) after esophagectomy, but not 
after gastrectomy. However, for gastrectomy, the number of high volume resections in 
the current study was too low to detect a statistical significant difference in outcomes 
when compared with low volume resections. This study indicates an urgent need for 
improvement in the treatment of resectable gastric cancer in the Netherlands.
chapter 15 describes the results of a study on the effect of hospital type on outcomes 
after esophagectomy and gastrectomy in the Netherlands. Hospitals were categorized 
into university hospitals, teaching non-university hospitals, and non-teaching hospitals. 
Three-month mortality after esophagectomy in university hospitals was 2.5%, compared 
to above 4% in non-university hospitals (P = 0.006). After gastrectomy, three-month 
mortality was 4.9% in university hospitals, and 8.7% in non-university hospitals (P < 
0.001). Both after esophagectomy and gastrectomy, three-year survival was higher in 
university hospitals compared to non-university hospitals. No differences in mortality 
or survival were found between teaching and non-teaching non-university hospitals. 
However, when analyzing differences between individual hospitals, there were non-
university hospitals with excellent outcomes. Therefore, it can be concluded that centers 
of excellence can not be designated solely by hospital type, and that detailed information 
on case-mix and outcomes is needed to identify centers of excellence.
In chapter 16, the results of an international study on esophagogastric cancer surgery 
between 2004 and 2009 in several European countries are described. Differences in 
resection rates, postoperative mortality, survival and hospital volumes were compared 
between the Netherlands, Sweden, Denmark, and England. In the Netherlands, 
postoperative mortality was average after esophagectomy (4.6%), but significantly higher 
after gastrectomy (6.9%) when compared to the other countries. Although increasing 
hospital volume was associated with lower 30-day mortality both after esophagectomy 
and gastrectomy, differences in outcomes between countries could not just be explained 
by existing differences in hospital volumes. To further investigate the differences in 
outcomes, a European upper GI audit is currently initiated.
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Het onderzoek in dit proefschrift richt zich op verschillende aspecten van de behandeling 
van het maagcarcinoom: de stagering en het voorspellen van de prognose, de behandeling 
met chemotherapie en radiotherapie (bestraling) en de kwaliteit van de chirurgie.
deel i - stagering en het voorspellen van prognose
Stageren (het classificeren van tumoren) is een van de basisactiviteiten binnen de 
oncologie. Al meer dan 50 jaar is de TNM classificatie de standaard voor het anatomisch 
classificeren van maligne tumoren. In 2010 werd door de International Union Against 
Cancer (UICC) en de American Joint Committee on Cancer (AJCC) de 7e editie van de 
TNM classificatie gepubliceerd. hoofdstuk 2 beschrijft de verschillen tussen de 6e en 7e 
editie van de TNM classificatie van het maagcarcinoom en vergelijkt de complexiteit en 
voorspellende nauwkeurigheid van beide systemen. In de 7e editie zijn de afkapwaarden 
voor de N-classificatie (aantal tumorpositieve lymfeklieren) gewijzigd, waardoor een 
meer gelijke verdeling van patiënten over de N-categoriën ontstaat. Hierdoor is de 
voorspellende nauwkeurigheid van de N-classificatie verbeterd. In zijn geheel is de 
TNM classificatie van het maagcarcinoom complexer geworden, met een toename van 
het aantal TNM groepen van 56 naar 80. Dit heeft echter niet geleid tot een verbeterde 
voorspellende nauwkeurigheid. In verband met gebruikersgemak moet hier in de 
toekomst rekening mee gehouden worden.
Een andere vernieuwing in de 7e editie van de TNM classificatie is het gebruik van 
de differentiatiegraad voor de bepaling van het tumorstadium bij vroege stadium 
slokdarmcarcinomen. Slecht gedifferentieerde vroege stadium slokdarmcarcinomen 
hebben een slechte prognose, en kunnen daarmee in aanmerking komen voor 
preoperatieve chemotherapie. Maar dan moeten deze tumoren wel bij de preoperatieve 
diagnostiek geïdentificeerd kunnen worden. In hoofdstuk 3 wordt de nauwkeurigheid 
van het preoperatief bepalen van de differentiatiegraad van adenocarcinomen van de 
slokdarm-maagovergang onderzocht. De nauwkeurigheid voor het bepalen van de 
differentiatiegraad is 73%, maar bij vroege stadium adenocarcinomen is de sensitiviteit 
voor het detecteren van een slecht gedifferentieerde tumor slechts 43%. Hierdoor wordt 
21% van de patiënten met een vroege stadium tumor van de slokdarm-maagovergang 
in een verkeerd tumorstadium ingedeeld. Het stageren van patiënten met een 
adenocarcinoom van de slokdarm op basis van gegevens van een preoperatieve biopsie 
moet daarom met terughoudendheid worden uitgevoerd.
Hoewel de TNM classificatie kan worden gebruikt om de prognose van een patiënt te 
bepalen, zijn er hulpmiddelen voor het bepalen van de prognose van individuele patiënten 
ontwikkeld die een significant betere voorspellende nauwkeurigheid hebben dan de TNM 
classificatie. Voor het maagcarcinoom is een nomogram (statistisch model) ontwikkeld 
dat gebaseerd is op een database uit één Amerikaans ziekenhuis en dat gevalideerd is 
in verschillende internationale datasets. hoofdstuk 4 beschrijft de ontwikkeling van een 
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nieuw nomogram voor maagkanker dat niet alleen een voorspelling doet voor patiënten 
direct na een maagresectie, maar ook voor patiënten die al een periode overleefd hebben 
na een maagresectie. Dit nomogram heeft een hoge voorspellende nauwkeurigheid. 
Het overleven van één, twee of drie jaar na een maagresectie geeft een verbetering van 
de 5-jaars overleving van respectievelijk 7,2%, 19,1% en 31,6% in vergelijking met de 
voorspelling direct na de operatie. Dit nomogram baseert zijn voorspelling op gegevens 
die bekend zijn bij de operatie, terwijl gegevens verkregen bij controle afspraken na de 
operatie (zoals gewichtsverlies en conditie van de patiënt tijdens de controle afspraak) de 
voorspellende nauwkeurigheid van dit nomogram niet verder verbeteren.
In hoofdstuk 5 wordt de voorspellende waarde van het al eerder gepubliceerde nomogram, 
dat gebaseerd is op patiënten die chirurgie ondergingen zonder chemotherapie of 
radiotherapie, onderzocht in een groep patiënten die postoperatieve chemoradiotherapie 
ondergingen na maagresectie. De door het nomogram voorspelde 5-jaars overleving 
voor deze patiënten was significant te laag, hetgeen wijst op een overlevingsvoordeel 
voor patiënten die chemoradiotherapie ondergaan ten opzichte van patiënten die alleen 
chirurgie ondergaan. Daarnaast wijst deze studie op de noodzaak van het ontwikkelen 
van nomogrammen die ook kijken naar het gebruik van chemotherapie en radiotherapie.
deel ii - chemotherapie en radiotherapie
Gedurende de laatste tien jaar zijn veel studies uitgevoerd waarin het effect van 
chemotherapie en radiotherapie op de overleving bij het resectabel maagcarcinoom wordt 
onderzocht. hoofdstuk 6 geeft een overzicht van de literatuur naar de behandeling van 
het maagcarcinoom, waarbij de verschillende soorten behandelingen aan de orde komen. 
Geaccepteerde behandelschema’s zijn onder andere postoperatieve monochemotherapie 
met S-1 in Azië en perioperatieve chemotherapie en postoperatieve chemoradiotherapie 
in Europa en de Verenigde Staten. 
In hoofdstuk 7 worden recidief- en overlevingspatronen van patiënten die postoperatieve 
chemoradiotherapie kregen vergeleken met recidief- en overlevingspatronen van 
patiënten die alleen geopereerd werden. Het lokale recidiefpercentage (een recidief tumor 
op de plaats waar de maag zat) was significant lager in de chemoradiotherapie groep 
(5% versus 17%). Een subgroepanalyse liet zien dat dit verschil zelfs nog groter was bij 
patiënten die een maagresectie met een beperkte (D1) lymfeklierdissectie ondergingen 
(2% versus 18%), terwijl geen verschil werd gevonden bij patiënten die een uitgebreide 
(D2) lymfeklierdissectie ondergingen. Aanvullende analyses waarbij patiënten langer 
in de tijd gevolgd werden toonden een hogere 2-jaars overleving voor patiënten die na 
een D1 lymfeklierdissectie postoperatieve chemoradiotherapie kregen in vergelijking 
met patiënten die alleen geopereerd werden. Bij patiënten die D2 lymfeklierdissectie 
kregen werd dit verschil niet gevonden. Postoperatieve chemoradiotherapie was 
ook geassocieerd met een significant hogere 2-jaars overleving bij patiënten die een 
microscopisch irradicale (R1) resectie ondergingen (66% versus 29%). Resultaten van 
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deze studie laten zien dat, vooral na een beperkte (D1) lymfeklierdissectie, postoperatieve 
chemoradiotherapie een grote invloed heeft op het aantal lokale recidieven en de algehele 
overleving. Postoperatieve chemoradiotherapie zou gegeven moeten worden aan 
patiënten die een microscopisch irradicale (R1) resectie ondergaan.
In hoofdstuk 8 worden de resultaten van een studie naar het aantal gevonden 
lymfeklieren na maagresecties beschreven. Terwijl wordt geadviseerd om ten minste 
vijftien lymfeklieren te verwijderen en te onderzoeken om een maagcarcinoom accuraat 
te kunnen stageren, is het aantal klieren dat wordt gevonden in Europa en Amerika laag. 
Het effect van preoperatieve chemotherapie op de lymfeklieropbrengst is onbekend. Deze 
studie vergelijkt de lymfeklieropbrengsten van patiënten die preoperatieve chemotherapie 
kregen met patiënten die alleen chirurgie kregen. Preoperatieve chemotherapie is niet 
geassocieerd met een daling in het aantal gevonden lymfeklieren, hetgeen erop wijst 
dat het evalueren van meer dan vijftien klieren na een maagresectie haalbaar is, ook na 
preoperatieve chemotherapie.
hoofdstuk 9 beschrijft het studieprotocol van de internationale CRITICS studie. Deze 
studie vergelijkt de huidige twee standaardbehandelingen van het maagcarcinoom in de 
Westerse wereld: postoperatieve chemoradiotherapie en perioperatieve chemotherapie. 
Alle patiënten krijgen drie kuren ECC (epirubicine, cisplatine en capecitabine), 
gevolgd door D1+ chirurgie (D2 maagresectie zonder milt- en pancreasstaartresectie). 
Postoperatief volgen nog drie kuren met ECC, of wordt chemoradiotherapie met cisplatine 
en capecitabine gegeven. De resultaten van deze studie worden rond 2015 verwacht.
deel iii - kwaliteit van chirurgie
Als introductie op deel III van dit proefschrift beschrijft hoofdstuk 10 de resultaten 
van een systematisch onderzoek naar de literatuur over kwaliteitsindicatoren bij 
maagkankerchirurgie. Een hoog ziekenhuisvolume (het aantal operaties dat een 
ziekenhuis per jaar uitvoert) is sterk gerelateerd aan een lagere postoperatieve sterfte 
en een betere langetermijnoverleving. Er worden verschillende kwaliteitsindicatoren 
over de operatietechniek gevonden, waaronder het uitvoeren van een uitgebreide 
lymfeklierdissectie, het niet routinematig verwijderen van de milt en de pancreasstaart, 
en het gebruik van een reservoir gemaakt van een stuk darm (pouch). Ook zijn tumorvrije 
snijvlakken sterk geassocieerd met een betere langetermijnoverleving.
In hoofdstuk 11 en hoofstuk 12 wordt de incidentie (het aantal nieuwe gevallen per jaar) 
en overleving van tumoren van de slokdarm, de slokdarm-maagovergang en de maag 
gedurende de afgelopen twintig jaar in Nederland beschreven. Terwijl de incidentie van 
het adenocarcinoom van de slokdarm is verdubbeld, daalde de incidentie van tumoren 
van de slokdarm-maagovergang en de maag. Deze bevindingen zijn niet het resultaat 
van veranderingen in diagnose of een andere indeling, maar geven zeer waarschijnlijk 
echte verschillen in incidentie weer. De toenemende incidentie van slokdarmkanker kan 
toegewezen worden aan de toenemende incidentie van overgewicht en zuurbranden. 
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Gedurende de studieperiode verbeterde de vijfjaarsoverleving voor niet-uitgezaaide 
slokdarmcarcinoom sterk (van 12% naar 25% voor adenocarcinomen, van 12% naar 
19% voor plaveiselcelcarcinomen), terwijl de vijfjaarsoverleving voor niet-uitgezaaide 
tumoren van de slokdarm-maagovergang (20%) en de maag (32%) gelijk bleef. hoofstuk 
13 beschrijft de behandeling van het maagcarcinoom in Nederland gedurende de 
afgelopen 20 jaar. Terwijl het percentage patiënten dat geopereerd wordt stabiel blijft 
rond de 85%, is het gebruik van preoperatieve en/of postoperatieve chemotherapie sterk 
gestegen sinds 2005. In 2008 werd bijna 40% van de patiënten met een stadium I-III 
maagcarcinoom behandeld met chemotherapie en waarschijnlijk is dit percentage de 
laatste jaren alleen maar verder gestegen.
hoofdstuk 14 beschrijft de resultaten van een studie naar ziekenhuisvolumes (het aantal 
operaties dat een ziekenhuis per jaar doet), sterfte, en langetermijnoverleving voor 
slokdarm- en maagkankerchirurgie in Nederland tussen 1989 en 2009. In Nederland 
werd een minimale volumestandaard van tien slokdarmresecties per jaar geïntroduceerd 
in 2006, terwijl er tijdens de studieperiode geen minimale volumestandaard voor 
maagkankerchirurgie was. Tijdens de afgelopen twintig jaar zijn slokdarmresecties in 
Nederland sterk gecentraliseerd en in 2009 werd 64% van deze operaties uitgevoerd 
in volumes van meer dan twintig per jaar. Maagresecties werden niet gecentraliseerd 
en in 2009 werd slechts 5% van alle maagresecties uitgevoerd in volumes van meer 
dan twintig per jaar. Terwijl de postoperatieve sterfte en de langetermijnoverleving 
zowel na slokdarm- als maagresecties verbeterde, was deze verbetering significant groter 
voor slokdarmresecties. Een hoog ziekenhuisvolume werd geassocieerd met een lagere 
6-maanden sterfte en een langere 3-jaars overleving na slokdarmresecties, maar niet na 
maagresecties. Echter, het aantal hoogvolume maagresecties in de huidige studie was te 
beperkt om een statistisch significant verschil in overleving aan te tonen tussen laag- en 
hoogvolume resecties. Deze studie laat wel zien dat er een dringende noodzaak is voor 
de verbetering van maagkankerchirurgie in Nederland.
hoofdstuk 15 geeft de resultaten weer van een studie naar het effect van het type ziekenhuis 
op de overleving na slokdarm- en maagkankerresecties in Nederland. Ziekenhuizen 
werden geclassificeerd als universitaire ziekenhuizen en perifere opleidings- en niet-
opleidingsziekenhuizen. De 3-maanden sterfte na slokdarmresecties in universitaire 
ziekenhuizen was 2,5%, vergeleken met meer dan 4% voor perifere ziekenhuizen. De 
3-maanden sterfte na maagresecties was 4,9% in universitaire ziekenhuizen en 8,7% in 
perifere ziekenhuizen. Zowel na slokdarm- als maagresecties was de 3-jaarsoverleving 
hoger in universitaire ziekenhuizen vergeleken met perifere ziekenhuizen. Tussen 
perifere opleidings- en niet-opleidingsziekenhuizen werden geen verschillen gevonden. 
Bij het analyseren van verschillen tussen individuele ziekenhuizen presteerden enkele 
perifere ziekenhuizen bovengemiddeld goed. Hieruit kan geconcludeerd worden dat de 
beste ziekenhuizen niet alleen op basis van het type ziekenhuis geselecteerd kunnen 
worden.
283summary in dutch (nederlandse samenvatting)
In hoofdstuk 16 worden de resultaten van een internationale studie naar slokdarm- en 
maagkankerchirurgie van 2004 tot 2009 in verschillende Europese landen beschreven. 
Verschillen in het percentage geopereerde patiënten, de postoperatieve sterfte, de 
langetermijnoverleving en ziekenhuisvolumes werden vergeleken tussen Nederland, 
Zweden, Denemarken en Engeland. In Nederland was de postoperatieve sterfte in 
vergelijking met de andere landen gemiddeld na slokdarmresecties (4,6%), maar het 
hoogst na maagresecties (6,9%). Hoewel een toenemend ziekenhuisvolume geassocieerd 
was met een lagere 30-dagen sterfte zowel na slokdarm- als maagresecties konden 
verschillen in uitkomsten tussen landen niet alleen verklaard worden door verschillen in 
ziekenhuisvolumes. Om deze verschillen verder te onderzoeken wordt gewerkt aan een 
grote Europese slokdarm- en maag registratie.
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